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Transplantation is the preferred treatment for patients with end-stage kidney disease. 
However, antibodies against blood group and histocompatibility antigens on 
transplanted organs pose a high risk of accelerated humoral rejection. Allograft 
transplantation into sensitised recipients initiates complement activation and early 
thrombotic processes. The aim of the research described here was to determine whether 
cell protective therapy targeting the complement and coagulation cascades is effective at 
preventing graft rejection in highly sensitised renal allograft recipients.  
 
In this thesis, using novel membrane targeting (cytotopic) technology, a therapeutic 
complement regulator Mirococept (APT070) and coagulation inhibitors (PTL006, 
Thrombalexin/PTL004) were delivered to the endothelial surface within organs. In these 
studies, a rat model of hyperimmune rejection of renal allografts from fully MHC 
disparate donors and recipients was established. In vivo studies revealed the potential of 
the therapeutic reagents by assessment of graft survival, renal function and pathology.  
Mirococept only provided modest protection of the endothelium and in renal function, 
without any prolongation of survival compared to recipients of control-treated grafts. In 
contrast, treatment of kidneys with either anticoagulant agent (PTL006 or 
Thrombalexin/PTL004) alone resulted in significant prolongation of graft survival 
correlating with delayed loss of renal function compared to controls. To explore 
whether these findings were suitable for translation to clinical application, the 
investigations were extended to include standard immunosuppressive agents. However, 
Cyclosporine A treatment was associated with toxic effects in the rats, whereas therapy 
including Rapamycin failed to prevent lymphocyte migration into the grafts.  
This study provides evidence that ex vivo graft perfusion of locally acting biological 
response modifiers can have therapeutic effects in the transplant setting.  The approach 
targets donor organs rather than the recipient. Additional and effective inhibition of 
cellular immune responses may demonstrate the full potential of this approach to attain 
graft acceptance against the most severe of immune barriers. These findings make this 
study clinically relevant.  
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     Chapter 1 – Introduction 
 
1.1 The Kidney  
1.1.1 Function of the Kidney 
The kidneys form a pair of sophisticated and vital organs whose main function is to 
remove breakdown waste products of tissues found in the blood. In this way, the 
kidneys filter the blood and remove toxic substances such as urea, forming a dilute 
solution in the process, urine. The kidneys apart from being an important part of 
excretion and homeostasis, also have some endocrine activity.  
 
1.1.2 Structure of the Kidney 
1.1.2.1 Blood Supply 
The process of the removal of harmful substances begins with the blood entering the 
kidney through the renal artery, diverging into afferent arterioles carrying blood into the 
cortex (Figure 1.1). Blood is directed from the glomerulus into the medulla, through the 
efferent arterioles, where they start descending into the peritubular capillaries. The 
peritubular capillaries form small veins which eventually merge to the large renal vein, 
where the blood exits the organ.  
1.1.2.2 The Nephron  
The cortex contains the most important part of the kidney, the nephron (Figure 1.2). 
Each kidney has about a million nephrons and these are the structures where the actual 
process of removal of metabolic waste products takes place. This functional part is 
composed of the glomerulus (network of blood vessels) and the tubules (urine-
collecting tubes).   
 
The filtering of the blood takes place in the glomerulus, a tight network of capillaries 
engulfed by podocytes. Those epithelial cells are responsible for separating the urine 
passing from the glomerulus ensuring only blood cells and large proteins remain in the 
blood. At the end of each glomerulus a tubule is found.  
The renal tubules are a series of tubes that recover all the necessary nutrients, initially 
filtered into the urine, to the blood (proximal convoluted tubules) or carry urine from 
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the glomerular capsule, and through the collecting duct into the renal pelvis (distal 
convoluted tubules). Consequently, the urine leaves the kidney through the ureter and 
into the bladder.  
 
 














































The concept of organ transplantation for therapeutic purposes dates back to ancient 
times and in particular Hua-To (136-208 A.D.) who replaced failing organs with healthy 
ones, in patients who were anaesthetized with a mixture containing Indian hemp. The 
realization that organ rejection was an immunological response came as early as the 16
th
 
century. Italian surgeon Gasparo Taggliacozzi, known for his method of reconstructing 
noses and ears from patients’ skin, noticed that skin from a different donor often led to 
the failure of the procedure. This would be recognized later, by his successors, as 
transplant rejection.  
The era of modern transplantation began at the beginning of the 20
th
 century. In 1902, in 
Vienna, Emerich Ullmann conducted kidney transplantation experiments in dogs 
making him the first surgeon to perform allotransplantation experiments (Druml, 2002 
1).  In 1906, Mathieu Jaboulay performed the first transplants, between species, by 
connecting the renal vessels of a sheep and a pig kidney to the brachial vessels in two 
patients with renal failure (Morris PJ, 2004 2).  Subsequent attempts failed because of 
vascular thrombosis. Against a background of failure, the first successful transplantation 
took place in 1954, when a team of doctors in Boston, transplanted a kidney from a 
healthy individual to his twin brother. The graft was accepted, since donor and recipient 
were genetically identical (Merrill et al., 1956 3). However, it was not until Peter 
Medawar’s groundbreaking skin transplantation studies in animal models, that a better 
understanding was obtained and led to its clarification as a form of specific immunity 
(Medawar PB, 1944 4; Medawar PB, 1945 5). With this came the realization that 
immunosuppression was required for successful transplantation and marked the 
beginning of the use of anti-rejection drugs. During the 60’s and 70’s, progress was 
slow with total-body irradiation achieving immunosuppression but being lethal for the 
majority of patients (Murray JE et al., 1960 6; Murray JE et al., 1962 7) and the use of 
6-mercaptopurine which was later replaced by the less toxic azathioprine (AZA).  This 
period was characterized by high mortality among patients until cyclosporine A (CsA) 
was introduced to the clinic in the early 1980’s. The use of the cyclosporine A 
calcineurin inhibitor dramatically improved graft outcome. Currently, a variety of 
immunosuppressive drugs are available for use in the transplant clinic including 
tacrolimus (FK-506), mycophenolate mofetil (MMF) and rapamycin and so on, each 
with different specificity, efficacy and safety.   
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1.3 Effector Mechanisms in Allograft Rejection  
In the absence of immunosuppression, the transplantation of tissue from one individual 
to another of the same species (allotransplantation) results in rejection of non-self by the 
recipient. Foreign antigens, provided by the allograft, are responsible for the activation 
of the recipient’s immune response which ultimately results in injury to and destruction 
of the transplanted organ. There are three major immune elements which contribute to 
graft rejection by disparate mechanisms, the contribution of which may vary and all of 
which may act simultaneously (Rocha PN et al., 2003 8):  
1. CD4+ T-helper cells directed against donor antigens, activate monocytes and 
macrophages by secretion of proinflammatory cytokines and chemokines by a delayed 
type hypersensitivity response (DTH).  




3. Donor specific antibody (DSA) binds to the graft endothelium, activates 
complement and coagulation, resulting in tissue injury and rejection.   
Graft rejection is characterized as hyperacute, acute or chronic; a classification 
established according to the time course of rejection and not the mechanisms (i.e 
cellular or humoral) involved (Colvin RB et al., 2005 9). Another category of rejection 
which has recently been described, is subclinical rejection, which manifests itself as the 
rare occurrence of acute cellular rejection in the absence of graft dysfunction (Böhmig 
GA et al., 2004 10). Indeed there can be resistance of a transplanted organ to injury, in 
the presence of anti-donor antibodies against donor endothelial cells, a situation known 
as accommodation (Dehoux JP et al., 2008 11). Most importantly, the histopathologic 
pattern is what determines the type of graft rejection. The different types of rejection 
and their characteristics are described in table 1.1. The main subject of this thesis is 




Table 1.1 Types and characteristics of renal allograft rejection (adapted from Colvin RB, 2007 12) 
 Clinical presentation Histology Pathology 
Complement 
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Serology Outcome  
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 T-cells and 
















(within months to 
years) clinical 





cells in glomeruli and 
PTC; intimal/interstitial 
fibrosis, tubular atrophy; 




















(within months to 
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deterioration of graft 
function 
Arterial intimal fibrosis 




cells within the thickened 
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Challenging. Therapy 















antibodies   
Reversible with 
appropriate treatment. 
Often a prediction for 
chronic damage and 
deterioration of graft  












not yet defined 
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1.4 The Role of B cells in Clinical Transplantation 
Solid-organ transplantation is the preferred treatment for patients with end-stage kidney 
disease (Wolfe RA et al., 1999 13). For decades, T lymphocytes seemed to be the 
predominant cells targeted in preventing kidney rejection. As a result, they became the main 
focus of experimental transplantation and less research was focused on alloantibody and B 
lymphocytes. As the barrier of T-cell-mediated rejection was gradually overcome, by the 
plethora of T-cell targeted therapies, interest in humoral responses re-emerged. It was only 
then that it became evident that DSA was not only responsible for hyperacute rejection, but 
was also strongly associated with an increased incidence of acute rejection incidents as well 
as chronic damage to the kidney (Stegall MD et al., 2010 14).  This realization prompted 
transplant researchers to achieve a better understanding of the genesis of the alloantibody 
response, a response which involves a variety of cells with different functions and 
characteristics (Clatworthy MR et al., 2011 15).    
B cells are a cell population of lymphoid origin, which overall express a variety of cell 
surface immunoglobulin (Ig) receptors. The B cell population as a whole recognizes 
multiple specific antigenic epitopes, thus making the B cell impressively diverse 
(Parsons RF et al., 2012 16). Importantly, throughout their development and maturation, 
different surface markers are expressed, such as CD19, CD20, CD22, CD23, CD27 and 
CD38 which often reflect different functions (Clatworthy MR, 2013 17).  
Traditionally, there are two B cell subsets, which can be distinguished based on their 
requirement for T-cell help for activation, expansion and differentiation (LeBien TW et 
al., 2008 18). Bone marrow derived B1 cells, generated during foetal development, are 
T-cell independent (T-I) and reside within pleural/peritoneal cavities and in few 
numbers within the spleen (Clatworthy MR, 2013 17). They mainly produce low 
affinity IgM antibodies specific for multimeric sugar and lipid (T-I) antigens (Yammani 
RD et al., 2013 19). B2 cells, often considered the conventional B cells, are T-cell 
dependent (T-D) and bone marrow derived. They are responsible for the development of 
high affinity antibodies and long-lasting specific immunological memory (Tangye SG, 
2013 20).  A rare, more recently described subset of B cells, are B10 cells. These 
participate in the negative regulation of inflammation rather than activation of immune 
responses (DiLillo DJ et al., 2010 21). Their inhibitory activity is mediated by their 
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ability to express IL-10, thus often referred to as B10 cells, and constitute 1%-3% of B 
cells residing in the spleen (Iwata Y et al., 2011 22).  
B cell activation is a complicated, multistep process which occurs upon encounter with 
an antigen in a secondary lymphoid organ (spleen/lymph node) (Parsons RF et al., 2011 
16). Once activated, B cells enter the T cell areas generating either plasmablasts (early 
short lived plasma cells) which secrete low affinity antibody or they enter the germinal 
centre reaction (GC) (Stegall MD et al., 2010 14). In this environment, B cells undergo 
clonal expansion, somatic hypermutation (SHM) and isotype class switch recombination 
(CSR). These cells eventually differentiate into memory B cells and long lived antibody 
secreting cells (ASCs) (Clatworthy MR et al., 2010 23).  
In principle, a strong alloantibody response requires activation of T-D B cells. During 
the sensitisation period, T cells are presented with the alloantigen through the direct 
pathway in the grafts and at a later stage, through the indirect pathway in the lymph 
nodes (Baratin M et al., 2004 24). Antigen specific B cells internalize epitopes from 
allogeneic cells, and through their surface major histocompatibility complex (MHC) II 
molecules, these are presented to CD4
+ 
T-helper cells (Mitchison MA et al., 2004 25). 
Studies in mice have demonstrated that for a proper IgG-mediated response the above 
pathway is required (Steele DJ et al., 1996 26). From that point onwards, long-lived 
plasma cells become permanently differentiated and migrate to the bone marrow 
synthesizing antibody indefinitely, in the absence of T cells (Shapiro-Shelef M et al., 
2005 27). On the other hand memory B cells are generated, and although they do not 
secrete antibody, upon re-stimulation with alloantigen they rapidly transformed to ASCs 
(Yoshida T et al., 2010 28).          
1.5 Hyperacute Rejection (HAR) 
HAR is the most exuberant example of antibody-mediated rejection (AMR). It affects 
patients who are pre-sensitised either due to antibodies against ABO blood group 
antigens or HLA antigens.  Preformed antibodies (DSA) in the blood of the recipient 
pose a significant barrier to transplantation.  Those antibodies against the donor organ 
are responsible for immediate graft loss, which can take place within minutes post-
revascularization (Singh N et al., 2009 29). This instant and complex response involves 
the binding of these antibodies to a variety of antigens expressed on the surface of the 
donor endothelium, triggering the activation of the complement and coagulation 
 25 
cascades which lead to graft injury.  In renal transplantation, the graft lacks normal 
reperfusion and as a result the kidney looks flaccid, mottled and in extreme cases 
completely black, resulting in the patient undergoing a nephrectomy (Nankivell BJ et 
al., 2010 30). Tissue is deeply characterized by major neutrophilic infiltration, extended 
coagulopathy and overall infarction (Table 1.1).  
1.5.1 ABO Antigens 
In the early days of transplantation, HAR often resulted from high titres of pre-existing 
IgM antibody directed against a foreign antigen. Such “natural antibodies” were 
generated in response to carbohydrate epitopes on glycolipids and glycoproteins which 
pre-existed in a naive host prior to transfusion. The classical example of these are 
antibodies against the ABO blood group antigens, specific for A and B antigens (Colvin 
RB et al., 2005 9). These oligosaccharide antigens are generated by 
glycosyltransferases, present in the Golgi apparatus responsible for the biosynthesis of 
polysaccharides on lipids and proteins (Shaper JH et al., 1992 31).  They are not only 
found on the surface of red blood cells, white cells and platelets but are also widely 
distributed on endothelial cells and renal tubular basement membranes (Yaich S, 2013 
32). Successful transplantation across an ABO barrier has been achieved using 
immunoadsorption and plasmapheresis protocols which non-selectively remove all 
antibodies from the circulation (Genberg H et al., 2010 33). Following these procedures, 
anti-ABO antibodies return, often at pre-operative levels, yet they generally do not 
damage the endothelium. This unusual phenomenon of the organ resisting HAR has 
been described as ‘accommodation’, a mechanism not fully understood (Chopek MW et 
al., 1987 34).   
1.5.2 α1,3GT Antigens 
In contrast to ABO-incompatible allotransplantation, HAR still remains the main 
obstacle to xenotransplantation. ABO-incompatible transplantation and 
xenotransplantation share many similarities, most importantly in that the xenoepitope, 
generated by the activity of α1,3galactosyltransferase (α1,3GT), bears a striking 
resemblance to the structure of blood groups A and B (Milland J et al., 2006 35). The 
presence of natural xenoreactive antibodies against the carbohydrate galactose-α-1,3-
galactose (Galα1, 3Gal, α-gal) prevents transplantation of  xenogeneic pig organs to 
human recipients (Parker W et al., 1994 36).  Furthermore, xenografts are especially 
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vulnerable to damage mediated by complement, since porcine complement regulators 
fail to suppress human complement activation on the pig endothelium (McCurry KR et 
al., 1995 37). As a result, the development of xenotransplantation, which is being 
considered as a solution to the lack of human organs, still has a long way to go before 
being a clinical possibility. However, the resemblance between the α-gal epitope and the 
ABO antigens provides valuable information regarding carbohydrate biology, giving 
insight into the role of antibodies in HAR (Galili U, 2006 38).   
1.5.3 HLA Antigens 
In the current clinical setting, the focus is on antibodies against protein alloantigens 
such as the major histocompatibility antigens expressed on the surface of donor cells. 
Patients may be sensitised to MHC antigens by blood transfusions, pregnancies or 
rejection of a previous graft, leading to the recipient developing anti-human leukocyte 
antigen (HLA) antibodies against the donor organ tissue. Since, in this case, the 
recipient’s immunological reactivity is generated prior to transplantation, the subsequent 
graft may be rejected in a hyperacute manner, usually mediated by antibodies of the IgG 
subtype (Steele DJ et al., 1996 26). The main antigenic targets being allogeneic MHC 
Class I and II molecules (van Saase JL et al., 1995 39). MHC Class I molecules are 
expressed on the surface of all nucleated cells including endothelial cells whereas MHC 
Class II molecules on resting cells, have a more restricted expression including on 
dendritic cells (DCs), B cells and vascular (capillaries, veins and arteries) endothelial 
cells (Baldwin WM III et al., 2010 40).  In contrast to human endothelium, murine 
endothelium does not express class II antigens in the resting state, however upon 
activation due to local inflammation, MHC II expression of antigens can be rapidly 
induced (Goes N et al., 1995 41).  
The HLA system is a series of genes located on chromosome 6. There are 
approximately 200 genes which are heavily involved in antigenic presentation to T cells 
and some of them display extreme polymorphism (Becks S et al, 2000 42). They are 
categorized into 2 main groups: MHC Class I and II antigens. There are three class I 
MHC proteins in humans, HLA, -B and -C, and there are three class II MHC proteins 
HLA-DR, -DQ and –DP (Sheldon S et al., 2006 43). These genes are the most 
polymorphic loci in the human genome, with some having hundreds of alleles (Erlich 
HA et al., 2001 44). The extreme polymorphism of the HLA enables antigen presenting 
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cells (APCs) to display a vast repertoire of peptide fragments to T cell receptors 
(Nankivell BJ et al., 2010 30). Small discrepancies between donor and recipient in 
amino acid sequence, within the MHC peptide-binding groove is enough to alter peptide 
presentation and elicit severe graft rejection. In general, the HLA class I molecules 
consist of an α and β2 microglobulin chain and present endogenous antigen to CD8
+ 
T 
cells. The HLA Class II molecules consist of an α and β chain and present peptide of 
exogenous antigens to CD4
+ 
T cells (Neefjes J et al., 2011 45).  
HAR no longer poses a threat to clinical transplantation due to crossmatching, which 
was introduced in 1969 (Patel R et al., 1969 46). This involves testing the recipients’ 
serum for the presence of preformed antibodies against the potential donor. This has 
significantly reduced the risk of HAR. Methods for detection have been improved 
overtime and currently include highly sensitive solid-phase immunoassays (SPI) (Mahdi 
BM, 2013 47). 
1.5.4 MHC Antigens in the Rat 
Histocompatibility research has led to dissection of the rodent MHC. In the rat, the RT1 
complex is the major histocompatibility complex in and like the MHC of other species, 
it comprises a group of closely related genes (Günther E et al., 2001 48) and is located 
on the RNO chromosome 20 (Locker J et al., 1990 49). The rat has been consistently 
used in transplantation studies and the antigen-specific immune responses have been 
attributed to class I genes, RT1.A, RT1.C and RT1. E and class II genes, which are 
found in the RT1B/D region (Palmer M et al., 1983 50). Strong graft rejection has been 
closely associated to RT1.A and RT1.B/D (Günther E et al., 2001 48; Günther E et al., 
1984 51).  The RT1.A genes are analogous to the mouse H-2K, D and L (Günther E 
et al., 2001 48) and exhibit a similar level of polymorphism to the mouse H-2 (Cami B 
et al., 1981 52; Pease LR et al., 1982 53).   
1.6 Acute Antibody-Mediated Rejection 
Although the utilization of sensitive crossmatching techniques has virtually eliminated 
HAR, antibodies play a significant role in acute allograft dysfunction post 
transplantation. First of all, presensitisation still remains a major risk factor as it poses a 
serious threat for an anamnestic alloantibody response. This memory immune response 
is generated by past exposure to the donor specific antigen, generating high titres of 
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complement-fixing antibody upon re-exposure (Terasaki PI, 2003 54).  Secondly, 
although patients can have a negative crossmatch, they may develop a primary immune 
response with de novo synthesis of DSA.  AAMR manifests itself as a sudden 
deterioration of graft function which usually takes place within days or a few weeks 
after transplantation (see table 1.1). Nonetheless, AAMR can occur years after 
transplantation, often due to changes in the recipient’s immunosuppression regimen 
(Colvin RB, 2007 12).  As with HAR, the main targets of preformed and de novo 
antibodies are the MHC and ABO antigens on the donor endothelium, however, all 
antigens expressed on endothelial cells (ECs) can potentially serve as targets. Examples 
include minor histocompatibility antigens (miHA) and non-HLA antigens.  Upon 
histopathological analysis, the injury mediated by these antibodies displays similar 
morphologic characteristics to HAR, although as a general rule AAMR is less severe 
(Puttarajappa C et al., 2012 55). At present, AAMR is well characterized in the human 
renal biopsies (Table 1.2) (Truong LD et al., 2007 56). A major contribution to the 
diagnosis of AAMR has been made by the introduction of staining for the deposition of 
complement fragment, C4d, a marker of classical pathway complement activation, into 
routine transplant pathology. This was initially proposed by Feucht (Feucht HE et al., 
1993 57) and it reveals a strong correlation between DSA and complement activation. 
1.7 Chronic Antibody-Mediated Rejection 
There is strong recent evidence supporting the involvement of HLA antibodies in the 
slow deterioration of graft function. Dysfunction is manifested in structural changes in 
the microcirculation (Table 1.1) which involves glomeruli and PTC, arteries and general 
damage of the kidney through interstitial fibrosis and tubular atrophy (Mengel M et al., 
2012 58). This type of rejection is termed chronic antibody-mediated rejection (CAMR) 
and is considered to be a major complication and challenge in the long-term survival of 
kidney grafts, despite the plethora of immunosuppressive agents and sensitive HLA 
screening assays (Carter V et al., 2005 59). Due to its arduous nature, multiple 
controversies have arisen regarding CAMR. First of all, there is a debate concerning the 
definition of “chronic” rejection; is it simply an established scar formation or active 
chronic changes which therefore have the potential for treatment (Cohen D et al., 2011 
60)? Regarding the second hypothesis, DSA to HLA antigens can promote rejection 
with subsequent complement activation, thus making C4d a suitable marker of an 
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ongoing immunological reaction (Colvin RB, 2007 12). DSA, especially specific for 
allogeneic MHC class II, has been associated with transplant glomerulopathy and 
arteriopathy and there are many studies highlighting the strong association of those 
histological features with C4d (Regele H et al., 2002 61; Rotman S et al., 2005 62; 
Lorenz M et al., 2004 63). In addition, studies have revealed that patients positive for 
C4d, had greater chances of developing CAMR, leading to the assumption that this 
biomarker predicts early stage of glomerulopathy (Regele H et al., 2002 61; Loupy A et 
al., 2009 64). Secondly, although a combination of alloantibody and C4d deposition has 
been an acceptable marker for the diagnosis of CAMR, there is a substantial number of 
patients exhibiting all the histological features of chronic graft impairment but in the 
absence of HLA antibody (Akalin E et al., 2007 65) or C4d staining at the time of 
biopsy. Studies where there is a lack of C4d as a marker (Al Aly Z et al 2005 66; Sis B 
et al., 2007 67) propose a form of humoral rejection (in a chronic but not acute 
background) whose mechanism is complement independent.  
Antibodies, regardless of whether they fix complement or not, have the ability to alter 
the activation state of the donor endothelium upon binding the cells. Consequently, they 
can induce proinflammatory responses which recruit cells of the innate arm of the 
immune system (Lee CY et al 2005 68) leading to scarring of the graft. Adding to the 
challenge of CAMR is the well established fact that chronic allograft rejection can take 
place in the absence of any HLA-specific antibody (Rose ML, 2004 69). Furthermore, 
autoimmune responses may contribute to graft loss through exposure of peripheral self-
antigens, adding to existing damage caused by alloantibody. These non-HLA- specific 
auto-antibodies are directed against targets such vimentin (Carter V et al., 2005 59) 
which is not normally expressed on the endothelium but maybe induced upon 
inflammation or angiotensin II type 1 (AT1) receptor (Dragun D, 2007 70).  In addition, 
glutathione-S transferase (GSTT1) expression can promote damage to the graft, when 
the organ from a GSTT1-positive donor is given to a GSTT1-negative recipient (Akgul 
SU et al., 2013 71). Finally, polymorphic endothelial MHC-class I related chain A 
(MICA) and chain B (MICB) antigens participate in chronic rejection (as well as HAR 
and AAMR). These host-specific antigens, including miHA, are of particular interest 
since they escape detection by traditional cross-matching techniques (Grafft CA et al., 
2010 72). Increasing evidence that highlights the impact of non-HLA-specific 
antibodies to graft loss is accumulating. Recent data reveal that 10-23% of renal 
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transplant recipients are presensitised to non-HLA antigens (Jackson AM et al., 2011 
73; Qin Z et al., 2011 74) and 22% develop de novo non-HLA-specific antibodies after 
transplantation (Sigdel TK et al., 2012 75). For this reason, high-density arrays are 
being used in research to identify target antigens for non-HLA-specific anti-endothelial 
cell antibodies (AECAs) in transplant recipients experiencing AMR (Jackson AM et al., 
2014 76). These observations have highlighted the need for markers that use endothelial 
transcripts as indicators of CAMR (Sis B et al., 2010 77). 
CAMR is a problematic condition that greatly affects graft survival. It is not known 
what drives antibodies to cause acute rejection in one patient and chronic in another. It 
is possible that factors such as antibody titre, avidity and effector mechanisms directed 
at the endothelium, contribute to the outcome. As a result of the extremely complex 
situation, a standard therapy for CAMR is currently not agreed (Cohen D et al., 2012 
60).     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 Table 1.2. Diagnostic criteria for acute antibody-mediated rejection (adapted from 
Haas M et al., 2014 78)  
1. Morphologic evidence of acute tissue injury 
I. Acute tubular infarction 
II. Neutrophils and/or mononuclear cells in peritubular and/or glomerular 
capillary 
III. Glomeruli and/or capillary thrombosis; arterial fibrinoid necrosis 
2. Immunopathological evidence for the action of antibodies  
I. C4d deposition in PTC and GBM (less often) 
II. Presence of immunoglobulin and complement in PTC and arteries (rare) 





1.8 Effector Mechanisms of Antibody-Mediated Rejection  
1.8.1 Resting vs Activated Endothelium 
Microvascular endothelium is the primary interface between the transplanted organ and 
the recipient’s immune response (Turgeon NA et al., 2009 79).  Resting endothelium is 
a well-organized network of tubules with distinct morphology which strongly supports a 
monolayer of endothelial cells connected at tight junctions. The undisturbed 
endothelium, free of any surface disruptive stimuli, is crucial to providing a barrier 
between the vascular and extra vascular spaces (Liptak P et al., 2005 80). The main 
target of antibody-mediated rejection is the glomerular and PTC endothelial 
compartment of the kidney. Here, high levels of DSA against both MHC I and II 
antigens directly activate the endothelium promoting cell lysis and death. In addition, 
the anti-HLA antibodies mediate complement activation and rapid upregulation of 
adhesion molecules and growth factor expression (Table 1.3) (Wehner J et al., 2007 81). 
These lead to inflammation of the microvasculature and breakdown of the endothelial 
barrier with leakage of intravascular fluids to the tissue. In addition, there is platelet 
aggregation/coagulation cascade leading to cell apoptosis and ultimately destruction and 
rejection of the graft (Liptak P et al., 2005 80; Dranchenberg CB et al., 2013 82). 
 
Table 1.3. Chemokines, adhesion molecules and growth factors expressed by 
endothelial cells in response to both antibody and complement (adapted from Wehner J 















von Willebrand factor; P-selectin;
VCAM-1, ICAM-1
MCP-1, IL-8, CCL5







1.8.2 Direct Effects of DSA on the Donor Endothelium  
1.8.2.1 Crosslinking of MHC antigens by Antibodies results in Endothelial and 
Smooth Muscle Cell Proliferation 
Exposure of alloantibodies to human HLA antigens displayed on the graft has multiple 
effects on the donor endothelial cells. In vitro experiments have revealed that cross 
linking of the antigens by antibodies induces complement-independent upregulation of 
surface proteins as well as intracellular signalling by growth factor receptors (Naemi 
FM et al., 2013 83). The consequent induction of integrins and growth factors, such as 
basic fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) is 
associated with cell proliferation and survival (Zhang X et al., 2012 84). Interestingly, 
the higher the concentration of anti-HLA Class I antibody the stronger the stimulus for 
FGF receptor expression on the EC surface (Jindra PT et al., 2006 85). In addition, 
expression of another growth factor,  PDGF (platelet-derived growth factor) serves as a 
potent mitogen for cells of mesenchymal origin (Bunte MC et al., 2008 86). Finally, 
engagement of alloantibody to their antigenic targets activates transcription factors, 
such as nuclear factor-kB (NF-κB).  These are responsible for proinflammatory and 
procoagulant cell mediated proliferation (Zhang X et al., 2009 87).  
1.8.2.2 Crosslinking of MHC antigens by Antibodies activates Leukocytes through 
Fc Receptors 
Accumulation of leukocytes on injured vessel walls can be mediated by signalling 
through their Fc Receptors (FcRs). Binding of these receptors to the Fc portion of the 
tissue ligated antibody, activates the leukocyte to strongly promote graft injury (Joudeh 
A et al., 2013 88). Furthermore, it provides an important link between the innate and 
adaptive immune responses (Nimmerjahn F et al., 2007 89). There are four main types 
of Fc receptors: FcγRI, FcγRIII, FcγRIV and inhibitory FcγRIIB expressed by a variety 
of inflammatory cells such as neutrophils, monocytes/macrophages, and NK cells 
(Sunay Erdinc MM et al., 2013 90). The responses of these Fc-bearing inflammatory 
cells to bound antibodies, cause damage to the transplanted tissue.  This can be the 
result of cytokine and chemokine release, leukocyte degranulation leading to 
phagocytosis and apoptosis through antibody-dependent cellular cytotoxicity (ADCC) 
(Joudeh A et al., 2013 88). These mechanisms that potentiate graft rejection heavily 
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depend on the specificity of the FcRs involved. Neutrophils and macrophages express 
high affinity FcγRIII (CD16) (Giorgini A et al., 2008 91) and FcγRI (CD64) 
(Nimmerjahn F et al., 2008 92) respectively, and low affinity FcγRIV and inhibitory 
FcγRIIB (CD32) (Baldwin WM 3rd et al., 2012 93). Activation of these cells results in 
upregulation of proinflammatory MCP-1, IL-8, IL-6 (Wasowska BA, 2010 94) and 
induction of TNF-α and IL-1-α (Abrahams VM et al., 2000 95). Other cells expressing 
FcγRIIB include endothelial cells and platelets although their function is not well 
understood (Wehner J et al., 2007 81). Interestingly, B cells which express inhibitory 
FcγRIIB, and NK cells, are the only cell types that can express only activating or 
inhibitory receptors alone (Nimmerjahn F et al., 2007 89). NK cells mediate ADCC 
through the release of cytotoxic granules containing perforins and granzymes, at the site 
of injury, leading to cell apoptosis and graft rejection (Lee CY et al., 2007 47). In 
addition, NK cells, through activation of FcγRIII can mediate elevated expression of 
multiple cytokines such as IFN-γ, a major participant in allograft rejection (Akiyoshi T 
et al., 2012 96).   
1.8.2.3 Crosslinking of MHC antigens by Antibodies promotes Leukocyte Adhesion 
and Chemotaxis 
As previously stated, antibody ligation on the graft’s surface induces growth factors, 
adhesion molecule expression and cytokine production (Zhang X et al., 2009 87). 
Studies on acutely rejected renal allografts showed upregulation of intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on 
the endothelium (Lucchiari N et al., 2000 97). Interaction of adhesion molecules with 
surface receptors on leukocytes results in the migration of cells through the basement 
membrane (Yadav R et al., 2003 98). Furthermore, recent data have indicated that 
bivalent IgG interactions with allo MHC antigens, stimulates rapid exocytosis of von 
Willebrand factor (vWf) from the subenthothelium. vWf is an important link between 
endothelial cell activation, platelet aggregation and leukocyte recruitment (Morrell CN 
et al., 2007 99). Upon release of vWf, a series of events is initiated which is not only 
proinflammatory but procoagulant as well. This protein is the initial stimulus for platelet 
adherence to the endothelium and consequently aggregation of activated platelets 
(Lowenstain CJ et al., 2005 100). Platelets contain a plethora of molecules, such as 
chemokines and cytokines which strongly contribute to EC activation and leukocyte 
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localisation to the graft (Turgeon NA et al., 2009 79). Importantly, stimulated 
endothelial cells and activated platelets release P-selectin. P-selectin is an adhesion 
molecule and once externalized induces further platelet recruitment and initiates first 
stages of leukocyte trafficking (Celi A et al 1994 101). As a result, a large influx of 
proinflammatory cytokines, such as IL-1, IL-8, tumor necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ) are secreted at the site of leukocyte activation (Le Meur Y et al., 
2002 102) further adding to tissue damage. It is clear from published data that without 
adhesion molecules, platelet-derived factors and inflammatory components, generated 
during an alloantibody response, leukocyte trafficking could not be sustained.  
1.8.2.4 Crosslinking of MHC antigens by Antibodies induces Procoagulant 
Responses 
Critically, the previously discussed alloantibody-endothelium-vWf-platelet interactions 
are not only associated with vascular inflammation but also create a procoagulant 
interface which strongly promotes thrombosis (Sis B, 2012 103). Activated platelets 
promote the release of tissue factor (TF) from the subenthothelium (Kirk AD et al., 
2009 104). TF is an integral membrane protein and is the principal initiator of the 
extrinsic pathway of the blood coagulation cascade (Chu AJ, 2005 105). A series of in 
vitro experiments addressing xenogeneic responses, provided evidence for human 
stimulated platelets also releasing substantial amounts of TF on porcine endothelial cells 
(Bustos M et al., 2001 106).  On the other hand, P-selectin, apart from orchestrating 
leukocyte reactions at the site of inflammation, is responsible for the expression of TF 
on the surface of polymorphonuclear (PMNs) cells and monocytes (Celi A et al 1994 
101). As a result, TF is responsible for the initiation of the clotting cascade generating 
large amounts of thrombin, a serine protease which is a key potent effector of 
coagulation (Chen D et al., 2009 107). Therefore, alloantibodies against the transplanted 
graft may cause sufficient endothelial exocytosis of TF which in turn induces rejection 
by inflammation and thrombosis. Increasing evidence for the involvement of 
coagulation in the process of AAMR, includes functional analysis of endothelial cell-
associated transcripts (ENDTAs).  Interestingly, vWf was identified as the most 
prevalent transcript in AAMR biopsies (Sis B, 2012 103). In vitro experiments on a 
human endothelial cell line, stimulated with anti-MHC I and II antibodies, revealed the 
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speed at which vWf is released by the endothelium (within minutes) and its sustained 
exocytosis (60 minutes) post activation (Yamakuchi M et al., 2007 108).  
1.9 The Blood Coagulation Cascade 
1.9.1 Activation of Platelets 
The surface of a quiescent endothelium provides an antithrombotic environment with a 
tendency for thrombosis when there is injury. With damage, the response is to promote 
coagulation and this is mainly controlled by the generation of thrombin (Cines DB et al., 
1998 109).  During the initiation stage of the coagulation cascade, transplant-associated 
endothelial injury will result in the activation of platelets and inevitably the formation of 
a platelet plug (Bunte MC et al., 2008 86). There are two distinct pathways leading to 
the activation of platelets: these involve subendothelial exposure of vWf and collagen 
and secondly, thrombin generated by tissue factor (discussed later) (Furie B et al., 2008 
110).  
Platelets express receptors that allow them to be recruited from the blood flow to the 
site of injury. Platelet adhesion is promoted by receptor GPVI forming low affinity 
interactions with collagen and the glycoprotein complex (GP) Ib-V-IX promoting strong 
interactions with vWf (Varga-Szabo D et al., 2008 111). After the initial tethering, 
which results in platelet activation, platelets release the contents of their alpha granules 
containing P-selectin, ADP and thromboxane A2 (TXA2). These cause further platelet 
aggregation and activation (Denis CV et al., 2007 112) which enables one of the main 
haemostatic functions of activated platelets, that is to provide the surface for the 
assembly of coagulation complexes for generation of thrombin and formation of 
insoluble fibrin (Jackson SP, 2011 113).  
1.9.2 Pathways to Coagulation  
The coagulation cascade has been divided into two complex pathways, the intrinsic and 
the extrinsic pathway, and involves numerous clotting factors (Table 1.4). The sequence 
of coagulation events is a series of conversions of inactive zymogens to activated 
enzymes which generally takes place on the phospholipid surfaces of endothelial cells 
and platelets in the presence of Ca
++
 (Camerer E et al., 1996 114). Both pathways 
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converge at the activation of factor X (common pathway) and the ultimate generation of 
thrombin (Tanaka KA et al., 2009 115).   
1.9.2.1 Contact Activation (Intrinsic) Pathway  
The intrinsic pathway of activation involves blood coming into contact with negatively 
charged surfaces. As a result, proteins such as prekallikrein (PK), high molecular weight 
kininogen (HMWK) and factor XII (FXII) and XI (FXI) initiate the activation cascade 
(Camerer E et al., 1996 114). Active FXIIa cleaves PK to kallikrein which in turn 
generates more FXII. Through numerous enzymatic conversions (Figure 1.3) FXIIa 
activates FXI to FXIa and in reactions that require Ca
++
 FXIa converts FIX to FIXa. 
Active FIXa activates FXa. This process needs the formation of a complex which is 
formed on the surface of the activated cell. Here, membrane bound VIIIa, which acts as 
a cofactor to FIXa, and forms the tenase complex, activates FX to FXa (Renné T, 2012 
116).  All the activators of the contact pathway are intrinsic to the blood, and this has 
led to the logical hypothesis that this pathway is initiated in vitro only, and that fibrin 
formation in vivo, is usually generated, if not completely, by the extrinsic (tissue factor) 












Table 1.4 Blood coagulation factors  
Name  
 
Pathway  Function  
High molecular weight kininogen 
factor (HMWK) 
(Fitzgerald or Flaujeac factor)  
Intrinsic Co-factor in kallikrein and XII 
activation 
Prekallikrein (PK), Fletcher factor 
 
Intrinsic Activated form, kallikrein, 
interacts with HMWK and XII 
Fibrinogen (factor I) 
 
Both Cleaved by thrombin to form 
the fibrin clot 
Prothrombin (factor II) 
 
Both Activated form, thrombin, is 
the main coagulation enzyme 
Tissue factor (factor III) 
 
Extrinsic Co-factor for factor VII, 
initiator of extrinsic pathway 




ions necessary for 
coagulation reactions 
Factor V (Labile factor) 
 
Both Activates prothrombin to 
thrombin, forms the 
“prothrombinase” complex 
Factor VII (Proconvertin) 
 
Extrinsic Forms TF-VIIa complex, 
initiates extrinsic pathway 
Factor VIII (Antihemophilic factor) 
 
Intrinsic VIIIa forms the “tenase” 
complex, activates factor X 
Factor IX (Christmas factor) 
 
Intrinsic IXa forms the “tenase” 
complex, activates factor X 
Factor X (Stuart-Prower factor)   Both Xa initiates the common 
pathway, forms the 
“prothrombinase” complex 
Factor XI (plasma thromboplastin 
antecedent)  
Intrinsic XIa activates factor IX  
Factor XII (Hageman factor) Intrinsic Activated form initiates the 
intrinsic pathway 
Factor XIII (Fibrin stabilizing 
factor) 
 
Both Transamidase that stabilizes 
fibrin clot by cross-linking  
        







1.9.2.2 Tissue Factor (Extrinsic) Pathway 
Tissue factor (TF) is the principal initiator of the extrinsic pathway at the site of injury, 
resulting in the sequential activation of clotting factors FVII, FX, prothrombin and the 
production of fibrin clot (Chu AJ, 2005 105). The TF pathway (Figure 1.3) can be 
further divided into an initiation phase and an amplification phase. The initiation phase 
involves TF binding circulating FVIIa to form a TF-FVIIa complex which instantly 
generates FXa (Thomas WS et al., 1993 117). Newly generated FIXa binds to its 
cofactor FVIIIa to form the tenase complex (in a similar fashion to the intrinsic 
pathway) resulting in the activation of FX. The activation of FX to FXa enters the final 
(common) pathway (Figure 1.3). FXa binds to membrane bound FVa, forming the 
prothrombinase complex witch converts prothrombin to thrombin, the final enzyme in 
the coagulation cascade. During this stage, small amounts of thrombin are generated 
which enter the amplification phase (Johari V et al., 2012 118). During this phase, the 
thrombin which has been generated, amplifies itself by activating FVIII and FV to form 
the tenase and prothrombinase complexes respectively. These are responsible for a 
second larger burst of thrombin generation (Furie B et al., 2008 110). Additionally, this 
protease has been considered to be able to activate FXI of the intrinsic pathway. This 
demonstrates how the components of the intrinsic pathway complement TF-mediated 
blood coagulation (Chu AJ, 2011 119). On the activated platelet surface, thrombin 
concentrates fibrinogen which is converted to fibrin, a requirement for a stable 
haemostatic plug (Ni H et al., 2000 120). Finally, thrombin promotes polymerization of 
fibrin monomers, through activation of plasma and platelet FXIII (Tanaka KA et al., 
2009 115), resulting in a cross-linked fibrin clot.  
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Figure 1.3 The blood coagulation cascade 
 
 

























Tissue factorNegatively charged surface
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1.9.3 Key Mediators of Coagulation  
The coagulation cascade is a tightly regulated network of catalytic reactions undertaken 
by active coagulation components. However, these mediators promote responses which 
extend further than thrombosis. They are major initiators of inflammation.  Among 
these, is TF which mediates increased vascular permeability through the up regulation 
of IL-1β (Puhlmann M et al., 2005 121), and plasma levels of IL-6 (Chu AJ, 2011 119). 
Absence of coagulation factor VIIa impairs inflammatory responses (Xu H., 2006 122) 
whereas FXa correlates with expression of IL-8, monocyte chemotactic protein-1 
(MCP-1), and the upregulation of adhesion molecule expression (Senden NH., 1998 
123). Nonetheless, it is the serine protease thrombin which is the central modulator of 
haemostasis and vascular inflammation (Fenton II JW et al., 1991 124) and this will be 
discussed later.   
1.9.3.1 Thrombin  
Thrombin is a mulfunction serine protease (Figure 1.4) generated at sites of tissue 
injury, thus making it a key regulator of homeostatic processes, and the main effector 
enzyme in the blood coagulation system (Coughlin SR, 2005 125). Its role in 
inflammation is well characterized and in general, these type of responses can be 
amplified through thrombosis (generation of fibrin) or signalling through protease 
activated receptors (PARs) (discussed later) (Chen D et al., 2009 126).  
As previously stated, TF is the principle initiator of the extrinsic pathway of coagulation 
and therefore important to thrombin generation. Upon activation, a series of positive 
feedback loops amplify further thrombin resulting in extensive cross-linked fibrin clots 
(Figure 1.3). Fibrin, apart from being important in stabilizing the haemostatic plug, is in 
fact highly proinflammatory. It induces NF-κB (Liu X et al., 2000 127), and mediates 
the release of IL-1β and IL-8 (Lee ME et al., 2001 128; Liu X et al., 2000 127). In 
addition to thrombin’s amplification role, it is also capable of negatively regulating 
thrombotic responses by activating protein C and thrombin-activatable fibrinolysis 
inhibitor (TAFI) (Tanaka KA et al., 2009 115).  
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Thrombin can have direct effects on a variety of cells, such as platelets, smooth muscle 
cells and endothelial cells (Coughlin SR, 2000 129). These cellular responses to 
thrombin are mediated by a family of G protein-coupled protease-activated receptors 
(PARs) (Coughlin SR, 2005 125). These receptors are unique in the aspect that they 
carry their own ligand which remains masked unless the receptors are cleaved to reveal 
the tethered ligand (Danckwardt S et al., 2013 130). Thrombin is responsible for the 
proteolytic cleavage and activation of the receptor which consequently induces 
autocrine and paracrine signalling (Chen D et al., 2009 126).  
Thrombin is without doubt, the most potent platelet agonist. Platelet activation, which is 
crucial for effective haemostasis, is mediated by surface expression of PAR1 and PAR2. 
Thrombin interaction with either receptor, leads to the activation and further 
aggregation of platelets (Coughlin SR, 2005 125) although it has been suggested that 
the role of PAR1 might be most important (Covic L et al., 2000 131). In contrast to 
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human platelets, mouse platelets utilise PAR3 and PAR4 to respond to thrombin (Kahn 
ML et al., 1998 132). Activation results in the expression of a plethora of immune-
modulatory molecules, such as adhesion molecules, chemokines and coagulation factors 
(Popović M et al., 2012 133). Furthermore, the interaction of platelets with thrombin 
leads to the production of microparticles (MPs) which are generated by budding of the 
cell membrane upon disruption of the phospholipid bilayer (Herring JM et al., 2013 
134). MPs are rich in TF and contain surface receptors for FVIII and FV (Barry OP et 
al., 1999 135) providing procoagulant activity close to the platelet activation site. In 
addition, platelet derived MPs contain P-selectin glycoprotein ligand-1 (PSGL-1) which 
promotes platelet-platelet interactions and aggregation (Fourcade O et al., 1995 136). 
Finally, thrombin can activate, through PARs, vesiculation of both leukocytes and 
endothelial cells. Leukocyte-derived MPs bearing TF, increase its concentration at the 
inflamed site (Popović M et al., 2012 133) and they stimulate inflammatory responses 
through expression of cell adhesion molecules (Herring JM et al., 2013 134). Finally, 
vesicle shedding from endothelial cells stimulated by thrombin, results in increased 
endothelial-leukocyte interactions (Bizios R et al., 1988 137). 
 
1.9.4 Regulation of the Blood Coagulation Cascade 
One of the most important functions of the endothelium is to maintain the balance 
between thrombosis and fibrinolysis. Intact endothelium sustains blood in its fluid state 
by regulating platelet and coagulation activation (Figure 1.5). Platelet activity is 
controlled by the endothelium through the release of vasoactive mediators, prostacyclin 
(PGI2) and nitric oxide (NO).  The effects of PGI2 release is mediated by G-protein 
coupled receptor signalling on the platelets which results in an increase in their cAMP 







Figure 1.5 Regulators of the coagulation cascade 
 
 
NO, in a similar fashion to PGI2  interacts with platelets to cause reduced adhesion and 
aggregation at the site of injury (Tschudi MR et al., 1996 139). 
Endothelium controls coagulation by targeting active thrombin. Antithrombotic tissue 
factor pathway inhibitor (TFPI) is a serine protease inhibitor which is primarily 
expressed by endothelial cells and to a smaller extent by platelets and leukocytes, and is 
considered the only known modulator of TF (Lwaleed BA et al., 2006 140). Its 
mechanism of action targets the TF-fVIIa complex and this subsequently inactivates 
excessive FX and FIX (Tanaka KA et al., 2009 115). Direct inhibitory activity results 
from production of the natural anticoagulant, vitamin K-dependent, protein C.  This 
degrades the cofactors of the tenase and prothrombinase complexes (Dahlbäck B et al., 
2005 141). Indeed, thrombin negatively regulates itself when bound to endothelial cell 
surface thrombomodulin (TM) since this activates protein C (APC) which results in the 
proteolytic cleavage of FVIIIa and FVa (van der Wouwer M et al., 2004 142). This is 
supported by the activation of protein S which is a vitamin K-dependent plasma protein 
(Dahlbäck B, 2005 143).   
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Regulation of thrombin also takes place by specific thrombin inhibitors, particularly 
antithrombin III (AT-III) a serine protease inhibitor (serpin) whose action is mediated 
by heparinoids (van’t Veer C et al., 1997 144). AT-III can also degrade and expression 
of heparan sulphate (a glycosaminoglycan) on cell surfaces provides a substrate for 
antithrombin. Antithrombin adheres to these factors resulting in inactivation due the 
conformational change of these proteins. (van’t Veer C et al., 1997 145).   
Lastly, targeting the final stage of coagulation, which is the formation of the fibrin clot, 
is mediated by endothelial cell derived tissue-plasminogen activator (t-PA), the main 
enzymatic activator of the fibrinolytic system. The role of t-PA is to cleave 
plasminogen, an inactive protein synthesized in the liver, into its active form, plasmin. 
Plasmin, a serine protease, degrades fibrin and factors V and VIII (Tanaka KA et al., 
2009 115). More specifically, fibrin expresses positively charged lysine residues which 
attract t-PA and plasminogen. As a result, plasmin is generated and incorporated into 
the fibrin, leading to clot dissolution (Esmon CT, 2003 146).  TM, in antithesis to its 
anticoagulant nature, also promotes thrombin-activatable fibrinolysis inhibitor (TAFI) 
which removes the fibrin lysine residues. This procedure, although it reduces plasmin 
activation, does not terminate clot lysis (Bajzar L et al., 1996 147). However, at sites of 
severe inflammation, the fibrinolytic system is effectively controlled by serine protease 
inhibitor, plasminogen activator inhibitor-1 (PAI-1) by neutralizing t-PA in plasma 










1.10 Indirect Effects of DSA on the Donor Endothelium  
 
In addition to the direct effects that DSA has on the transplant endothelium, specific 
subclasses of antibodies can activate complement with devastating effects to the graft 
(Wehner J et al., 2007 81). Here, complement acts as an effector of the antibody 
response, mediating inflammation. Complement is considered the pivotal pathway 
mediating HAR and AAMR due to its ability to coordinate both innate and adaptive 
immune responses (Kumar V et al 2006 149). 
 
 
1.10.1 The Complement Cascade  
 
Complement is an elaborate system of at least 35 molecules, which function as 
activators, receptors (Table 1.5) and regulators (Table 1.6) and was first described in the 
late 19
th
 century as a heat labile bactericidal “alexin” before being redefined by Paul 
Ehrlich to its modern nomenclature (Ehrnthaller C et al., 2011 150). Its pathogenic 
power derives, firstly, from the generation of biologically active split products through a 
series of enzymatic reactions. Secondly, these split products have the ability to 
orchestrate and amplify responses from platelets and inflammatory cells, as well as to 
stimulate direct lysis and apoptosis of target cells (Wehner J et al., 2007 81). Currently, 
there are three established pathways (classical, lectin, alternative) to complement 
activation, (Figure 1.6) which ultimately result in three main events: C3 and C5 
convertase formation and the assembly of the terminal membrane attack complex 







Table 1.5 Proteins of the complement cascade  
Pattern recognition  Pathway  Function  
C1q 
 
CP Forms the C1 complex; recognizes CRP, 




LP Recognizes CRP and some IgM and IgG  
Ficolins (M, L, H) 
 
LP Recognize carbohydrate patterns 
Properdin 
 
AP Recognizes PAMP; stabilizes AP 
convertases 
Proteases  Pathway  Function 
C1r     CP 
 












Binds to collectins/ficolins; cleaves C2; 












Undefined; binds to MBL/ficolins; does 




































Table 1.5 continued  
Complement  
Components   
Pathway  Function  
C3 
 
CP/LP/AP Generates C3a, C3b, iC3b, C3dg, C3d; 
forms AP convertase and all C5 convertase 
C4 
 
















TP Assembly of C5b-9; initiation of pore 
formation  
C9 TP Assembly of C5b-9; undergoes 
polymerization for formation of lytic pore  





Binds C3b/iC3b/C4b/C4d; induces 






































Binds iC3b/C3c; induces phagocytosis; 











Binds C1q; induces phagocytosis; inhibits 





Binds C1q; induces phagocytosis 
 
 






1.10.2 Complement Activation by Antibodies  
1.10.2.1 The Classical Pathway (CP) 
The classical pathway of complement activation is dependent on circulating antibody 
bound to antigen. Antibodies provide the binding site for C1q (as part of the C1 
complex), which, as a pattern recognition molecule, also has the ability to bind 
pathogens either directly or indirectly via interaction with C-reactive protein (CRP) 
which has itself bound pathogens (Gaboriaud C et al 2004 152). Only IgG and IgM have 
the potential to bind to the globular domains of C1q resulting in full complement 
activation (Colvin RB et al., 2005 9). Binding of C1q to the Fc tail of the antibody, 
leads to activation of C1r and cleavage of C1s. C1s enzymatically cleaves C4 and C2 to 
form C4a, C4b, C2a, and C2b fragments. The soluble anaphylatoxin C4a and the small 
fragment C2b remain in fluid phase and diffuse away. The larger fragment C4b forms 
ester or amide bonds to nearby proteins or carbohydrates and with C2a, generates the 
C3 convertase, C4b2a (Murata K et al., 2009 153). With the formation of the C3 
convertase, the CP enters the common step of C3 activation which results in the 
cleavage of C3 to generate anaphylatoxin C3a and opsonin C3b. Addition of C3b to the 
C4b2a gives rise to the C5 convertase (C4bC2aC3b) and activation of the terminal 
pathway (Koscielska Karsprzak K et al., 2013 154). 
1.10.3 The Lectin Pathway (LP) 
Activation of the lectin pathway relies upon the recognition and binding of pathogen 
associated molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs) by lectin proteins. There are three main proteins associated with this pathway: 
mannose binding lectin (MBL) (Reid KB et al., 1994 155), ficolin-L and ficolin-H 
(Fujita T et al., 2004 156). However, ficolin-M which is a less well characterized 
protein, has been shown, like its other family members, to be capable of activating the 
lectin pathway (Liu Y et al., 2005 157). MBL and the ficolins are C-type lectins, 
composed of collagen and globular domains, similar to C1q. However, they form 
carbohydrate recognition domains (CRD) and bind to N-acetyl glucosamine and 
mannose structures (Carroll MC, 2004 158).  MBL along with the proenzymes MBL-
associated serine proteases, MASP-1 and MASP-2 (themselves resembling C1r and 
C1s) form a complex resulting in cleavage of C2 and C4. In a similar manner to the 
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events of the CP, the convertase C4b2a is formed leading to C3 and C5 cleavage 
(Ehrnthaller C et al., 2011 150). A third serine protease MASP-3 has been identified, 
but its role is less well defined. However, it has been associated with inhibiting MASP-
2-mediated cleavage of C4 and C2 (Dahl MR et al., 2001 159).  
Traditionally, the MBL pathway has not been associated with AMR, nonetheless there 
is evidence for MBL binding to IgM (McMullen ME et al., 2006 160) and some classes 
of IgG (Wasowska BA, 2010 94). The exact mechanism of how MBL binds to the 
carbohydrate portion of the antibody is not known (Wasowska BA, 2010 94). Evidence 
that alloantibodies activate complement through MBL has come from a murine model 
of AMR (Murata K et al., 2007 161). Results indicated that in MBL-KO mice C4d 
deposition (as a measure of complement activation) was decreased, even when animals 
were reconstituted with high doses of complement fixing IgG2a and IgG2b. These data 
support a role for MBL interacting with C1q resulting in the activation of complement. 
Data from human studies is limited, however a study in 2007 found a correlation 
between low serum MBL and superior graft survival (Berger SP et al., 2007 162). 
Finally, in humans co-localisation of C4d in kidney biopsies, with peritubular capillary 
ficolin-H and IgM (Imai N et al., 2006 163) as well as MASP-1 (Sund S et al., 2003 
164) suggest a possible link between MBL pathway and AMR.    
1.10.4 The Alternative Pathway (AP) 
The alternative pathway, similarly to the LP and in contrast with the CP, can proceed in 
an antibody-independent manner. It is activated by the recognition of specific structures 
such as the foreign cell membranes of bacteria, yeasts and viruses as well as CRP, 
polysaccharides and apoptotic tissue (Thurman JM et al., 2006 165). AP activation is 
initiated in plasma with the spontaneous hydrolysis of C3, (Muller-Eberhard HJ, 1988 
166). Through this fluid phase “tick over” mechanism, factor B becomes accessible to 
protease factor D. This cleavage generates Ba and Bb fragments. The latter (Bb) 
remains attached to C3(H2O) forming the alternative pathway convertase C3(H2O)Bb 
(Bexborn F et al., 2007 167). Properdin, a pattern recognition molecule itself, further 
stabilizes the convertase complex (Harboe M et al., 2008 168).   
The AP is highly relevant to transplant rejection whether alloantibody is present or not 
since complement can be activated on surfaces or in the fluid phase, by the 
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amplification loop (Lutz HU et al., 2006 169). Initial activation of the classical and 
lectin pathways gives rise to C3b, which along with factors B, D and properdin 
generates the convertase C3bBb. This results in more C3 cleavage (more C3b) and the 
generation of C5 convertase. Indeed, the majority of C3b is attributed to this mechanism 
of generation (Harboe M et al., 2004 170). The huge contribution of this loop is 
demonstrated upon analysis of the transplant biopsies where C4b and C3b products are 
detected more readily than alloantibody, even when titres are extremely high (Wehner J 
et al., 2007 81). More support for the crucial role of the alternative pathway in 
transplant rejection, comes from the fact that, undoubtedly, the classical and lectin 
pathways require engagement of the AP for effective tissue injury (Thurman JM et al., 
2006 165).  
1.10.5 The Terminal Pathway  
The final and common stage of all three activation pathways is the formation of 
membrane attack complex (MAC, C5b-9), also known as the terminal complement 
complex (TCC) which is responsible for complement’s lytic activity (Podack ER et al., 
1984 171). If complement activation proceeds beyond cleavage of C3, into C3a and 
C3b, then additional C3b binds to the C3 classical or alternative convertases. As a 
result, the C5 convertases formed by the CP and AP, C4bC2aC3b and C3bBbC3b 
respectively, are formed whose role is to cleave C5 into C5a and C5b. C5b marks the 
beginning of a protein assembly process leading to the initiation of the terminal pathway 
(Muller-Eberhard HJ, 1986 172). C5b along with complement components C6, C7, C8 
and C9 promote lysis and cell death. C9 is the prevalent molecule, since it undergoes 
polymerization to generate a pore-like structure deposited on affected surfaces (Cole DS 
et al., 2003 173). This tubular structure disrupts phospholipid bilayer surfaces either by 
creating a “leaky patch” (Esser AF, 1991 174), without forming a pore, or, the 
formation of a rigid hydrophilic channel (pore) penetrating the membrane and thereby 
disrupting the cell (Bhakdi S et al., 1991 175). In AMR, large amounts C5b-9 trigger 
disruption of vascular surfaces but sublytic amounts of C5b-9 can be enough to activate 
the endothelium. The latter can have more devastating effects than cell lysis itself 
(Wehner J et al., 2007 81).   
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1.10.6 Effects of the Complement System  
The main effector function of complement, being an important part of innate immunity, 
is defense against infections through proinflammatory responses, chemotaxis and 
opsonization (Ricklin D et al., 2010 176). In addition, complement not only initiates 
inflammation, but also clears it, by removal of immune complexes and apoptotic cells 
(Flierman R et al., 2007 177). Furthermore, acting as a bridge between innate and 
adaptive immune responses, it triggers and orchestrates B cell (Marsh JE et al., 2001 
178; Carroll MC, 2008 179) and T cell responses (Heeger PS et al., 2011 180). 
Extensive work has been carried out in our department signifying the fundamental role 
of complement in the T cell alloresponse (Pratt J et al., 2003 181; Peng Q et al., 2006 
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182; Zhou W et al., 2006 183; Sacks SH et al., 2012 184). Furthermore, it is now known 
that complement is a multifunctional system whose role extends far beyond pathogen 
clearance. Complement plays an important role in homeostasis, interacts with other 
biological systems, such as Toll-like receptors (TLRs) (Hajishengallis G et al, 2010 
185) and coagulation (Markiewski MM et al., 2007 186) and participates in tissue repair 
(DeAngelis RA et al., 2006 187) and metabolism (Raisz LG, 2001 188). The main 
effector mechanisms of complement are summarized in figure 1.7.  
 
1.10.7 Regulation of the Complement Cascade 
Complement is a potent network with multiple effector mechanisms that can be directed 
against the host. For that reason, it is crucial that its activity is tightly regulated as 
uncontrolled activation of the complement cascade would result in consumption of its 
factors, and lead to damage of healthy tissue. Evidence for this requirement is the 
existence of a large number of regulators, categorized into two classes; fluid phase and 
membrane bound regulators (Table 1.6) (Zipfel PF et al., 2009 151).  
 
1.10.7.1 Soluble Regulators   
A number of fluid phase regulators are found in human plasma. C1 inhibitor (C1-INH) 
inhibits both the classical pathway serine proteases, C1r and C1s as well as lectin 
pathway MASP-1 and MASP-2 (Ehrnthaller C et al., 2011 150). C4BP, with factor I 
(fI), inhibits both the classical pathway (CP) and alternative pathway (AP) convertases 
(Ricklin D et al., 2010 176). Factor H (fH) and the factor H-like protein 1 (FHL-
1/reconectin) act with fI to target the AP convertase by degrading C3b (a process known 
as cofactor mediated cleavage) or alone to remove the Bb fragment from the C3 
convertase (a process known as decay acceleration) (Józsi M et al., 2008 189). Upon 
cleavage, C3 and C5 anaphylatoxins are formed, which carboxypeptidase N rapidly 
inactivates to less active C3a desArg and C5a desArg respectively (Noris M et al., 2013 
190). Furthermore, factor H-related protein 1 (FHR-1) has a distinct function to fH. It 
targets the C5 convertase, and therefore inhibits the formation of MAC (Heinen S et al., 
2009 191). Similarly, clusterin and vitronectin (S-protein) target the terminal pathway 
by binding to C7 and C5b-9 respectively, thereby preventing MAC formation and 
integration into membranes (Noris M et al., 2013 190). It should be noted that, many of 
these fluid phase control proteins such as fH, FHL-1, FHR-1, C4BP, vitronectin and 
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clusterin are also found on cell surfaces to aid and maintain complement regulation 
(Zipfel PF et al., 2009 151). 
 
 




1.10.7.2 Membrane Bound Regulators 
Regulatory proteins attached to cells include membrane cofactor protein (MCP/CD46) 
which acts as a cofactor for fI and induces C3b and C4b cleavage (Thurman JM et al., 
2011 192). Decay accelerating factor (DAF/CD55) is another surface bound protein and 
it regulates complement activity by binding to C3b dissociating C2a from the CP and 
LP convertase and Bb from the AP convertase (Hourcade DE et al., 2002 193). CR1 
(CD35) is widely distributed on the surface of erythrocytes (RBC), leukocytes and 
kidney glomerular basement membrane and is considered to be the most powerful 
surface bound complement regulator. CR1 displays both decay acceleration as well as 
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cofactor activity for factor I. It promotes cleavage of C3b to iC3b, C3c and C3dg as well 
as C4b to iC4b, C4c and C4d (Kim DD et al., 2006 194). This is of particular 
importance since these fragments are ligands for cells with complement receptors CR1, 
CR2, CR3 and CR4. For this reason, endothelial injury mediated by complement is 
accompanied by extensive leukocyte infiltration which mediates phagocytosis and 
clearance (Murata K et al., 2009 153). CD59 (protectin) inhibits cell lysis by preventing 
polymerization of C9 for MAC formation and consequently the integration of pores into 
the cell membrane (Morgan BP, 1995 195).  
 
1.10.7.3 Rodent Complement Regulators 
The importance of complement regulator proteins in protecting the host from 
homologous complement attack is supported by a wealth of experimental data. This has 
resulted extensive knowledge of complement regulators in mice and rats. In mice, CR1 
is expressed by B cells, phagocytes and resting granulocytes and in contrast to humans 
it is not expressed by rodent T cells (Kinoshita T et al., 1988 196). Functionally, mouse 
CR1 has similar regulatory function to human CR1 acting as a C3 receptor thereby 
protecting host tissue from complement-mediated damage (Molina H et al., 1992 197). 
Furthermore, human CR1 is functional in rats as indicated by experiments using human 
soluble CR1 in a rat model to reduce immune complex-mediated vasculitis (Mulligan 
MS et al., 1992 198).  Interestingly, Molina H et al. identified a C3b-derived protein, 
p65, which is widely distributed in a variety of tissue such kidney, brain, lung, pancreas 
and skin (Molina H et al., 1992 197) as well as lymph nodes and expressed on 
peritoneal macrophages and erythrocytes (Li B et al., 1993 199). This additional 
molecule has identical biochemical properties to human regulatory DAF and MCP (Kim 
YU et al., 1995 200). It acts as a cofactor for factor I-mediated cleavage of C3b and C4b 
and targets the CP and AP convertases acting through decay-acceleration. This molecule 
was named Crry (Complement receptor 1-related protein Y) and it was also found to be 
expressed on platelets, neutrophils and endothelial cells (Quigg RJ et al., 1995 201). 
Crry in mice has been found to be involved in CD4
+
 T cell activation, acting as a co-
stimulatory molecule (Centero-Fernandez E et al., 2000 202).  
Rats and mice also express an analogue of human DAF (Hinchcliffe et al., 1998 203). In 
the rat, DAF is widely distributed on the endothelium, erythrocytes, platelets and B cells 
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as well as numerous organs such as the kidney, lungs, liver and spleen (Spiller OB et al., 
1999 204) and functions to inhibit complement across species. For example, rat DAF 
has been found to inhibit the CP-mediated haemolysis of antibody sensitised cells 
incubated with mouse or human sera (Harris CL et al., 2000 205).  
The rodent homologue of MCP has also been identified. Indeed, the structures for 
mouse and rat MCP are very similar (Mead R et al., 1999 206). Mouse MCP is 
expressed in testis whereas in rats it is found in testis and the acrosome of developing 
spermatozoa (Mizuno M et al., 2004 207). This contrasts with the more widespread 
tissue distribution of MCP in humans (Liszewski MK et al., 1992 208). Again, species 
cross-reactivity has been shown. Mouse MCP inhibits cell lysis by human complement 
(White DJ et al., 1992 209).  
Membrane bound CD59 has also been described in the rat. Tissue expression is similar 
to that in humans with wide distribution on all circulatory cells and endothelium of 
arteries, veins and capillaries. CD59 is also expressed in organs such as the liver, 
kidney, heart and lungs (Funabashi K et al., 1994 210). Expression of rat CD59 on 
Chinese hamster ovary (CHO) cells was able to successfully inhibit cell lysis in pig, 
rabbit or human sera. The degree of protection against human serum was highest 
showing minimum evidence for species selectivity (Rushmere NK et al., 1997 211). 
More recently, murine CD59 protein has been found to be encoded by two homologous 
genes, giving rise to CD59a and CD59b protein products. CD59a has a broad tissue 
distribution in contrast to CD59b which is found in the testis (Harris CL et al., 2003 








Table 1.6 Regulators of the complement cascade  
Soluble Regulators  Pathway  Function  
C1-INH (SERPIN 1) 
 




AP Cofactor for factor I; decay acceleration 
activity for C3 convertases 
FHL-1 (reconectin) 
 
AP Cofactor for factor I; decay acceleration 
activity for C3 convertases 
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AP   Inhbition of C5 cleavage 
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convertases 






















1.10.8 Complement Activation of Leukocytes and Endothelial Cells 
An important mechanism by which acute graft injury is mediated is the accumulation of 
inflammatory cells at the site of injury. The presence of neutrophils, monocytes and 
macrophages is typical of AMR (Murata K et al., 2009 153) and the release of large 
quantities of cytokines such as IL-1, IL-12, TNF-α and IFN-γ by activated leukocytes 
has been demonstrated in graft impairment (Jose MD et al., 2003 213; Sund S et al., 
2004 214). These events are largely the result of leukocytes and endothelial cells 
responding to the products of the complement activation cascade. 
Proinflammatory anaphylatoxins, C3a and C5a, are highly potent chemoattractants and 
their effects are mediated by the expression of surface receptors on leukocytes, C3aR 
and C5aR (CD88) (Haas PJ et al., 2007 215). A second receptor, C5L2, has also been 
found to bind C5a with high affinity, although its function remains controversial (Li R 
et al., 2013 216). C3a is spasmogenic and upon interaction with macrophages, 
prostaglandin E2 (PGE2) is released, inducing chemotaxis and cytokine production 
(Fischer WH et al., 1999 217). C5a, on the other hand, is considered to be the most 
potent anaphylatoxin of the two with additional functions to chemotaxis, such as 
influencing proinflammatory responses in leukocytes, promoting oxidative burst and 
phagocytosis (Mollnes TE et al., 2002 218).  
Initial activation of leukocytes by C3a and C5a induces upregulation of complement 
receptors CR1 and CR3. These receptors are specific for complement split products 
C4b, C3b, iC3b and C3d deposited on allografts further enhancing their opsonization 
(Wehner J et al., 2007 81). CR3, upon cytokine stimulation, has been shown to be 
involved in leukocyte trafficking and synapse formation (Ricklin D et al., 2010 176).       
Endothelial cells are activated directly by complement due to their expression of C3aR 
and C5aR, resulting in increased secretion of proinflammatory cytokines and 
chemokines (Saadi S et al., 2001 219). In vitro, C1q engagement on human endothelial 
cells stimulates the release of the chemokines MCP-1 and IL-8 (van den berg RH et al., 
1998 220). C3a and C5a effects on the capillary endothelium involve the production of 
cytokines (IL-1, IL-6), chemokines (CCL5, CXCL8) (Monsijon T et al., 2003 221) and 
also upregulation of adhesion molecules (E-selectin, ICAM-1, VCAM-1) (Jagels MA et 
al., 2000 222).   
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C5b-9 deposition has an additive effect to chemotaxis and adhesion, especially through 
its stimulation of IL-1, even at sublytic levels (Saadi S et al., 2000 223).  Endothelial 
cells activated by the MAC, elicit proliferation signals through secretion of PDGF and 
bFGF (Benzaquen et al., 1994 224).  
1.10.9 Complement and B cells  
Another mechanism, by which complement promotes an antigen-specific immune 
response, is the stimulation of B cells through their CR1 (CD35) and CR2 (CD21) 
receptors. Both CR1 and CR2 form the B cell co-receptor complex in association with 
CD19 and CD81 (Carroll MC, 2008 179). C3d opsonized antigen, bound to CR1 and 
CR2 on the B cell co-receptor, results in an enhanced signal. Co-ligation of 
CR/CD19/CD81 co-receptor with the B cell receptor lowers the threshold for B cell 
activation by several degrees of magnitude (Carroll MC, 2004 158). In this manner, C3d 
act as an adjuvant to the B cell response (Fearon DT et al., 1996 225). Thus, C3d 
deposition on cells, such as those expressing allogeneic HLA, acts as a positive 
feedback mechanism enhancing a pre-existing antibody response. The link between the 
complement system and B cell responses was further supported by experiments carried 
out using C3-deficient mice. These showed impaired allogeneic IgG responses when 
they received fully MHC mismatched skin grafts (Marsh JE et al., 2001 178). In 
addition, complement induces an antibody response through C5aR signalling on 
macrophages by upregulating the expression of activating FcγRI and FcγRIII, and 
downregulating inhibitory FcγRIIB (Shushakova N et al., 2002 226). Finally, follicular 
dendritic cells (FDC) are crucial for B cell immunity, as they also bear CR1 and CR2 
receptors. In this way, FDC can efficiently trap and retain C3d-coated antigen within the 
lymphoid follicles to support long term memory and antibody production (Fang Y et al., 
1998 228).   
1.11 Interplay between the Complement and Coagulation Cascades during Graft 
Rejection 
Complement and coagulation, although throught to be derived from a common ancestral 
pathway, have traditionally been considered to be two distinct cascades. However, there 
is increasing evidence for the extensive cross-talk between these two pathways, 
occurring at an early stage of inflammation (Amara U et al., 2010 228). Although this 
remains controversial, it is quite possible that, in most pathophysiological situations, 
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their activation takes place simultaneously resulting in the parallel expression of 
effector products. In this manner, these two pathways are able to support, amplify and 
even regulate each other, acting together in response to inflammation, aiming at 
restoring balance to a disturbed system (Markiewski MM et al., 2007 186). In contrast, 
it remains possible that one pathway precedes the other (traditionally, traditionally 
coagulation following complement activation, however this is now being questioned, as 
mentioned below). This topic remains controversial, with evidence supporting both 
hypotheses.  
Communication between the complement and coagulation cascades appears to be 
extensive (Figure 1.8), which may be of no surprise considering the similarities they 
share. First of all, both systems act in response to an inflammatory stimulus and both act 
locally where altered or (in the case of rejection) foreign surfaces cause their activation. 
Furthermore, it is of pivotal importance, that both cascades have an initiation and 
amplification stage. Indeed, interactions with target cells, or directly with each other, 
often results in amplification of one system by the other. Finally, the potency of these 
serine protease cascades is evident by the fact that both of them require tight regulation 
by a variety of control molecules. If present at the same time, this can result in 















* blue-coloured lines refer to amplification of complement by coagulation, red-coloured 
lines refer to amplification of coagulation by complement and dotted lines refer to 
inhibitory actions of the pathway.  
 
1.11.1 Coagulation initiating the Complement Cascade 
Although both systems respond rapidly at the site of inflammation, the concept of 
coagulation potentially initiating complement has recently been addressed and 
supported by an extensive body of work. This evidence challenges the dogma that it is 
complement activation that invariably is responsible for the activation of coagulation 
cascade. It is well recognised that clotting factor XIIa is capable of initiating the C1 
complex formation, thereby activating the complement classical pathway (Ghebrehiwet 
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B et al., 1981 230), the primary pathway involved in AMR. In addition, it is interesting 
that, C1-esterase inhibitor not only inhibits all three complement pathways, but also 
inhibits the intrinsic coagulation cascade (Davies AE 3
rd
, 2004 231). These two 
observations reveal the close interaction of the two cascades, as well as the necessity to 
control complement early in its activation cascade, well before the convertase 
formation.  
Particular interest has derived from the ability of certain coagulation enzymes to directly 
cleave C3 and C5 revealing a bypass mechanism for complement activation. In vitro 
studies showed that thrombin, plasmin, factors IXa, Xa and XIa were all able to cleave 
C3 and C5, giving rise to anaphylatoxins with competent chemoatraction abilities 
(Amara U et al., 2010 228). These results have been additionally supported by liver 
studies, in which thrombin and plasmin were capable of activating C3 in experimental 
systems where all three complement activation pathways had been disrupted (Clark A et 
al., 2008 232). Finally, in a lung injury model, using C3
-/-
 mice, thrombin was able to 
directly cleave C5 and generate biologically active C5a anaphylatoxin (Huber-Lang M 
et al., 2006 233).  Krisinger et al. extended these studies by identifying a new site where 
thrombin cleaves C5, and confirming the strong lytic activity of C5b-9 generated by 
thrombin cleavage (Krisinger MJ et al., 2012 234).  
Additionally, thrombin may indirectly interfere with complement activation through its 
ability to activate platelets. Thrombin, is considered one of the most potent stimulators 
of platelets and therefore essential for secondary haemostasis. Platelets, although 
somewhat ignored in the field of graft rejection, have been of increasing interest since 
they influence complement activation by expressing receptors for C1q. Upon binding 
C1q, the initiator of the classical pathway of complement activation, P-selectin 
expression is induced which binds C3b. Through this interaction, platelets prolong the 
lifespan of the C3b (Ekdahl KN et al., 1999 235) and activate the alternative pathway 
(Nilsson-Ekdahl K et al., 2001 236).  Thus, the activation of platelets by thrombin leads 
to complement activation and complement-mediated injury.  
Finally, at sites where both cascades are activated, it has been shown that thrombin 
activation of PAR-1 negatively regulates complement activation by inducing DAF 
expression, in diseases such atherosclerosis and vasculitis (Lidington EA et al., 2000 
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237). In addition, although TAFI is associated with inhibition of fibrinolysis, it can also 
inactivate C3a and C5a (Oikonomopoulou K et al., 2012 229).    
1.11.2 Complement initiating the Coagulation Cascade  
Although the above evidence strongly suggests an initiating role for the coagulation 
cascade, extensive data support the procoagulant properties of complement, which may 
therefore precede the coagulation pathway. Recently, the MBL pathway has been 
implicated in a novel role in activation of the clotting cascade. In an animal model of 
arterial thrombosis, MASP-1/-3 knockout (KO) mice had significantly reduced 
thrombogenicity, with MASP-1 in particular exhibiting thrombin-like activity (La Bonte 
LR et al., 2012 238). Krarup et al showed similar findings, using C3
-/-
 mice, in which he 
was able to demonstrate the ability of MASP-2 to activate prothrombin in a similar 
manner to fXa (Krarup A et al., 2007 239).  
However, possibly the most significant studies showing profound activation of 
coagulation by complement involve C3a and C5a. C3a and C3a desArg can directly 
induce platelet adhesion and aggregation (Volanakis JE et al., 1989 240). C5a, on the 
other hand, has multiple effects on both endothelial and inflammatory cells. C5a has the 
ability to modulate endothelial cell surfaces to favour clot formation. C5a in 
combination with alloantibodies on the endothelial surface promotes the shedding of 
heparan sulfate, which is responsible for the preservation of an anti-coagulant 
environment (Platt JL et al., 1991 241).  This finding has been strongly associated with 
HAR and AMR (Colvin RB et al., 2005 9). C5a enhances the propensity for 
intravascular thrombosis not only by inducing TF on endothelial cells (Ikeda K et al., 
1997 242), but also on leukocytes (Muhlfelder TW et al., 1979 243). Furthermore, C5a 
causes upregulation of PAI-1 on leukocytes, which abolishes the enzymatic activity of t-
PA (Wojta J et al., 2002 244). It also induces IL-8 on endothelial and blood cells, and 
IL-6 on platelets which strongly promotes fibrin formation (Guo RF et al., 2004 245). 
C5a thereby shifts the balance towards a procoagulant clot forming phenotype.  
The formation of MAC (C5b-9) reinforces activation of the coagulation cascade since 
stimulation of platelets with C5b-9 results in further activation of platelets by release of 
their granules (Ando B et al., 1988 246) and TF bearing MPs (Sims PJ et al., 1988 247). 
Since platelets are the primary surface at which the prothrombinase complex occurs, 
MAC interactions propagate thrombin generation. Finally, MAC deposition on 
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endothelial cells disrupts the monolayer exposing the subendothelium to the blood, 
initiating coagulation (Bossi F et al., 2004 248).    
Complement can positively regulate coagulation where C4BP has been deposited onto 
affected surfaces. Here C4BP forms a complex with Protein S, a cofactor for the 
anticoagulant APC system. This binding results in the loss of its cofactor ability, 
therefore decreasing Protein C inhibitory activity. As a result, complement can be 
responsible for increasing the tendency for thrombus formation (Dahlbäck B et al., 2005 
141).   
 
 
In conclusion, it is clear that antibodies against antigens on transplanted organs are a 
serious obstacle to short and long term graft survival. AMR is a dynamic process which 
is characterized by complement activation as well as complement-independent 
mechanisms. As a result, antibody-mediated mechanisms such as endothelial activation, 
inflammatory alterations and intravascular coagulation make AMR a complex challenge 
to overcome, and therefore the optimal strategy for effective prevention has been far 
from clear. The effector mechanisms involved in humoral rejection are summarized in 




Figure 1.9 Diagram illustrating the major antibody-mediated processes leading to graft rejection 
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1.12 The Role of T cells in Clinical Transplantation 
Cellular rejection involving T cells is the most common form of allograft rejection. 
Cellular rejection is initiated through the process of allorecognition, where T cells 
recognize donor antigen (major and/or minor histocompatibility) (Ingulli E, 2010 249). 
Allorecognition and priming of recipient T cells is mediated through three distinct 
pathways. The direct pathway involves the donor’s antigen presenting cells (APCs) 
carrying intact alloantigen from the graft to the recipient’s secondary lymhoid organs, 
where alloreactive T cells respond to it (Nankivell BJ et al., 2010 30). These donor-
derived APCs exist in limited numbers and eventually, although the direct pathway is 
responsible for the initiation of rejection, the indirect pathway of allostimulation is 
thought to take over in maintaining the donor-specific T cell response. Through the 
indirect pathway, the recipient’s APCs present peptides from degraded donor MHC 
contributing to the activation of T cells and destruction of the graft. Eventually the 
indirect pathway will be the dominant pathway of allostimulation and it occurs for as 
long as the organ remains in situ (Wood KJ et al., 2012 250). This pathway is associated 
with chronically rejected grafts (Ingulli E, 2010 249). Finally, a more recently defined 
pathway of allorecognition, is the semi-direct pathway in which the host’s APCs acquire 
and present intact donor MHC-peptide complexes as well as presenting domor peptides 
on their on MHC (Afzali B et al., 2008 251).      
As a consequence of allorecognition, activation of alloreactive T cells occurs.  This 
process is mediated by two signals: signal 1 is antigen specific and results from the 
engagement of the T cell receptor (TCR) with a MHC-peptide complex. Signal 1 on its 
own is not enough for full activation, for which a second signal is needed. Signal 2 
results from a series of costimulatory molecules binding their ligands. CD28 is the best 
defined costimulatory molecule on T cells and binds members of the B7 family (CD80 
and CD86) expressed on APCs. Signalling through CD28 is of pivotal importance since 
it lowers the threshold for T cell activation, is responsible for the release of cytokines 
for proliferation and resistance to apoptosis (Wood KJ et al., 2012 250). T cells also 
express CD154 (CD40L) which is the ligand for CD40, expressed not only on APCs 
(Ridge JP et al., 1998 252) but also B cells. The interaction of CD154 and CD40 on B 
cells is necessary for T-dependent B cell activation, B cell differentiation and antibody 
production (Tarlinton DM et al., 2008 253). CTLA-4 (CD152) is transiently expressed 
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on T cells, however, its ligation to the B7 molecules delivers an inhibitory signal 
(Walunas TL et al., 1996 254).  Its tightly controlled surface expression is critical to 
regulating T cell immunity.   
Following activation, T cells proliferate and differentiate into subsets with distinct 
cytokine signatures. CD4
+ 
T helper cells may largely be defined as being Th1 or Th2, 
however many other helper subsets exist such as Th17, Th9 and Tfh (follicular helper 
cells). The characteristic Th1 cytokine is IFN-γ whereas the Th2 subset secrete IL-4, IL-





T cells with a suppressing role, regulatory T cells (Tregs). Tregs 
(naturally occurring or induced) may generate and maintain a state of tolerance in vivo 
(Wood KJ et al., 2003 255).  
Following this elaborate process by which naïve T cells pass from the circulation to the 
secondary lymphoid organs, become activated and differentiate into effector T cells, 
they migrate to the transplanted tissue. This movement to the graft requires a variety of 
chemokines and integrins (such as LFA-1) binding to adhesion molecules on the graft 
endothelium (such as CD54/ICAM-1). These interactions facilitate the rolling and the 
tethering of alloreactive T lymphocytes (Briscoe DM et al., 1998 256). T cells 
extravasate through the endothelium, infiltrate the interstitium and in the case of a 
kidney transplant, invade the renal tubules (Robertson H et al., 2003 257).   
T cells cause the destruction of the transplanted organ via two mechanisms: delayed 
type hypersensitivity (DTH) and CD8
+ 
mediated cytotoxicity. DTH involves CD4
+ 
helper T cells (Th) releasing highly proinflammatory cytokines such as IFN-γ. This 
results in the influx of monocytes, macrophages, neutrophils and eosinophils. Th 
lymphocytes are also responsible for the production of activating mediators such as 
nitric oxide (NO), reactive oxygen species as well prostaglandin E2 and thromboxane 
(Wood KJ et al., 2012 250). Furthermore, activated alloreactive CD8
+ 
T cells release 
cytotoxic molecules, granzyme B and perforins, upon identification of their target 
antigens. Killing is mediated by inducing apoptosis (Barry M et al., 2002 258).   
1.13 Immunosuppression  
Due to the recipient’s alloresponse to the graft, organ transplantation between non-
identical individuals generally cannot be successful in the absence of aggressive and 
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continuous immunosuppression (Table 1.7). The immunosuppressive regimen used may 
differ according to the transplant centre and over time to provide an ideal balance 
between preventing the alloresponse whilst maintaining the ability to fight infection and 
malignancy. Furthermore, different immunosuppression may be used as induction and 
maintenance at the time of transplantation and thereafter. Absence of 
immunosuppression in these circumstances will lead to the destruction of the graft. 
Allograft failure can occur due to immunological and/or non immunological reasons. 
Immune causes involve acute and chronic rejection, mediated by HLA differences 
between the donor and recipient (Vathsala A, 2005 259). The identification and 
minimization of HLA disparities as well as the use of potent immunosuppression has 
enabled excellent outcomes following acute rejection. In contrast, although early renal 
failure has become rare, late graft loss still remains problematic (Hardinger KL et al., 
2013 260). In addition, non immunological complications, such as ischaemia, 
malignancies, hypertension, infections and calcineurin inhibitor toxicity compromise the 
success of long term accepted grafts (Vathsala A, 2005 259).  
An area which still provides an obstacle to successful transplantation, especially in 
chronically failed organs, is humoral rejection. AMR is difficult to treat because the 
mechanism is only partially understood, as reflected in the poor response to 
conventional immunosuppressive drugs (Hardinger KL et al., 2013 260) Typically, 
AMR is treated with plasmapheresis, intravenous immunoglobulin (IVIG) and 
Rituximab. However, further options are needed further investigation as long term 
effects regarding toxicity and efficacy are still unclear. Several clinical trials have 
focused their attention on complement with particular interest in Eculizumab. 
Eculizumab is a humanized monoclonal antibody which binds and blocks the activity of 
the complement protein C5. Eculizimab has been successfully used in the treatment of 
atypical haemolytic uremic syndrome (aHUS) (Châtelet V et al., 2010 261) and 
thrombotic microangiopathy (Chadran S et al., 2011 262). In solid organ 
transplantation, the successful use of Eculizumab has been reported in a small number 
of cases of AMR in patients with high DSA (Lonze BE et al., 2010 263; Stegall MD et 
al., 2012 264). Despite the promising effects shown by eculizumab, it also has 
drawbacks as it is administered systemically, causes a number of side effects such as 
nausea, fatigue, headaches, infection (Hardinger KL et al., 2013 260) and it has been 
involved in fatal immune haemolytic aneamia (Rovira J et al., 2013 265). 
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A particular issue in the clinic has been the rise in the number of sensitised renal 
patients requiring transplantation. These transplants have been made possible by the 
introduction of increasingly aggressive immunosuppressive regimens: although 
sensitised recipients no longer lose their graft to HAR, their high DSA levels contribute 
to acute rejection episodes and associated long-term damage to the kidney. For these 
graft recipients intense desensitisation protocols are undertaken to avoid HAR, 
including plasmapheresis, IVIG and suppression of B cells and plasma cells. This 
process is not only time-consuming and costly, but the long term results are not yet 
certain. In addition, due to their high risk of AAMR, pre-sensitised patients tend to 
remain on the transplant list for a long time and may die while waiting for a suitable 
graft. These people constitute as one-third of the kidney transplant waiting list. Even if a 
suitable donor is found the incidence of acute rejection remains high, maybe up to 60%. 
In the UK, the average waiting time before receiving a donor kidney is 1156 days (3 















Table 1.7 Main immunosuppressive agents   
Drugs Mechanism of Action  
Prednisolone 
(induction/maintenance) 
Corticosteroid; down-regulates T cell and APC 
cytokine and cytokine receptor expression  
Cyclosporine (CsA) 
(maintenance) 












Anti-proliferative; Prodrug for mercaptopurine; 
inhibits purine biosynthesis and CD28 signalling 
Sirolimus (Rapamycin) 
(maintenance) 
Anti-proliferative; A inhibitor of the mammalian 
target mTOR; inhibits IL-2 responses  
Everolimus 
(maintenance) 




Chimeric mouse-human monoclonal antibody against 
IL-2 receptor (CD25); blocks B7-CD28 signalling 
Anti-thymocyte globulins  
(ATG) (induction) 
Polyclonal rabbit antibodies against T cells  
Alemtuzumab (Campath 
1H) (induction) 
Humanised monoclonal antibody against CD52; 
depletes T- and B-lymphocytes  
Intavenous 
immunuglobulins (IVIG) 
(induction)     
Polyclonal antibodies against T cells. 
     
For this reason, more research is needed to develop anti-rejection therapy that better 
balances the risks and benefits. An ideal immunosuppressive strategy would 
successfully improve long term acceptance of the graft but limit the systemic toxicity 
and risk of infection in the transplant recipient which remain a major cause of morbidity 
and mortality, especially in this disadvantaged and common group.   
1.14 Current Status of AMR and Animal Models  
Interest in the role of antibodies in graft rejection dwindled after decades of research 
which demonstrated that alloreactive T cells were an essential and common cause of 
rejection episodes together with the fact that HAR could largely be avoided by not 
transplanting those patients with DSA and high risk of HAR. However, interest in the 
role of antibodies was re-ignited following the observation that a small number or renal 
biopsies exhibited features of “pure” AMR (Halloran PF et al., 1990 266). 
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Subsequently, increased acknowledgment of alloantibodies contributing to graft injury 
resulted in the terms “acute” and “chronic antibody-mediated rejection” incorporated in 
the Banff classification in the beginning of 2000 (Durlik M, 2013 267). Indeed, AMR 
appears to be one of the main factors in acute and chronic rejection with both de novo 
and preformed antibodies actively participating in the process.  
Animal models have contributed to our understanding of AMR in a number of ways. 
Using immunoglobulin (Ig) KO mice, in a cardiac transplant model, Murata K et al. 
were able to demonstrate that complement was secondary to alloantibody production, 
such that deposited C3d and C4d were absent from grafts in KO mice compared to their 
transplanted wild type counterparts (Murata K et al., 2007 161). With the same model, 
passive transfer of antibody against donor MHC restored complement activation and led 
to graft rejection (Wasowska BA et al., 2001 268).  
Studies in mice with specific deficiencies in complement have further illuminated the 
role of complement in AAMR (Winn HJ et al., 1973 269) although it should be noted 
here that a number of wild type mouse strains have complement deficiencies (e.g. C5 
deficiency in A/J, AKR, B10D2, and DBA/2) which should be taken into account when 
interpreting the results (Chong AS et al., 2013 270). In addition, research into HAR 
using xenotransplantation models has been informative, in particular regarding the role 
of complement regulatory proteins and their ability to protect endothelial cells from 
antibody-mediated damage (Morgan BP, 1995 271). McCurry KR et al. developed 
transgenic swine expressing human DAF and CD59 proteins, and achieved prolongation 
of survival and reduced vascular injury of swine hearts transplanted into non-human 
primates (McCurry K R et al., 1995 272). These findings were further enhanced by 
reports that cardiac allografts lacking DAF were vulnerable to HAR in the presence of 
low anti-α1.3Gal antibodies against wild type hearts (Shimizu I et al., 2006 273). 
Interfering with complement not only protects from aggressive humoral responses but 
has also provided evidence about the poorly understood mechanism of accommodation. 
In a xenotransplant model where hamster hearts were grafted into rat recipients, 
inhibition of MAC not only prevented HAR but also achieved a state of accommodation 
of these grafts (Suhr BD et al., 2007 274).  
Allotransplantation in pre-sensitised rodents has done much to increase the 
understanding of the potential for complement regulation in HAR of donor hearts and 
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kidneys. Particularly promising results have been generated in models of both rats and 
mice that were pre-sensitised with donor skin (a powerful method for inducing 
alloantibody responses) prior to organ transplantation.  This revealed that inhibition of 
the terminal complement components can afford protection of the transplanted organ 
against acute and hyperacute rejection in both rats (Brauer RB et al., 1995 275) and 
mice (Wang H et al., 2007 276; Rother RP et al., 2008 277), confirming data from 
xenotransplant models. So, rodent allotransplant models reproducing some of the most 
aggressive types of AMR are amenable to intervention using modulators of the innate 
immune response in the presence of alloantibody.   
These results set the stage and direction for the research described in this thesis. The 
aim was to establish an appropriate rodent model in which to study HAR and determine 
the effects of localised inhibition of the complement (and coagulation) cascades. 
Whereas previous studies have used systemic anti-complement therapy often given in 
repeated doses, the aim was to avoid systemic or sustained disruption of the innate 
immune response, in order to minimize dangerous side effects including the risk of 
infection.   
1.15 The Development of Localised Complement and Coagulation Regulators for 
Therapeutic Use 
 
1.15.1 Membrane-Targeted Complement Regulator Mirococept (APT070) 
Mirococept, also known as APT070, is a derivative of the natural regulator complement 
receptor 1 (CR1; CD35). CR1 is expressed on the surface of a variety of cells including 
peripheral blood cells (erythrocytes and lymphocytes) and plays a key role in immune 
clearance and complement inhibition at the cell surface (Roozendaal R et al., 2007 278). 
CR1 is a 160-250 kDa glycoprotein which is composed of numerous short consensus 
repeat domains (SCRs), a transmembrane and a cytoplasmic domain (Ahearn JM et al., 
1989 279).  The most common allotype, the A-allotype, is composed of 30 SCRs and 
within this structure there is an internal homology with long homologous repeats (LHR) 
every seven SCRs (Klickstein LB et al., 1987 280) (Figure 1.10A).   
  
An alternative, recombinant form of CR1 which is soluble in plasma (Yoon SH et al., 
1985 281) has been produced by gene transfection of Chinese Hamster Ovary (CHO) 
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cells (Weisman HF et al., 1990 282). The soluble human CR1 (sCR1) has been used 
successfully in a non-sensitised rat kidney transplant model of allograft rejection with 
limited mismatch between donor and recipient. In this model systemic administration of 
sCR1 reduced the level of vascular rejection (Pratt JR et al., 1996 283) and influenced 
primary alloantibody responses (Pratt JR et al., 1997 284).   
Mirococept is produced by expression in Escherichia Coli with the potential for large 
amounts of protein to be generated (Dodd I et al., 1995 285). Mirococept, is not a 
traditional biopharmaceutical product, because it is not fully encoded by the gene with a 
synthetic tail incorporated into the agent by post-translational modification. Mirococept 
is a CR1 based chemically modified recombinant protein which is significantly smaller 
(24 kDa), than the native protein. It comprises the first three N-terminal short consensus 
repeats (SCRs) of human CR1 and a synthetic membrane-binding tail. More 
specifically, sCR1-3 of LHR-A is attached to a C-terminal cysteine, to enable it to be 
chemically linked to the membrane targeted tail. The design of the tail is such that it 
offers a two-site interaction with the phospholipid bilayer. The membrane inserting 
myristoyl forms hydrophobic interactions whereas a positively charged peptide 
sequence allows electrostatic interactions to occur with the negatively charged 
phospholipid bilayer (Figure 1.10B). As a result, haemolytic assays have shown that this 
cytotopic therapeutic has a 100-fold increased potency compared to the CR1 parent 
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Figure 1.10A: Structure of human CR1, B: Structure of Mirococept (Smith RAG, KCL) 
 
There are distinct advantages to this cell membrane targeted therapeutic technology, 
especially when trying to inhibit inflammation which is organ specific. It enables the 
interference of fluid-phase complement activation to be avoided (Mollnes TE et al., 
2006 287). This approach targets complement inhibition by introducing the therapeutic 
regulator into the donor organ where it remains bound and so does not put the recipient 
at risk of infections. The fact that Mirococept is a lot smaller than CR1 allows it to bind 
more effectively to the cell surface with a dissociation constant that is lower than the 
native molecule’s (Inflazyme Pharmaceuticals, research report 2005). 
Mirococept has been extensively used and found to have cytoprotective effects in 
various animal models. The first in vivo study of Mirococept was in a rat model of acute 
vascular shock in which 80% of rats injected, intravenously, with a rabbit antibody, 
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died. Treated rats showed dose dependent effects of Mirococept ultimately with 100% 
survival (Smith RAG, 2002 286). Other studies investigating the benefits of Mirococept 
therapy have included models of experimental rheumatoid arthritis in the rat (Linton SM 
et al., 2000 288), and myocardial infarction in pigs (Banz Y et al., 2007 289). Most 
importantly, Mirococept has been found to be effective in improving outcome in renal 
transplantation. In a mild model of rat transplantation between Fischer and Lewis rats, 
Mirococept prolonged survival with a marked reduction in leukocyte infiltration (Pratt 
JR et al., 2003 290). Finally, in a study where rat kidney isografts were used, intra-renal 
delivery of Mirococept protected the donor kidney from fatal ischaemia/reperfusion 
injury (Patel H et al., 2006 291). In humans, Mirococept has successfully completed 
Phase 1 (safety/tolerance trials) (study report ME0579, KCL, unpublished) and Phase 2a 
pilot (Smith R/Sacks S unpublished data) studies. It is imminently to be used in a 
multicentre clinical trial in which the donor kidney grafts are treated with the reagent 
prior to transplantation to try and reduce ischaemia/reperfusion injury and delayed graft 
function (DGF) in transplant patients.      
1.15.2 Membrane-Targeted Coagulation Regulators (PTL006, Thrombalexin-
PTL004) 
Using the same principle applied for the production of Mirococept (previously 
described) and other targeted therapeutics, a series of membrane-associated 
anticoagulants have been generated from a minimised form of hirudin. Hirulog-like 
peptide (HLL), a specific thrombin inhibitor, is isolated from the salivary glands of 
European medicinal leeches Hirudo medicinalis (Fenton JW 2nd et al., 1991 292). 
Thrombin is generated from prothrombin and it has multiple and diverse roles in 
coagulation, inflammation and wound healing. The product of activation is α-thrombin 
which has high fibrinogen clotting activity as opposed to β- and γ-thrombins (Fenton 
JW 2nd et al., 1991 293). Hirudin is a direct bivalent thrombin inhibitor and interacts 
with α-thrombin at two sites: the main classical active site (the catalytic site) and a 
unique, remote exosite (recognition site) which functions independently to the active 
site. Thrombin has multiple recognition domains, however, the structure of hirudin 
complements that of the fibrinogen recognition site (FRS) (De Cristofano R et al., 2003 
294). The FRS is recognized by a variety of protein ligands including fibrinogen, PAR-
1 on a variety of cells, heparin cofactor II, thrombomodulin (TM) and coagulation 
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factors V, VIII and XIII (De Cristofano R et al., 2003 294). The recognition site is 
critical for the enzyme’s efficient recognition and interaction with substrates and 
inhibitors and thereby pivotal to thrombin’s role in a variety of biological responses 
(Bode W et al., 1997 295).  
Following this multi-point ligand structure, the therapeutics PTL006 and PTL004 were 
generated as part of a series of cytotopic anticoagulants prepared by solid phase 
synthesis. They vary in the nature of their membrane binding tail as will be discussed. 
The HLL peptide has been C-terminally coupled to a membrane binding tail to create a 
conjugate.  PTL006 has a molecular weight of 5.3 kDa and it binds the cell membrane 
phosholipid bilayer via a synthetic tail containing a polyethylene glycol (PEG)-modified 
phospholipid (Figure 1.11). Two fatty acyl groups are also present to ensure stable 
insertion into the phospholipid bilayer. Binding of PTL006 to the cell surface relies on 
hydrophobic interactions between the tail and phospholipid bilayer 
 
 
Figure 1.11: Structure of PTL006  
 
 










Thrombalexin (PTL004), with a molecular weight of 4.6kDa, is composed of the HLL 
peptide with a disulphide link to a bis-myristoyl tail (Figure 1.12). The tail participates 
in both electrostatic and hydrophobic interactions with the cell membrane in a similar 
manner to Mirococept. The extra myristoyl group potentially results in a stronger 
interaction with the bilayer increasing stability at the cell surface.  
Both of these novel therapeutic cytotopic (modified proteins hich bind cell surfaces) 
reagents have shown great promise in vitro. PTL006 was successfully able to 
incorporate into the cell surface of endothelial cells and at the same time inhibit TNF-α-
induced TF expression. These cells effectively lost their procoagulant ability (Dorling 
A, unpublished data). Furthermore, in a cellular inhibition assay it was found that when 
red blood cells coated with either of the derivatives of tailed HLL, not only was 

















Figure 1.12: Structure of PTL004  
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These data demonstrate a potential for blocking thrombotic activity in transplantation 
cases where coagulopathy is associated with graft rejection. This thesis describes the 























Endothelial cell protection afforded by anchored therapeutic complement and/or 
coagulation regulators introduced into the donor kidney circulation will ameliorate graft 
loss associated with HAR. This will provide useful insight into the relative contribution 
of the complement and coagulation pathways in HAR. The data generated by this work 
will facilitate the transfer of the named inhibitors for the first studies in man. Hopefully 
this will ultimately contribute to better renal transplant outcomes in pre-sensitised 
patients.    
1.17 Aims  
The aims of my study were as follows:  
Chapter 3: To establish a rat renal allograft model of hyperimmune antibody-mediated 
rejection using MHC class I and II disparate donors and recipients.  
Chapter 4: To confirm both Mirococept inhibitory function in vitro and membrane 
binding ability in vivo. To test the ability of this membrane-targeted complement 
inhibitor to prevent rapid graft rejection in pre-sensitised recipients.  
Chapter 5: To investigate the in vivo activities of PTL006. More specifically, to 
determine the optimal dose of PTL006 that achieves maximal anti-coagulant activity, 
with minimal complications in the rat model.  Confirm the binding of PTL006 to cell 
membranes in vivo. To investigate the synergistic effect of the membrane-targeted 
complement (Mirococept) and coagulation regulator (PTL006) to prevent HAR in pre-
sensitised recipients 
Chapter 6: To test the ability of the membrane-targeted coagulation regulator PTL004 
(Thrombalexin), to prevent rapid graft rejection in pre-sensitised recipients.  To test the 
additive effect of standard T cell immunosuppression (Cyclosporin/Rapamycin) with 





Chapter 2 – Materials and Methods  
 
2.1 In vivo Experimental Procedures 
2.1.1 Animals  
All animals were purchased from Charles River (Kent, UK). Animals utilized in this 
project were inbred male DA (RT1
a
) rats used as skin donors, kidney donors and 
recipients. Inbred male Lewis (RT1
i
) rats were used only as transplant recipients. Third 
party controls were Sprague Dawley (SD, outbred). Due to differences in size, the 
naturally larger Lewis rats were ordered as young as possible (150 g) at the initiation of 
the pre-sensitisation period. DA rats were ordered at simultaneously at 200 g to 
maximize their weight at the time of kidney transplantation. Animals had free access to 
standard rat chow and water. All procedures were carried out in accordance with a 
Home Office license for animal experimentation.   
2.1.2 Pre-sensitisation of recipient Lewis rats by DA tail skin Transplantation 
Prior to transplantation, Lewis recipients were pre-sensitised by sequential grafting of 
three full thickness tail skin segments (~2 cm
2
) from DA donors. All rats were 
anaesthetised by inhalation of oxygen and isoflurane (Nicholas Piramar Ltd, distributed 
by IVAX Pharmaceuticals). The donor tail skin segments were placed in saline-soaked 
gauze at 4ºC while the recipients were prepared. A same size skin section was removed 
from the dorsal side of the recipient. The skin graft was held in place by applying a skin 
adhesive gel (Germolene New Skin, Boots), which was covered with a paraffin-coated 
dressing (Jelonet, Smith&Nephew, UK) and bandaged for seven days, after which the 
bandages were removed. Rejection was monitored by observation and defined as total 
necrosis of the tissue. The first two skin transplants were two weeks apart which was 
followed by a four week rest period. The third and final skin transplant was then given 




2.1.3 Therapeutic Agents  
The following reagents were kindly provided by Dr Richard Smith (KCL, London):    
APT070 (Mirococept): This complement inhibitor comprises of a recombinant SCR1-3 
of a human CR1 modified with a cytotopic peptide APT542. Mirococept was prepared 
on a large scale under cGMP conditions for clinical trials by Avecia Ltd (now Fujifilm 
Diosynth), Billingham, UK. 
APT542: The tail of APT070 is made up of a N-(myristoyl)-GSSKSPSKKKKKKPGD-
(S-2-thiopyridyl)-Cys-carboxamide sequence.  
APT154: This denotes soluble untagged SCR1-3 which retains inhibitory activity in 
solution. 
PTL006: This coagulation inhibitor is a conjugate of the 23 aminoacid hirudin-derived 
peptide (Hirulog/HLL).  
H-(D) FPRPGGGGDGDFEEIPEEYLGGC-amide with a membrane-inserting tail of 
DSPE-PEG (2000) PDP [1.2distearoyl-sn-glycero-3-phosphoethanolamine-N-PDP 
(polyethelene glycol)-2000] (Avanti Pharmaceuticals).  
PTL006-FAM: Inactive form of PTL006, labeled at the N-terminus of the peptide with 
FAM (carboxyfluorescein).   
 
PTL004 (Thrombalexin): Coagulation inhibitor comprising of a 23 amino acid 
hirudin-derived peptide (Hirulog/HLL) linked to the membrane-localizing tail (bis-
myristoyl). 
Structure: H-(D) FPRPGGGGDGDFEEIPEEYLGGC-amide with N-(bis-myristoyl)-
KSSKSPSKKDDKKPGD-(S-2-thiopyridyl)-Cys-carboxamide.  
Peptides were prepared by Cambridge Research Biochemicals, Billingham, UK. 
 
 
All reagents were perfused in Soltran kidney perfusion solution (Baxter Healthcare Ltd). 
This composed of: 
 
Potassium Citrate         8.6 g 
Sodium Citrate 8.2 g    
Mannitol 33.8 g  





2.1.4 Renal Transplantation 
The technique used was adapted from a previously published method (Fabre J et al., 
1971 296) and is life-sustaining when performed between syngeneic or allogeneic 
donors and recipients, due to nephrectomy of the native kidneys. All rats were 
anaesthetised by inhalation of oxygen and isoflurane (Nicholas Piramar Ltd, distributed 
by IVAX Pharmaceuticals).  
2.1.5 Donor Preparation  
Donors and recipients were prepared simultaneously so that there was no cold ischaemia 
time. To enable this to happen, all donors were prepared by Dr Conrad Farrar as I 
prepared the recipients and subsequently carried out the perfusion and renal transplant 
procedure. DA rats were used as kidney donors.  For the donor preparation, a warm heat 
mat was placed underneath the animal to maintain a constant body temperature. A 
midline laparotomy was performed isolating the left kidney, the renal vein and artery, 
aorta and inferior vena cava (IVC). All arterial branches from the aorta and artery were 
tied off using 7/0 braided silk wax sutures (Pearsalls Ltd, UK). Ligatures were also 
placed above and below the renal pedicle. This ensured that all reagents were delivered 
directly to the kidney and could not go elsewhere.  
2.1.6 Ex vivo Perfusion of Therapeutic Agents prior to Transplantation  
The protocol for the cytotopic delivery of therapeutic reagents is well established in our 
department and has been successfully used in rat models of allotransplantation (Pratt JR 
et al., 2003 290) and ischaemia/reperfusion injury (Patel H et al., 2006 291). A portex 
catheter (Smiths Medical, Kent, UK) attached to a three-way tap, was inserted in the 
aorta and intrarenal delivery of 5ml of Soltran perfusion solution (Baxter Healthcare 
Ltd, UK), with or without therapeutic reagent, was performed. The perfusion was over 5 
minutes, at 1ml/min. This protocol was used for the delivery of Soltran, complement 
inhibitor APT070 and untagged inhibitor APT154 into the kidney. The procedure was 
modified to include two extra steps when delivering coagulation inhibitor PTL006, 
PTL006-FAM, and PTL004. These were: 1) a ten minute wait period post-perfusion. 
During this time the heat mat was switched off whilst the kidney graft was constantly 
bathed in with ice cold saline. Subsequently there was a wash through step: 2) A second 
perfusion of the kidney with 5ml of Soltran alone at a rate of 1 ml/min. The kidney was 
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then excised and immediately transplanted into the recipient. A schematic presentation 



















Figure 2.1: Intragraft delivery of Soltran perfusion solution 
 
 
DA Donor Kidney 
Intragraft Delivery  




Schematic of protocol used for the perfusion of the vehicle Soltran solution. The inferior vena cava and aorta were isolated and a 
portex catheter attached to a syringe, containing 5 ml of Soltran, was inserted into the aorta. During this procedure, the preservation 
solution was delivered through the renal artery directly into the kidney at a rate of 1 ml/min, for a total 5 minutes.        
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2.1.7 Recipient Preparation 
For the recipient preparation, a heat mat was placed underneath the animal to maintain 
constant body temperature. A midline laparotomy was performed followed by removal 
of the left kidney. Microaneurysm clips (Johnson & Johnson, UK) were used to clamp 
the renal vein and artery. The donor kidney was transplanted orthotopically in an end to 
end anastomosis with the renal vein, artery and ureter using 10/0 sutures (Bear Medic 
Corp. Japan). Following a warm ischaemic time of approximately 25 minutes, the clips 
were removed to restore blood flow to the transplanted kidney. Finally, a second native 
nephrectomy was carried out to ensure that the survival of the recipient was dependent 
on the transplanted kidney alone. The end point of graft survival was defined by death 
of the recipient or when the animal had to be culled due to signs of distress.  
As predicted, technical failures accounted for approximately 20% of the transplants 
performed. They were attributed to either failed perfusion of the reagents (thus not 
successful intrarenal delivery of therapeutic reagents) or complications during or after 
anastomosis. Surgical complications were mainly due to mismatch in the size of the 
donor (smaller) and recipient (larger) arteries. Furthermore, approximately 30% of 
recipient rats (Lewis) had two renal arteries thus complicating the arterial anastomosis 
between the graft and recipient. Post-operative complications included abdominal urine 
leakage due to ureteric obstruction resulting from inconsistency in size of the donor and 
recipient ureters.  
2.1.8 Administration of Cyclosporine A and Rapamycin 
Treatment of rats with Cyclosporine A (Sandimmune®, Sandoz Pharmaceuticals, 
Surrey, UK) commenced 2 days prior to renal transplantation at a dose of 10mg/kg/day 
intraperitoneally. Rapamycin (LC Laboratories, Woburn, MA, USA) was administered 
on the day of transplantation at a dose of 1.5mg/kg/day intraperitoneally. Both 







2.1.9 Collection of Blood and Extraction of Serum  
Pre- and post- renal transplantation blood samples were collected by tail vein sampling. 
During the pre-sensitisation period, weekly samples of ~20 μl of blood were taken from 
the tail vein of the Lewis rats into 1.5 ml eppendorf tubes. For serum preparation, this 
whole blood was then centrifuged for 10 minutes at 14000 rpm. The serum was 
collected and the spin repeated. Sera were stored at -70 °C until required for analysis. 
Serum taken prior to renal transplantation was used to assess alloantibody titres, during 
the sensitisation period. Post-renal transplantation, Lewis rats were bled daily to 
measure BUN, thereby monitoring renal function until death of the recipients. Terminal 
blood samples were collected by cardiac puncture.  
2.1.10 Rat Splenocyte Extraction 
Rat splenocytes were obtained by disruption of the newly harvested spleen by pressing 
through a 70 μm sieve over a 50 ml falcon tube containing ~20ml of sterile PBS 
(Fischer Scientific, UK). The cells were spun down by centrifugation and resuspended 
in 10 ml red blood cell (rbc) lysis buffer for 5 minutes on ice. Lysis was terminated by 
adding PBS/2%/ FCS (Sigma-Aldrich, UK) up to 50 ml. The remaining PBMC were 
spun down, resuspended in 20 ml PBS/2%/FCS and then re-spun. The final washed cell 
pellet was resuspended in 10 ml of sterile PBS/2%/FCS and viable cells were counted 
using a haemocytometer (Neubauer Improved, Germany) with trypan blue viability dye 










    Red blood cell (rbc) lysis buffer  
    4.17 g of NH4Cl 
    0.0185 g of EDTA 
    0.5 g of NaHCO3 all dissolved in 500 ml of deionised H2O. 
    The solution was autoclaved and stored at 4 ºC until required. 
 
 
2.1.11 Freezing Splenocytes for Storage 
Splenocytes were collected by centrifugation and resuspended, drop by drop in sterile 
freezing mix comprising 10% DMSO (Sigma-Aldrich, UK) and 90% FCS.  The cells 
were then aliquoted into cryogenic vials (Nalgene, UK), stored in a freezing container 
(Mr Frosty, Thermoscientific) overnight at -70 °C before long term storage in liquid 
nitrogen.  
2.1.12 Thawing of Splenocytes  
Under sterile conditions, cells were transferred from the cryogenic vials in 15 ml tubes 
containing 10 ml RPMI/ 10% FCS. Cells were spun down at 1600 rpm for 5 minutes. 
The cell pellet was resuspended in 10 ml RPMI/ 10% FCS and counted before used, as 
previously described. 
 
2.2 In Vitro Experimental Procedures 
2.2.1 Detection of Alloreactive IgG   
During the sensitisation period, blood was acquired weekly by tail vein bleeding for 
serum analysis of alloantibodies and BUN. Serum was prepared as previously described 
(2.1.9) and stored at -70 ºC until required for analysis. Donor DA or third party SD 
splenocytes were aliquoted (1x10
6
/well) into wells of 96 well v-bottom plates and spun 
down by centrifugation at 1600 rpm for 5 minutes. After flicking off the supernatant the 
cells were pre-blocked by resuspension in 50μl PBS/2% BSA containing 20% normal 
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mouse serum. The cells were left on ice for 20 minutes. For gating of T-cells, mouse 
anti-rat CD3-PE (clone G4.18, Ebioscience Ltd) monoclonal antibody was added and 
incubated at 4 ºC for 20 minutes. Cells were then washed and resuspended in PBS/2% 
BSA into which serum was added to give final dilutions of 1:10, 1:50, 1:250, 1:1250 
and 1:6250. Cells were incubated on ice for 20 minutes. Splenocytes were washed twice 
with PBS/2% BSA as before and then incubated with mouse polyclonal anti-rat IgG-
FITC (H+L, eBioscience Ltd,) for 20 minutes on ice. Cells were then washed twice and 
fixed in 2% paraformaldehyde before being analysed on a FACScan flow cytometer 
(BD).  
2.2.2 Assessment of Renal Function by measuring Blood Urea Nitrogen (BUN) 
Tail vein blood was taken daily from the rats post transplantation and serum prepared as 
previously described (2.1.9). For BUN analysis 5 μl of serum was added to 500 μl of 
Infinity Urea (BUN Infinity, Fisher Scientific, Loughborough, UK) and two readings, at 
30 seconds and then 90 seconds, were measured on a spectrophotometer (Beckman 
Coulter, Oxford, UK)  after standards were determined using a urea/glucose standard 
(Thermotrace, Australia).  The readout was absorbance at 340 nm and BUN values were 
calculated according to the manufacturer’s instructions.  
2.2.3 Harvesting Tissue for analysis of Renal Pathology 
At appropriate time points kidneys were removed and preserved in 4% 
paraformaldehyde (Sigma-Aldrich, UK). They were then processed overnight using a 
Tissue Tek processor before embedding in paraffin. Tissue sections (2μm) were then cut 
using a sledge microtome (Leica) and floated in a 44 ºC water bath. Sections were 
transferred onto super premium microscope slides (VWR International, Leicestershire, 
UK) and allowed to air-dry. Prior to staining, sections were placed in a 65 ºC oven for 1 
hour to melt the wax. The sections were then de-waxed by immersion in xylene for 5 






2.2.3.1 Histological Procedures  
2.2.3.2 Haematoxylin & Eosin (H&E) Staining  
Re-hydrated tissue sections were immersed in haematoxylin (RA Lamb, UK) for 7 
minutes followed by a 15-20 minute wash with running water. Sections were then 
dipped in eosin (RA Lamb, UK) for 5 minutes and rinsed briefly in water. They were 
then dehydrated by immersing through increasing concentrations of alcohol (90%, 
100%). Finally, sections were cleared in xylene and mounted in DPX (dibutyl phthalate 
containing xylene) (VWR, UK). Haemotoxylin stains the nuclei of cells dark blue and 
the cytoplasm is stained pink by eosin. 
2.2.3.3 Periodic Acid Schiff (PAS) 
Rehydrated tissue sections were placed in 1% periodic acid (Sigma) for 10 minutes 
followed by a 5 minute wash with distilled water. Sections were then placed on a rack 
and Feulgen’s Schiffs (RA Lamb Ltd) was dropped onto each section and left for 10 
minutes. After washing in running tap water for 5 minutes, sections were immersed in 
haematoxylin for a further 3 minutes. Following a final wash in running tap water for 
15-20 minutes, sections were dehydrated as previously described, then mounted in 
DPX. PAS stains periodic acid positive tissue pink. Haemotoxylin stains the nuclei of 
cells dark blue. 
2.2.3.4 Martius Scarlet Blue (MSB) 
De-waxed and rehydrated kidney tissue sections were placed in a 3% potassium 
dichromate/10% acid alcohol (Sigma) solution for 5 minutes followed by a short rinse 
with running water. Iron alum was then added for 5 minutes followed by a 5 minute 
immersion in haematoxylin. The sections were then washed with running tap water for 
10-20 minutes, rinsed briefly with 95% ethanol and immediately stained with martius 
yellow for 5 minutes. Following a brief rinse with distilled water the sections were 
stained with brilliant scarlet crystal for 20 minutes. Finally, using a pastette, soluble 
blue was dropped carefully onto each section and left for precisely 1 minute. The 
sections were then blotted lightly on tissue paper, then dehydrated, cleared in xylene 
and mounted in DPX as previously described. MSB stains fibrin scarlet, the muscle 
pink, the RBC’s yellow and collagen blue.  
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    3% potassium dichromate/ 10% acid alcohol buffer 
    3 parts of 3% potassium dichromate and 1 part 10% hydrochloric acid in 95% alcohol 
    Iron alum buffer 
    15 g ferric ammonium sulphate dissolved in 300 ml dH2O 
    1.5 g of celestine blue was added to the solution and boiled for 3 minutes  
    Once cool, the solution was filtered by pouring through a pre-cleared filter paper                 
funnel       
    42 ml of glycerol was added. 
    0.5% martius yellow buffer 
    1.5 g martius yellow and 6 g phosphotungstic acid in 300 ml of 95% EtOH 
    1% brilliant crystal scarlet buffer 
    3 g of brilliant crystal scarlet in 392.5 ml dH2O and 7.5 ml acetic acid 
    0.5% soluble blue buffer  
    1.5 g of aniline blue and 3 ml acetic acid in 297 ml dH2O 
    All solutions were stored at room temperature until required 
 
 
Features of rejection were evaluated and assessed by Dr Catherine Horsfield 










2.2.4 Haemolytic Assay for the Activation of the Classical Complement Pathway 
and Inhibition by APT070 (Mirococept)  
This assay was used to determine the functional inhibition of the classical complement 
pathway by the inhibitor Mirococept. Antibody-sensitised sheep erythrocytes (EZ 
complement cells, Diamedix Labmedics, Oxford) were aliquoted into the wells of a 96-
well v-bottom plate (100 μl/well) and incubated with rat serum (50 μl) at a 1:160 
dilution in CPHAD buffer. This caused maximal haemolysis of the EZ cells. In other 
wells a titration of APT070 or non-tailed control APT154 was added at 125, 50, 20, 8, 
3.2 1.28, and 0.512 nM to a total volume of 200 μl. Duplicate wells were prepared, and 
all dilutions were carried out in classical pathway haemolytic assay diluents buffer 
(CPHAD). A lid was put on the plate which was gently agitated to mix the contents 
before incubation for 1 hour at 37 ºC in an incubator.  The plate was then centrifuged at 
1600 rpm for 3 minutes. Finally, 150μl of supernatant was transferred into a replica 96-
well flat-bottom plate and the absorbance was read at 405 nm using a microplate reader 
(Spectromax, UK). 




t = mean OD for a sample  
A° = cells and buffer alone (spontaneous lysis) 







    Classical pathway haemolytic assay diluents buffer (CPHAD) 
    11.9g of HEPES (BDH) 
    4.4g of NaCl (BDH) 
    300ml of deionised H2O in a 500 ml bottle. 
 Gelatin (1.5g) was then added (Sigma) and the solution was heated in    SHORT        
bursts in microwave until the gelatin was dissolved.        
    pH was adjusted to 7.4 and the volume was made up to 500ml with dH20 
    The solution was warmed to 37 °C, filtered into a new bottle and and stored at 4 °C 
 As required, an aliquot (50 ml) was heated to 37 °C and then maintained at RT for    
use 
   
2.2.5 Tissue Collection for Frozen Sections 
At appropriate time points grafted kidneys were removed and placed on cork disks (RA 
Lamb) in silver foil cups and coated with optimal cutting temperature (OCT) compound 
(RA Lamb) for snap freezing in liquid nitrogen. Tissue sections were cut (5μm) using a 
cryostat (Bright Instrument Ltd, Huntington, UK) and transferred onto multispot glass 
slides (Hendley-Essex, Loughton, UK). They were left to air dry overnight before being 
stained and analyzed or stored at -70 ºC in 50 ml falcon tubes for processing at a later 
date.  
2.2.6 Immunofluorescence (IF) 
2.2.6.1 C4d Staining  
Frozen tissue sections on slides (as previously described) were fixed in ice cold acetone 
for 10 minutes, then left to air dry for 30 minutes. Sections were blocked with 20% 
rabbit serum (the species of origin of the secondary reagent) for an hour and after a brief 
wash (PBS), sheep anti-rat C4d antibody (courtesy of Dr Sarah DeFreitas) was added at 
a 1:80 dilution (PBS) for 90 minutes. After 3 washes in PBS, sections were incubated 
with rabbit anti-sheep IgG FITC (Santa Cruz, distributed by Insight Biotechnology, UK) 
at a 1:200 dilution for 75 minutes at RT. Three PBS washes followed before a final 5 
minute wash was performed with water. The slides were then mounted in fluoromount 
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(Permafluor, Fisher Scientific, UK) and covered with glass cover slips for analysis using 
a fluorescence microscope (Olympus, UK).  
 2.2.6.2 APT070 (Mirococept) Staining  
Detection of Mirococept in rat tissue followed the same immunofluorescent principles. 
Frozen tissue samples were fixed in ice cold acetone for 10 minutes, then left to dry for 
30 minutes. Non-specific binding was prevented by blocking the sections with 20% goat 
serum for 1 hour at room temperature. After a brief wash in PBS, sections were 
incubated with mouse anti-human SCR1-3 (3E10, Adprotech) for 1 hour at a 1:100 
dilution (PBS). Sections were then washed three times in PBS for 5 minutes, on a 
rotating platform. The secondary reagent goat anti-mouse IgG FITC (Jackson, UK) was 
applied to the sections at a 1:200 dilution for 30 minutes then washed three times as 
before. A final 5 minute wash was performed with water. The slides were then mounted 
in fluoromount (Permafluor, Fisher Scientific, UK) and covered with glass cover slips, 
before analysis using a fluorescence microscope.  
2.2.6.3 C5b-9 (Membrane Attack Complex) Staining  
Frozen tissue samples were fixed in ice cold acetone for 10 minutes, then left to dry for 
30 minutes. Non-specific binding was prevented by blocking the sections with 10% 
FCS in PBS for 30 minutes followed by 20% goat serum in PBS at RT. After a brief 
wash in PBS, sections were incubated with mouse anti-rat C5b-9, (Hycult Biotech, UK) 
for 1 hour at a 1:50 dilution. Sections were then washed three times in PBS for 5 
minutes, on a rotating platform. The secondary goat anti-mouse IgG FITC (Jackson, 
UK) was applied to the sections at a 1:200 dilution (PBS) for 30 minutes then washed 
three times as before. A final 5 minute wash was performed with water. The slides were 
then mounted in fluoromount (Permafluor, Fisher Scientific, UK) and covered with 
glass cover slips. All sections were stored in the dark at -4 ºC before analysis using a 






2.2.6.4 PTL006-FAM Detection  
Snap frozen tissue sections were cut as previously described (4.20) and allowed to air 
dry for 30min before adding PermaFluor aqueous mounting medium to each section. 
The sections, kept in the dark and at room temperature, until being analysed using a 
fluorescence microscope.  
2.3 Statistical Analyses 
BUN values and haemolytic assay data were compared using the Student’s t test. 
Survival data were analysed using the Kaplan Meier method (log-rank test) to show the 
significance in survival between animal groups. A difference was considered significant 

















Chapter 3 - Establishing a Rat Hyperimmune Kidney Transplantation Model  
 
3.1 Introduction  
Transplants are powerful stimulants of alloantibody generation (Wehner J et al., 2007 
81) and this is pivotal to graft rejection and loss. Previous studies in animal cardiac 
transplant models have demonstrated that alloantibodies (mainly of the IgG type) bind 
onto endothelial cells in the arteries, capillaries and veins post transplantation mediating 
injury to the cardiac vasculature (Minami K et al., 2006 297). This was further 
supported by similar findings by Qian Z et al. where rat cardiac recipients, pre-
sensitised with blood transfusions, exhibited harmful vascular pathology associated with 
a strong IgG alloantibody responses (Qian Z et al., 2006 298). These experimental 
models clearly demonstrate the capacity of alloantibody to bind to large arterial 
endothelium and promote graft injury. More specifically, immune-mediated injury of 
the graft endothelium results in its activation and subsequent initiation of complement 
and coagulation cascades. These events contribute to damage and rejection of the graft.  
The most severe effect of alloantibodies on a transplanted organ is hyperacute rejection. 
Hyperacute rejection is, by definition, immediate, occurring within minutes to hours 
post revascularization and leading to necrosis of the graft. This type of immunological 
reaction (caused by antibody binding to the donor organ), results in the disruption of the 
vasculature, indicated by the presence of complement and fibrin. Hyperacute rejection is 
uncommon, mainly due to cross match techniques used to identify the presence of 
antibodies in recipients against potential donors. However, hyperacute responses can 
occur following previous exposure of a recipient to HLA and/or ABO antigens, and may 
prevent successful kidney transplantation.  
Animal models have aimed to investigate the role of alloantibodies in the rejection of 
transplanted organs. Most of this earlier research has focused on acute rejection rather 
than HAR, although the latter closely reflects the scenario of a sensitised patient in the 
clinic. HAR of vascularized transplants is difficult to achieve in rodent models even 
where there are high alloantibody titres. For this reason, HAR models have, in the past, 
been established through a xenotransplantation setting. Although in some respects 
xenoantibody responses are similar to the allogeneic response, they do not reflect the 
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situation in the clinic. Nonetheless, xenotransplantation models have furthered our 
understanding of how alloantibody and complement activation affect graft survival. 
Although rodent allotransplantation models offer significant knowledge on complement 
mechanisms, they have so far provided limited information regarding the thrombotic 
effects of vascular rejection, an area mainly covered by xenotransplantation models. 
The role of coagulation in acute rejection episodes is well recognised and intravascular 
thrombosis is considered a reliable marker of accelerated humoral rejection (Rose AG et 
al., 2000 299).   
The aim of the research described in this chapter was to establish a rat kidney transplant 
model of HAR in which cell-protective therapeutic strategies could later be tested. The 
validity of this model was established by reference to the tempo and pathological 
changes associated with accelerated AMR, as described in an earlier publication 
(Truong LD et al., 2007 56).  
 
3.2 Experimental Design  
A model of hyperimmune renal allotransplantation was established using Dark Agouti 
(DA) rats as donors and Lewis rats as recipients. This high responder DA to Lewis rat 
strain combination is a well-established model of fatal acute kidney rejection. More 
specifically, transplantation of kidneys between these two rat strains has been shown to 
lead to acute destruction of the graft and death of the recipient with a median survival 
time of 6 days (Lewin E et al., 1994 300).  The object of my experiments was to focus 
primarily on antibody mediated rejection. To enable this, the experimental design was 
adapted to incorporate a pre-sensitisation phase, as described in a previous study of rat 
cardiac allotransplantation. In this study, rats were sensitised with multiple donor strain 
tail skin grafts prior to heart transplantation (Brauer RB et al., 1995 275). In a similar 
fashion, the Lewis recipient rats in the model described for my work received a 
sequence of three DA full-thickness skin segments before being transplanted with a DA 
kidney. The rationale behind this design was to prime the immune response with two 
successive skin grafts and allow a gap for affinity maturation, to end up with a high 
affinity IgG response, which in clinical transplantation is associated with severe AMR. 
To boost the antibody titre prior to kidney transplantation, the animal received a third 
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skin graft from the same donor-strain. The DSA titre was determined at appropriate 
time-points after skin grafting. The read-out for the effect of pre-immunisation on 
subsequent renal transplantation in this model included: graft survival, graft 
morphology and immunopathology. A schematic of the hyperimmune kidney transplant 
































Schematic of the protocol used to develop a hyperimmune rat renal transplantation model. Lewis recipients received DA strain tail 
skin transplants on days 0, 14 and 49. Renal allografts from the MHC I/II disparate DA donors were orthotopically transplanted into 
the hyper-sensitized recipients at day 56, at which point they were checked to have developed high anti-DA specific antibodies. All 
transplants were performed on sensitized recipients without any deliberate cold ischaemia. In the follow up period, graft survival, 
renal function and pathology were assessed to check for the presence of the characteristics establish of HAR.                                                           
0          7          14           21          28          35          42           49          56
time points (days)











3.3 Effect of Skin Grafting on Alloantibody Response prior to Kidney 
Transplantation  
Recipient IgG responses measured by specific binding to donor (DA) are shown at 
different time points after skin transplantation (Figure 3.2). Donor-specific alloantibody 
shows a peak response at day 14 just prior to receiving a second skin graft. The dilution 
values performed after the third skin graft on day 49 confirm high titre alloantibody 
responses against donor splenocytes are present prior to kidney transplantation (Figure 
3.3 A). Representative histograms of control experiments showing detection of 
background Lewis IgG against SD (third party) and DA serum against syngeneic targets 
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Figure 3.2 A: Sera from individual rats (n=4) was analysed by flow cytometry to detect 
a DA alloantibody response elicited by three successive DA skin allografts (at time 
points shown by arrows) measured weekly at 1:10 serum dilution. These are mean 
values of percent positive cells obtained from gating on the CD3
+
 lymphocyte 
population. B: Titration curve of sera, from the same animals (n=4), analysed at day 56 
to ensure high alloantibody titres pre-kidney transplantation. Donor specific IgG was 
detected on serially diluted sera (1:10, 1:50, 1:250, 1:1250 and 1:6250) and compared 










Figure 3.3 A: Donor specific IgG was detected in serially diluted serum (1:10, 1:50, 
1:250, 1:1250 and 1:6250) from a sensitised Lewis recipient analysed at day 56 prior to 
kindey transplantation by FACS assay. High allo-antibody titres are shown. Top panel: 






















Figure 3.3 B:  The absence of donor specific IgG in serially diluted serum (1:10, 1:50, 
1:250, 1:1250 and 1:6250) from a DA syngeneic recipient analysed by FACS assay. 






















Figure 3.3 C:  The absence of donor specific IgG in serially diluted serum (1:20, 1:40, 
1:80, 1:160, 1:320, 1:640 and 1:1280) from a sentitised Lewis recipient against SD 
target splenocytes analysed by FACS assay. Top panel: isotype control (1:20).     
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3.4 Impact of Pre-existing Alloantibody on Tempo and Character of Renal 
Transplant Rejection 
 Pre-immunised rats (Lewis) showing high titres of DSA or control non-immunised rats 
(Lewis) were transplanted with kidneys from the same donor-strain (DA). Graft 
rejection was defined as high serum BUN, poor health or death of the animal. The 
results (Figure 3.4) show that graft loss is significantly shortened in the hyperimmune 
animals compared with non-sensitised controls. The mean survival times (MST) in the 












Figure 3.4: Kaplan-Meier survival curve showing graft survival in sensitised and non-
sensitised recipient rats. Non-sensitised Lewis recipients rejected the DA donor kidneys 
in an acute manner. Lewis recipients, pre-sensitised with three DA skin grafts (n=6), 
showed accelerated rejection resulting in kidney loss.    
 
  

























3.5 Clinical parallels in Macroscopic Appearance of the Transplant 
In clinical transplantation, HAR, due to preformed antibody results in immediate graft 
loss, usually within 24 hours after restoration of blood flow.  This is because 
alloantibodies in the recipient’s circulation instantly interact with the donor 
histocompatibility antigens on the donor vasculature thus initiating an acute vascular 
reaction which is ultimately responsible for necrosis of the graft. Progression of 
widespread capillary thrombosis results in a lack of perfusion. Typically, the kidney, 
within minutes, becomes flabby, mottled with purple patches and, in extreme cases, 
completely black.  
In my model, hyper-sensitised Lewis rat recipients, having developed DA donor 
specific antibodies, were expected to elicit an instant immune reaction to the DA 
transplanted kidney minutes after revascularization. Figure 3.5 shows the observations 
following transplantation of a DA kidney transplanted into a sensitised Lewis recipient 
from the moment the miscrosurgical clips are released (to permit blood flow after the 
vascular anastamosis has been completed) to 10 minutes after the clamps had been 
released. In approximately 10% of the transplants carried out, the kidney had 
completely blackened by the time the bilateral nephrectomy was completed (Figure 3.5 
E). This appearance is characteristic of diffuse thrombosis and tissue infarction, as 
described for HAR. In contrast, all syngeneic transplants survived the initial surgery, 
indicating that the surgical procedure was successful and HAR did not occur in the 












Figure 3.5: Photos of representative DA kidney transplanted into pre-sensitised Lewis 
recipient showing visible evidence of HAR. A: Isolated DA kidney, perfused with 
Soltran solution, prior to vascular anastomosis.  B: DA donor kidney with healthy pink 
appearance two minutes after reperfusion begins. C: DA donor kidney at five minutes 
post-reperfusion showing a mottled appearance consistent with patchy reperfusion due 
to HAR. D: DA kidney allograft at ten minutes post-revascularization showing more 









Figure 3.5. E: A DA kidney transplanted into a pre-sensitised Lewis recipient. In 
approximately 10% of the transplants, the donor kidney had turned black by the time the 
native nephrectomy had taken place (30 minutes after release of microsurgical clips), 













3.6 Histological Characteristics of Rejection in the Pre-sensitised Recipients  
The cardinal features of HAR are based on the appearance of human transplanted 
kidneys. Typically these include the presence of neutrophils in the peritubular 
capillaries (PTC), microvascular thrombosis, haemorrhage and fibrinoid necrosis of the 
vessel wall. These features can be readily distinguished from those of T cell mediated 
rejection, which involve T cell and macrophage infiltration of the renal tubules and 
interstitial space. In order to verify HAR in this model the rejected kidneys in the 
hyperimmune group were examined histologically and compared with rejected grafts 
from the non-sensitised control group (Figure 3.6)  
In the rejected kidneys from the pre-sensitised rats, typical features of HAR were 
present. These are illustrated in figure 3.6. In all, six kidneys in this group were 
examined, and representative results for three of these kidneys are shown. In contrast, 
the kidneys from the non-sensitised group (Figure 3.7) show extensive infiltration of the 
interstitial space and evidence of tubulitis consistent with T cell mediated rejection at 
around day 5 post transplantation. In addition, evidence of small vessel arteritis is 
present, as shown by arterial lymphocytic invasion and endothelial injury. Hence in the 
case of naïve recipients, the rejected kidney at day 5 post transplantation shows a mixed 
picture indicative of acute T cell mediate rejection and some features of early vascular 
(antibody-mediated) rejection, whereas the sensitised group of rejected kidneys show 
early and severe changes of HAR. The model developed for this study, therefore, 












Figure 3.6: Morphological appearances typical of HAR represent the findings in 
micrographs from 6 kidneys. A: Histology of a representative DA kidney allograft taken 
from a pre-sensitised Lewis recipient at day 2 post-transplantation.  Arterial fibrinoid 
necrosis of the vessel wall is seen (MSB; x200). B: Granulocytic cell infiltration of the 
PTC (H&E; x600). C: Multiple glomerular thrombi (MSB; x400). D: Appearances of a 
rejected kidney at day 1 post-transplantation, showing tubular necrosis and loss of 













Figure 3.7: Histological findings in kidneys rejected by non-sensitised recipients 
(representative micrographs from a group of 6 kidneys). A: Histology of a 
representative DA kidney allograft from a non-sensitised Lewis recipient at day 5 post-
transplantation showing extensive patchy lymphocytic infiltration (H&E; x100). B: 
Interstitial lymphocytic infiltration crossing the tubular basement membrane causing 
tubulitis (H&E; x400). C: Arterial wall infiltration by lymphocytes that are seen to 
adhere to the endothelium (MSB; x200). The inset shows endarteritis with penetration 
of lymphocytes in small artery (MSB; x400). D: Taken at day 7 post-transplantation, 
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histology showing both tubulitis and acute glomerulitis with mononuclear cells in the 
capillaries (PAS; x400).  E, F: Numerous peritubular capillaries invaded with 






















3.7 Immunopathological Evidence for the Presence of Antibody in the 
Microcirculation of DA Kidneys transplanted into the Pre-sensitised Lewis 
Recipients  
The identification of graft rejection due to the presence of DSA has become routine with 
the establishment of reliable detection of C4d, an inactive product of the complement 
classical pathway (Feucht HE et al., 1993 57). Its detection in transplant tissue 
correlates well with histological features of AMR in kidneys, such as the presence of 
neutrophils, monocytes and fibrinoid necrosis (Mauiyyedi S et al., 2002 301). C4d 
staining provides evidence of circulating complement fixing antibodies and it is 
considered a relatively specific and sensitive biomarker of AMR. The advantage of this 
small fragment generated from C4b is that, having an internal thioester moiety, it forms 
a strong covalent bond with nearby endothelial cells thus making it readily detectable.  
To evaluate the presence of C4d in the rejected organs, immunofluorescent (IF) C4d 
staining on cryosections of transplanted kidney was performed. The frozen-IF technique 
was selected rather than paraffin-immunohistochemistry (IHC), since it is widely 
considered to be more sensitive (Seemayer GA et al., 2007 302).  Diffuse C4d was 
detected in DA kidneys removed from the hyperimmune Lewis recipients at day 2 post-
transplantation (Figure 3.8). Normal rat kidney showed no specific staining for C4d 












Figure 3.8. C4d immunofluorescent staining in a rejected DA kidney allograft from a 
pre-sensitised Lewis recipient. A, B: Linear deposition of C4d in dilated peritubular 
capillaries between ghost outlines of the renal tubules (x400). C: C4d staining in PTC 









Figure 3.9. Negative controls for C4d immunofluorescent staining of DA kidneys. A: 
Frozen section of a normal on-transplanted DA kidney showing negative staining for 
C4d deposition (x100). B: DA kidney from transplanted sensitised Lewis recipient 














3.8 Discussion  
The aim of the work described in this chapter was to establish an aggressive model of 
AMR in rat kidney transplants, comparable to that seen in human kidney transplants in 
the presence of DSA.  Due to the use of cross-matching techniques this type of rejection 
is very rare in the clinic. The rationale for the development of this model and associated 
research was to provide a severe challenge for the development of a therapeutic strategy 
that ultimately could be applied in highly sensitised patients who are presently 
considered non-transplantable. In order to confirm the suitability of this model for such 
purposes, the following characteristics (of HAR) would be required: 
1. Donor-specific IgG antibody in the serum  
2. Immediate onset of rejection 
3. Histological evidence of the typical lesion  
4. C4d deposition on the peritubular capillaries  
A prerequisite for a successful model was to use an appropriate donor/recipient rat 
strain combination, so that upon sensitisation the recipient would produce high titre 
donor-specific antibodies. The method of sensitisation of the recipients was based on a 
study in which three successive allogeneic skin grafts led to HAR in a rat model of 
cardiac transplantation (Brauer RB et al., 1995 275). It was concluded form the cardiac 
study that multiple skin immunizations were necessary for the production of DSA 
whose level and potency were so great that they could elicit a different type of rejection, 
as compared with a naïve recipient. This method was pioneered by Guttmann during 
studies involving a series of heterotopic rat cardiac allografts in 25 different strain 
combinations (Guttmann RD et al., 1974 303). These experiments showed that HAR 
after recipient sensitisation only occurred in specific donor/recipient rat-strain 
combinations. Interestingly, organs from donors with the RT1
a 
haplotype, expressed by 
the ACI rats, consistently induced this phenotype. Thus, it was concluded that to 
reproduce the transplant setting in which the donor organ is highly immunogenic, the rat 
donor/recipient combinations have to be carefully selected. Furthermore, these studies 
are important because they showed the validity of using rats in transplantation models. 
In this particular case, the heart transplantation between ACI and PVG rats (also used 
by Brauer RB et al., 1995) proved to be a well suited model for such clinical type 
studies. For the purpose of my study, the well-established, high responder DA to Lewis 
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strain combination was used. DA rats share the same highly immunogenic, RT1
a  
haplotype, and represented an appropriate donor strain since ACI rats are not available 
in the UK. 
Having decided on the appropriate rat strain combination, recipient Lewis rats were pre-
sensitised with three DA full-thickness skin segments. Prior to kidney transplantation, 
all three skin grafts had been completely destroyed and were replaced by scar tissue 
upon visual inspection. This sensitisation protocol correlated with flow cytometric 
evidence that the sera from Lewis rats contained high titre DA specific IgG antibody. 
Although IgM fixes complement and has been associated with HAR in this model it was 
not systematically measured during the immunization schedule I used. IgM is relatively 
short lived, and considering the long duration of the sensitisation protocol, it is likely all 
IgM production would have switched to IgG, by the time the kidney transplantation was 
carried out. In addition, the observation that IgG antibodies are associated with poor 
prognosis and severe rejection, serum IgM analysis (McKenna RM et al., 2000 307) was 
not included in this model.   
The titre and expected affinity of the alloreactive antibodies generated by the pre-
sensitisation procedure was such that it was able to significantly accelerate rejection 
resulting in an MST of 2 days compared with 5 days for non sensitised recipients. By 
definition, HAR occurs within minutes to hours post revascularization of the organ. In 
this model, rejection (death) on day 1 or 2 post reperfusion is misleading. Whereas in 
heterotopic cardiac models, loss of graft function is immediately detectable by loss of 
heart-beat upon palpation, the cessation of kidney allograft function requires at least 24 
hours before the animal succumbs. However, as shown by direct inspection of the 
transplanted organ at the time of surgery, the loss of blood flow and onset of tissue 
infarction was instantaneous, occurring within minutes of the microvascular clips being 
released. These kidneys had ceased function long before the death of the recipients, 
which required some time before they succumbed to renal failure. Thus, the immediate 
circulatory collapse and characteristic changes in tissue morphology in the presence of a 
high titre of donor-reactive IgG antibody can be reasonably concluded to be due to 
HAR.      
Positive C4d staining in the PTC is now an accepted diagnostic criterion in the 
recognition of AMR and has consistently been associated with poor allograft outcome. 
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C4d is formed following the cleavage of complement factor C4 into C4b and thereafter 
into an inactive form and degraded to C4d, attached by a covalent bond on the 
activation site. As a result, it remains bound for a prolonged period of times and can be 
easily detected with IF and IHC protocols, serving as a marker of AMR. C4d has proven 
to be a marker of active AAMR and follow up biopsies in a patient survey revealed that 
C4d could be detected up to 58 days post transplantation following successful treatment 
of ongoing AMR (Koller H et al., 2004 305).  Detection of C4d has, in part, also solved 
the problem of immunohistological detection of IgG. IgG deposition on tissue has not 
proved a reliable marker of AMR in many reports, and this may be related to rapid 
shedding from the graft endothelial cells due to its weak interaction being mediated by 
weak van der Waals bonds (Cohen D et al., 2012 60) or possibly internalization of 
bound antibody by the endothelial cells. Furthermore, the detection of C4d, most 
importantly, shows involvement of the complement system, and although C3d is also 
deposited at sites of antibody binding, its presence is non-specific (Colvin RB, 2007 12) 
as C3 breakdown is central to all complement activation pathways. C3 is often detected 
on the tubular basement membrane, which is not a target for AMR. For this reason, in 
this study, confirmation of DSA and the involvement of complement relied upon C4d 
staining.  
Snap-frozen tissue was stained using standard immunofluorescent techniques (IF) and 
was found to be positive for C4d on the PTC of the kidneys transplanted into the pre-
sensitised Lewis rats.  However, it is important to note that at the time of this 
investigation, no anti-rat C4d antibody reagent was commercially available. Newly 
generated anti-rat C4d antibody (courtesy of Dr Sarah de Freitas) was tested in this 
model. This antibody was generated in-house specifically against the peptide sequence 
for rat C4d.  As previously stated, positive staining was observed and this pathology 
was confirmed by Dr Catherine Horsfield. Nonetheless, cautious interpretation of these 
data is required since subsequent staining with different batches of this new antibody, 
did not reproduce the result (confirmed by colleagues). Currently, new reagents have 
become available (Hycult biotech) and could be used in future studies.    
In conclusion the data reported in this chapter meet the criteria proposed at the outset, 
and appear to present a formidable challenge required for this study and described in 
more detail in the following chapters. The issue to be explored in these chapters is 
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whether intervention with complement or coagulation regulators can modify the 



























Chapter 3 described the immunological and pathological features of an aggressive 
model of hyperacute antibody-mediated rejection akin to HAR in human kidney 
transplantation. The present chapter explores the hypothesis that by increasing the local 
concentration of complement regulator on the endothelial cell surface by therapeutic 
means, the endothelial damage mediated by complement will be reduced and graft 
survival will be enhanced. Such a cell-protective (cytoprotective) approach is made 
feasible by the advent of ‘cytotopic’ technology, described by Dr Richard Smith and 
colleagues (Smith RAG, 2002 286). This method for localizing therapeutic agents on 
the cell surface was outlined in the Chapter 1. The prototype, Mirococept (APT070), is 
a derivative of soluble recombinant human complement receptor 1 (sCR1) attached to a 
membrane binding tail. The latter is composed of two parts: a membrane inserting 
myristoyl which forms hydrophobic interactions with the phospholipid membrane; and 
a positively charged peptide sequence which allows electrostatic interactions to occur 
with phospholipid heads which are negatively charged. The generation of membrane-
binding APT070 through the process of the ‘myristoyl-electrostatic switch paradigm’ 
(Smith RAG, 2002 286) makes cytotopic therapy achievable, especially in the transplant 
setting, where donor organs can be treated prior to transplantation (Pratt et al., 2003 290 
Patel et al., 291). It offers a strategy that is not only highly specific to the organ where 
inflammation is taking place, but also avoids interference with systemic complement 
(Mollnes TE et al., 2006 287). Membrane insertion increases retention time (reduces 
clearance) and the fact that APT070 is a small molecule (24kDa) in comparison to 
native CR1 (250kDa) (Dodd I et al., 1995 285), makes it less immunogenic in rodents 
(Patel H et al., 2006 290). APT070 has been used in a variety of animal models such as 
rat models of acute vascular shock (Smith RAG, 2002 254), experimental rheumatoid 
arthritis (Linton SM et al., 2000 256), myocardial infarction in pigs (Banz Y et al., 2007 
257) and ischaemia-reperfusion injury in rat kidney transplants (Pratt et al., 2003 290; 
Patel et al., 2006 291). These studies showed that APT070 is well tolerated and has 
impressive cytoprotective effects. Furthermore, a Phase 2a kidney transplant study 
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showed that the technique can be transferred to man (Smith R/Sacks S unpublished 
data). 
The rationale for using complement-based approaches to prevent or suppress HAR is 
supported by therapeutic animal and clinical studies. Previous studies in mice indicate 
that inhibition of the terminal complement components (C5b-9 and C5a) using with an 
anti-C5 monoclonal antibody can ameliorate HAR (Wang H et al., 2007 276). Wang et 
al. showed that anti-C5 in combination with immunosuppressive agents could prolong 
the survival of cardiac allografts transplanted into hyperimmune mouse recipients. 
Similarly, kidneys transplanted into pre-sensitised recipients injected with C5mAb 
achieved prolongation of graft survival compared to untreated control mice (Rother R P 
et al., 2008 277). In addition, promising results were obtained in a small number of 
sensitised human recipients who received anti-C5 antibody (Eculizumab) post-
transplantation. In a proportion of these patients, the incidence of AMR was decreased 
(Lonze BE et al., 2010 263; Stegall MD et al., 2012 264). The aim of the investigations 
described in this chapter was to determine whether APT070 can protect treated rat 
kidney against HAR. This is the first study using such a stringent model of AMR in 
allotransplantation in which complement is targeted locally rather than systemically.  
4.2 Experimental design 
Before proceeding with the in vivo evaluation of the effects of Mirococept in the rat 
hyperimmune transplant model, verification experiments were carried out for 
characterization of the reagents. Functional assays were performed to confirm the 
capacity of APT070 to inhibit complement activation in vitro and bind to cell surfaces, 
in vivo. The reagents utilized for this purpose were the tailed SCR1-3 (APT070) and 
untagged SCR1-3 (APT154) as control, (kindly provided by Dr R Smith, KCL). 
Inhibitory potency of APT070 was confirmed in vitro using a standard haemolytic 
assay. In this assay, antibody sensitised sheep erythrocytes activate complement and 
cause cell lysis. The ability of APT070 to inhibit complement activation and reduce cell 
lysis provides a measure of therapeutic functionality. The contribution of membrane 
binding to APT070-mediated protection was determined by comparison of the 
functionality using the untagged soluble peptide, APT154. In vivo experiments were 
subsequently carried out to confirm that DA kidneys treated with APT070 could bind 
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this inhibitor, with an appropriate tissue distribution following intra-arterial 
administration, as previously demonstrated (Patel H et al., 2006 291). Finally, after 
clarifying the inhibitory and binding efficacy of Mirococept, APT070-treated organs 
were transplanted into hyperimmune Lewis recipients, to determine the impact on graft 
survival.  
The in vitro functional analysis of Mirococept was carried out by performing a well-
established, classical pathway haemolytic assay (Morgan BP, 2000 306). Rat serum was 
used as the source of complement which was incubated with antibody sensitised sheep 
red blood cells. This interaction activates complement by the classical pathway through 
the formation of antigen-antibody complexes and results in haemolysis due to the 
formation of the MAC (C5b-9) in the red blood cell membrane. To determine whether 
the addition of APT070 protects the sheep red blood cells from lysis, haemolytic 
inhibition (% HI) was determined. This was compared to the non-tagged APT154.  
To establish the distribution of APT070 in the donor kidney following intragraft 
delivery, DA kidneys were perfused with a solution containing APT070 and the treated 
organs were transplanted into syngeneic recipients. Immunohistochemistry was 
performed on tissue sections of frozen kidney removed at 0.5 and 24 hours post-
transplantation. Control kidneys treated with the non-tagged agent APT154, were 
removed at the same time points and used for the analysis.  
Finally, after completion of % HI in vitro experiments and binding experiments in vivo, 
both inhibitory and control reagents were used in the hyperimmune model of 
allotransplantation. DA kidneys were perfused via the renal artery with Mirococept at 
two different doses, 40 or 80 μg/ml, before being transplanted into hyperimmune Lewis 
recipients. This dose regimen was based on an earlier dose schedule that was successful 
in reducing ischaemia/reperfusion injury (Patel H et al., 2006 291). The organ perfusion 
and renal transplantation procedure was adapted from that described for a rat model of 
chronic kidney transplant rejection between Fischer F344 (RT1
Iv1
) and Lewis (RT1
I
) 
rats (Pratt J et al., 2003 290). The control group was perfused with non-tailed CR1, 
APT154. Transplant survival in recipient rats was measured in conjunction with 
evaluation of renal function by daily analysis of serum blood urea nitrogen (BUN). 
Graft pathology was examined to determine any differences between the inhibitor- and 
control-treated groups with respect to the development of HAR. Graft rejection was 
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taken as the time of death of the recipient (or time of sacrifice as determined by Home 























4.3 In vitro activity of APT070 as a Complement Inhibitor 
The functional activity of APT070 as a complement inhibitor was verified in vitro and 
compared against the untagged control reagent APT154, using a standard haemolytic 
assay. In this assay, antibody-sensitised sheep red blood cells were incubated with 
serum from a normal DA rat at a pre-defined dilution, to which had been added APT070 
to give different final dilutions. APT070 was found to inhibit complement-mediated cell 
lysis in a dose-dependent manner. The concentration of APT070 found to inhibit 
classical pathway-induced haemolysis by 50% (IH50) was ~1.5 nM. The protective 
effect of the untagged control agent APT154 was substantially less, since the IH50 for 
APT154 was found to be ~ 85 nM (Figure 4.1). In other words, the potency of the tailed 
regulator in functional inhibition of complement was about 57x that of the non-tailed 
regulator 
In summary, this experiment confirmed APT070 to be a potent inhibitor of the classical 
pathway of complement activation in rat serum. The equivalent therapeutic non-tailed 
therapeutic fragment was substantially weaker in its ability to inhibit complement 
activity on the sensitised sheep red cell surface. These data demonstrate a distinct 
advantage of the cytotopic technology used to attach the complement regulatory 











































Figure 4.1 % Haemolytic Inhibition shows APT070 inhibition of complement-mediated 
cell lysis in a dose-dependent manner and IH50 ~1.5 nM in rat serum. The untagged 
control reagent APT154 shows less inhibitory effect, with IH50 ~85 nM in rat serum 
(p=0.0021). A titration of each reagent in rat serum was incubated with antibody-
sensitised sheep red blood in a haemolytic assay. % Haemolytic inhibition was 










4.4 Localisation of APT070 within treated Rat Kidney Isograft  
A key objective of my study was to ensure the delivery of the tagged complement 
regulator APT070 to the renal vascular endothelium after intra-arterial injection of 
carrier solution containing the APT070. Retention of APT070 at this site was 
considered essential to the proposed therapeutic action of APT070 in reducing the 
damage caused by HAR. In order to investigate the distribution of APT070, perfusion of 
DA kidneys with Soltran containing either 40 μg/ml of APT070 or untagged APT154 
was carried out. Treated organs were transplanted into syngeneic (DA) recipients, in 
order to first examine the distribution of the therapeutic agent in the absence of an 
alloimmune response. Analysis involved immunohistochemistry on frozen tissue 
sections prepared from the transplanted kidney after it had been removed from the 
recipient. The time points analyzed were 0.5 and 24 hours post transplantation, so as to 
cover the time span of rejection identified in the study of allogeneic hyperimmune 
transplants (Chapter 3). As shown in figure 4.2 binding of APT070 following perfusion 
was uniformly detected in a glomerular capillary pattern indicating that APT070 was 
attached to the endothelial surface 0.5 hours post transplantation. Less intense staining 
was detected on some peritubular capillaries. Staining tissue perfused with control 
reagent APT154 was negative at the same time point.  
In contrast to the bright staining in the glomeruli of tissue harvested after 30 minutes, at 
24 hours post transplantation, the complement inhibitor APT070 was no longer 
detectable on the endothelium. However, it was present, at low intensity in focal regions 
of the kidney. More specifically, positive staining seemed to localise on the apical side 
of the renal tubules rather than the tubular epithelium itself. Negative staining was 























Figure 4.2: Immunohistochemical staining with antibody against human CR1 following 
perfusion of DA donor grafts with APT070 (n=2) or control untagged reagent APT154 
(n=2) prior to transplantation into syngeneic recipients. Tissues were analysed at 0.5 
hours post transplantation. A, B: Heavy staining within the glomeruli is in the pattern of 
the glomerular capillary tuft. C, D: Positive deposition of APT070 is detected on both 
the glomerular and peritubular capillary walls consistent with endothelial staining 
shortly after perfusion. E, F: Negative staining of DA donor kidney perfused with non-
tailed agent APT154. Representative images were taken at x100 (A, C, E) and x200 (B, 










Figure 4.3: Immunohistochemical staining for human CR1 in DA donor grafts treated 
with APT070 (n=2) or control reagent APT154 (n=2) prior to transplantation into 
syngeneic recipients. Tissues were analysed at 24 hours post transplantation. A, B: 
Focal distribution of APT070 is observed on the renal tubular epithelium and more 
specifically in the lumen of the proximal and distal tubules. C, D: Negative staining of 
DA donor kidney perfused with non-tailed APT154. Representative images were taken 






4.5 Graft Survival in Pre-sensitised Lewis Recipients following Treatment of the 
DA donor Kidney with APT070 
Using in situ perfusion of DA donor kidneys with APT070 or control reagent APT154, 
the effect of the complement inhibitor on graft survival was monitored and requirement 
for membrane binding was determined. Kidneys pre-treated with 40 μg/ml of APT070 
did not exhibit prolongation of survival compared to the untagged SCR1-3 (APT154). 
Both groups showed rapid rejection, of similar speed and severity as had been observed 
in preliminary experiments using Soltran perfusion fluid alone to treat the donor organ 
transplanted into hyperimmune recipients (chapter 3). In the APT070-treated group 
(MST 1.4 days) 60% of animals survived past 24 hours (3 of 5) but none survived 
beyond the 48 hour time point. A similar trend was observed for the recipients of grafts 
treated with control reagent APT154 (MST 1.2 days). 75% of the animals survived past 
24 hours post-transplantation (3 of 4) whereas, again, none of the animals lived past 48 
hours (Figure 4.4A). Graft loss was defined as the death of the recipient or its 
requirement to be culled due to obvious distress, correlating with high serum BUN.  
Following these results with 40 μg/ml of the reagent, the dose of APT070 was increased 
to 80 μg/ml in a further experiment using an identical transplant procedure. Despite 
doubling the dose of APT070, there was no clear impact on graft survival, when 
compared to APT154 control-treated kidneys in the same experiment, or to Soltran-
treated kidneys in the earlier baseline study (chapter 3). 55.5% of animals that received 
APT070-treated grafts (MST 1.4 days) (5 of 9) survived to 48 hours post-transplantation 
compared with 50% of Lewis rats that received APT154-treated kidneys (MST 1.5 days 
post-transplantation) (2 of 4) (Figure 4.4B). Thus, treatment even with a higher dose of 
the complement inhibitor did not extend survival beyond 48 hours post transplantation.  
These data indicated that in this very aggressive model of hyperimmune kidney 
rejection, inhibition of complement with the membrane-localizing inhibitor, 
Mirococept, perfused at two different doses, 40 and 80 μg/ml, provided no benefit in 





















Figure 4.4: Graft survival following transplantation of DA kidneys treated with APT070 
or control agent APT154 into pre-sensitised Lewis recipients. A: APT070 treatment of 
donor organs with a dose of 40 μg/ml transplanted into pre-sensitised rats (n=5) 
achieved no significant prolongation of survival compared to the untagged APT154 
control group (n=4) (p=0.6547). B: APT070 treatment of donor organs with a dose of 
80 μg/ml transplanted into pre-sensitised rats (n=9) achieved no significant prolongation 





































































4.6 Renal Function of Pre-sensitised Lewis Recipients after transplantation with 
APT070-treated DA Kidney  
In the same groups of experimental rats described in Section 4.5 (with 40 or 80 ug/ml of 
therapeutic agent or control applied to the transplant), renal function in the Lewis 
recipients was monitored daily following transplantation until the time of the graft 
rejection. The results are shown in figure 4.5.  
At 24 hours post-transplantation, the BUN levels for pre-sensitised recipients of DA 
kidneys pre-treated with 40 μg/ml of APT070 were very similar to those of the APT154 
control-treated group, (i.e. >35 mmol/L). At 48 hours post-transplantation, the BUN 
levels for the surviving rats in both APT070 and APT154-treated groups remained high 
(> 35 mmol/L). Therefore no significant benefit was observed (Figure 4.5 A, B), in 
terms of reducing BUN towards levels in healthy rats (approximately 10 mmol/L, data 
not shown).  
In the group of Lewis recipients where the DA donor organ was treated with 80 μg/ml 
of APT070 or APT154, BUN levels showed a trend toward improved renal function in 
the APT070 group compared to the APT154 group, at both 24 and 48 hours post-
transplantation (Figure 4.5 C, D). However, these results were not statistically 
significant.  
These data showed that pre-treatment of DA donor kidney with either 40 or 80 μg/ml 
APT070 before transplantation into hyperimmune Lewis recipients had no major impact 
on renal function at both 24 and 48 hours post-transplantation compared to treatment of 









Figure 4.5: BUN measurements as an indicator of renal transplant function. A, B: 
APT070 or APT154 40 μg/ml used to treat the donor organ: A: Function at 24 hours 
post-transplantation (p=0.7302). B: Function at 48 hours post-transplantation (p=0.400). 
C, D: APT070 or APT154 80 μg/ml used to treat the donor organ: C: Function at 24 
hours post-transplantation (p=0.110). D: Function at 48 hours post-transplantation (no 







4.7 Renal Transplant Pathology of the Treatment and Control Groups 
Despite no clear prolongation of survival and only moderate improvement in renal 
function in Lewis recipients of APT070-treated DA kidneys, graft pathology was 
assessed. The purpose was to determine whether any improvement in the histological 
injury associated with APT070 treatment could be identified by histological analysis. As 
illustrated in figure 4.6, no morphological differences were observed between APT070 
and APT154-treated kidneys when the dose of reagent was 40 μg/ml. The treated DA 
kidneys exhibited extensive tissue necrosis and widespread thrombosis. Massive 
thrombosis in glomerular and arterial endothelium was evident (Figure 4.6).  
At the higher dose of APT070, DA donor kidneys transplanted into pre-sensitised Lewis 
recipients revealed subtle differences when compared to APT154 control-treated organs. 
APT070-treated organs, although infarcted, had dispersed patches of preserved tissue, 
which was not detected in the APT154 group. Furthermore, small vessel thrombosis 
was prominent in the APT070-treated group, whereas in the control group, the 
coagulopathy extended to the larger vessels, which showed fibrinoid necrosis of the 
vessel wall (Figure 4.7). 
Figure 4.8 shows that these intense thrombotic phenomena were accompanied by 
extensive inflammatory infiltration around the peritubular capillaries of both APT070- 
and APT154-treated grafts at day 1 post-transplantation.  
Nonetheless, the kidney injury observed in both treatment groups was extensive. 
Therefore, treatment with APT070 alone, in the stated doses, was insufficient to prevent 









Figure 4.6: MSB-stained histological sections of rejected transplants at x400 
magnification. Donor kidneys treated with 40 μg/ml of APT070 or control APT154. A: 
APT070-treated graft removed from a pre-sensitised Lewis recipient at day 1 post-
transplantation showing glomerular thrombosis. B: Artery of an APT070-treated graft 
showing fibrinoid necrosis at day 2 post-transplantation. C: APT154-treated graft from 
pre-sensitised Lewis recipient at day 1 post-transplantation showing presence of 
glomerular endothelial thrombi. D: Fibrinoid necrosis of the vessels in an APT154-
treated graft at day 2 post-transplantation. The pictures are representative of five 
APT070-treated kidneys and four APT154-treated kidneys examined after removal from 








Figure 4.7: Donor kidneys treated with 80 μg/ml of APT070 or control APT154. A: Representative DA kidney allograft treated with APT070 
(n=9, 3 sections/stain) taken from pre-sensitised Lewis recipients at day 1 post-transplantation showing glomerular thrombosis (MSB; x400). B: 
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Widespread thrombosis in the microvasculature with focal necrosis at day 2 post-transplantation (MSB; x100). C: Small vessel thrombosis at day 
2 post-transplantation (MSB; x200). D: Picture of a representative DA kidney allograft treated with APT154 (n=4, 3 sections/stain) taken from 
pre-sensitised Lewis recipients at day 1 post-transplantation showing presence of glomerular thrombosis (MSB; x200). E: Infarction, extensive 












Figure 4.8: Micrographs of PAS staining taken at x100 of donor kidneys treated with 80 
μg/ml of APT070 or control APT154. A: Histology of a representative DA kidney 
allograft treated with APT070 (n=9, 3 sections/stain) taken from a pre-sensitised Lewis 
recipient at day 1 post-transplantation showing focal infarction, glomerular thrombosis 
and leukocyte infiltration. B: Morphological features of a DA kidney allograft treated 
with APT154 (n=4, 3 sections/stain) taken from pre-sensitised Lewis recipients at day 1 
post-transplantation showing widespread infarction and leukocyte infiltration. Lower 













4.8 Discussion  
The aims of the experiments described in this chapter were to: 1) characterize APT070 
by performing an in vitro haemolytic assay to confirm its complement inhibitory 
activity; 2) investigate APT070 binding ability and distribution in the kidneys following 
intrarenal perfusion and; 3) determine the effects of the inhibitor in a rat model of HAR. 
This model represents the most severe type of rejection observed in sensitised recipients 
in the absence of a cross-matching protocol.  
In vitro experiments confirmed the ability of APT070 to inhibit complement. In these 
experiments the concentration of APT070 required for 50% inhibition of haemolysis, 
mediated by activation of the classical pathway (IH50) was measured. In this assay, 
APT070 (IH50 ~1.5 nM) protects antibody sensitised sheep erythrocytes from lysis. The 
functional moiety of APT070, like CR1, is known to bind C3b and C4b, thus 
inactivating the classical C3 and C5 convertases. Thereby, it prevents the formation of 
membrane attack complex (MAC) on the surface of the sheep red blood cells, and so 
prevents red blood cell lysis by osmosis (Cole DS et al., 2003 173). Some inhibitory 
action was observed by the soluble control untagged SCR1-3 (APT154), however it was 
substantially less effective (IH50 ~85 nM). These data demonstrate the impact of the 
membrane tagging technology, maximizing the reagent efficacy.  
One of the unique aspects of this work is that the therapeutic inhibitor is delivered to the 
donor kidney and not to the recipient. Systemic interference of complement is thus 
avoided and systemic complement as a host defense mechanism is maintained. Using 
the intrarenal delivery protocol it was confirmed that APT070 was able to distribute 
throughout the donor kidney in transplants carried out between syngeneic DA donors 
and recipients.  Staining of tissue sections with an antibody against the SCR1-3 
sequence of human CR1 showed that APT070 was still strongly detectible in the donor 
kidney at 0.5 hours post-transplantation, indicating that the inhibitor remained firmly 
bound. This is important considering the rapidity and site targeted by pre-formed 
antibody in this model. The primary target of AMR is the graft endothelium. It was 
evident that APT070 introduced by perfusion of the renal artery was localised to the 
microvasculature, both glomerular and peritubular. The larger vessel staining is difficult 
to interpret using the immunofluorescence due to non-specific staining. At 24 hours 
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post-transplantation, APT070 was focally located largely at the apical surface of the 
renal tubular epithelial showing that the inhibitor had been internalized. 
In view of the functional and binding capabilities of APT070, it was considered to be an 
ideal inhibitor for targeting complement in this model of HAR. My experiments 
therefore went on to test the therapeutic inhibitor delivered by this means to the 
microvascular surface of the transplant to identify its potential and limitations in the 
most stringent conditions. 
The initial dose of APT070 (40 μg/ml, 200μg) was based on previous findings in our 
lab, which showed a significant beneficial effect at this dose, in rat models of 
ischaemia-reperfusion injury and chronic rejection (Pratt J et al., 2003 290). However, 
APT070 at this dose had no major effect on graft survival or renal function compared to 
untagged inhibitory fragment of CR1 in my study of HAR. All animals died by 48 hours 
post-transplantation. Considering the severity of the injury in terms of speed of onset 
and degree of tissue damage in my model of HAR compared with the injury reported in 
the chronic rejection model, the concentration of APT070 was doubled to 80 μg/ml, 
400μg). The APT070-treated group showed slightly better BUN values at 24 and 48 
hours post-transplantation, compared with the control APT154 group, though the 
difference was not statistically significant. Histological analysis of both the APT070- 
and control-treated grafts revealed neutrophilic infiltration in the peritubular capillaries 
(PTC), tissue infarction and thrombosis. The apparent lack of effect of APT070 therapy 
to prolong graft survival was unexpected, due to the stringency with which APT070 
inhibited complement-mediated lysis in vitro and its ability to localise on the 
microvascular surface of the donor organ following blood reperfusion (the acute phase 
of rejection).  
Until recently, complement activation was considered to be a key mediator of HAR. 
Indeed, the endothelium of the microcirculation is the main target of HAR as 
alloantibody ligation to donor antigen expressed on the surface of the graft will almost 
certainly activate the complement system. This activation results in increased 
inflammation and loss of vascular integrity. In addition, initiation of complement 
activation has been associated with increased thrombosis (Colvin RB et al., 2005 9). 
Indeed, this model has a profound tendency for coagulation of the renal vasculature.  
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The failure of APT070 (at 40-80 μg/ml) to improve graft outcome in this model implies 
a complement-independent mechanism for initiating coagulation occurred. APT070 
inhibits complement activation and accordingly prevents the main effector products of 
complement from being formed. Recent interest has been focused on the role of the 
activated endothelium itself, which can be stimulated directly by alloantibody alone, in 
the absence of complement. Antibody ligation on vascular surfaces activates the 
endothelial cells, which release proinflammatory molecules such as E-selectin, ICAM 
(CD106) and VCAM (CD54).  This causes leukocyte adhesion and infiltration of 
inflammatory cells. These cells secrete cytokines such as TNF-α, IL-1 and IL-6 and 
upregulate endothelial expression of procoagulant tissue factor (TF). Most importantly, 
alloantibodies directly promote tissue injury by monocytes and NK-cells by antibody-
dependent cellular cytotoxicity (ADCC) through their Fc-receptors. This effector 
mechanism is not only complement-independent but can be initiated by non-
complement fixing antibodies (Lee CY et al., 2007 68); thus graft damage can occur in 
the absence of complement. In addition, it is of great importance, especially in this 
model, that antibody directly promotes exocytosis and release of vonWillebrand factor 
(vWf) resulting in proinflammatory (externalization of P-selectin and leukocyte rolling) 
(Sis B et al., 2010 77) and prothrombotic responses (initiation of coagulation and 
activation of cellular haemostasis) (Yamakuchi M et al., 2007 307). Furthermore, not 
only is it possible that coagulation is initiated independently of complement by such 
mechanisms, but it is also conceivable that coagulation might precede it. In this 
scenario, APT070 treatment of the graft might efficiently inhibit complement activation 
but due to coagulation taking place upstream of endothelial activation, it fails to prolong 
survival, leaving the donor organ subject to devastating thrombotic effects.  
Finally, a recent body of work has revealed that coagulation, and more specifically 
thrombin, may be able to activate complement by a bypass mechanism. Consequently, 
APT070 would have been unable to inhibit activation completely used as single 
therapeutic reagent.   
In conclusion, Mirococept is a potent inhibitor of the classical pathway of complement 
activation. Local use of this inhibitor is known to be active against all three 
complement-activation pathways, and it is of proven efficacy in the pathological setting 
of chronic rejection (Pratt J et al., 2003 290) and ischaemia/reperfusion (Patel H et al., 
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2006 291). These models differ from the HAR model presented here, in that the HAR 
model is dominated by the effects of DSA and has a short ischaemia time (no 
appreciable cold ischaemia and approximately 25 minutes of warm ischaemia). The 
limited effect of APT070 in the present (admittedly extreme) model may suggest that 
early activation of the rat complement system by anti-donor antibodies is less important 
than the complement independent rapid endothelial activation triggered by antibodies 
resulting in the local release of proinflammatory and procoagulant mediators. To further 
investigate this idea, a therapeutic approach was developed for targeting coagulation in 
the HAR model, specifically focusing on thrombin, which could have pivotal role in 












Chapter 5 – Impact of Therapeutic Coagulation Inhibitor PTL006 on HAR 
 
5.1 Introduction  
The lack of therapeutic benefit with the complement regulator APT070 and large 
amount of residual thrombotic microangiopathy prompted an investigation into the 
effect of coagulation blockade in this model of extreme HAR. My hypothesis was that 
endothelial cell protection against thrombogenesis would ameliorate the consequences 
of HAR initiated by preformed DSA in the transplant recipient. The focus of the present 
chapter is a prototype membrane-targeted antithrombotic agent PTL006, developed in 
our laboratory. The effect of donor organ pre-treatment with this agent on HAR was 
investigated. 
PTL006 is a powerful anticoagulant which incorporates the hirulog like (HLL) peptide 
isolated from hirudin and a membrane localizing tail. Its anticoagulant ability is 
attributed to the fact that bivalent interactions with thrombin inhibit the enzyme and 
consequently impair a variety of biological responses. In the hyperimmune model, 
therapeutic intervention with PTL006 could target thrombin’s procoagulant and 
proinflammatory action against the transplanted kidney to improve outcome. 
In a similar fashion to APT070, PTL006 is an engineered therapeutic (though an 
anticoagulant) which directly binds to the graft endothelium via its tail. PTL006 is the 
first in a series of cytotopic anticoagulant reagents and its tail differs from the one 
possessed by APT070. PTL006 binds to the membrane, forming hydrophobic 
interactions with the phospholipid bilayer through a PEGylated modified tag. 
Characterization of this reagent was a starting point for my work, which then went on to 
evaluate its effect in the hyperimmune model. Using the intrarenal perfusion protocol, a 
series of syngeneic and allogeneic transplants were performed to confirm the 
appropriate working concentration of the tailed antithrombin, to examine its ability to 
bind to cells and determine whether administration by this route induced systemic 
anticoagulation. The anticoagulant used for the in vivo experiments was PTL006 and 
then FAM-labelled PTL006 (PTL006-FAM) for immunohistochemistry. This novel set 
of agents were generated and kindly provided by Dr R Smith (KCL).  
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After determining an appropriate dose, PTL006 was perfused via the renal artery into 
DA donor kidneys and the PTL006-treated kidneys were transplanted into pre-sensitised 
Lewis recipients. The allotransplantation model used in these studies was characterized 
by thrombotic microangiopathy, making it an ideal model for dissecting the contribution 
of coagulation to graft outcome. This approach is unusual as catastrophic coagulation in 
humoral immune responses has mainly been addressed using xenotransplantation 
models. For instance, in a cardiac xenotransplantation model, mouse hearts were 
transplanted into rat recipients, whose fibrinogen had been depleted using ANCROD, a 
snake venom. In this study acute xenograft-mediated rejection was delayed by treatment 
(Chen D et al., 2006 308). More relevant to this study, hearts from transgenic mice 
expressing the anticoagulant protein hirudin, expressed on the endothelium of the 
xenograft, were transplanted into rats. These experiments demonstrated that inhibition 
of thrombin resulted in elimination of xenograft rejection (Chen D et al., 2004 309). 
Based on these findings, my experiments addressed the hypothesis that intrarenal 
delivery of anticoagulant PTL006 could reduce antibody-mediated coagulopathy and 
inflammation. Furthermore, the model I developed (Chapter 3) uses inbred rats in an 
allotransplantation setting rather than transgenic organs in xenotransplantation. In this 
regard, the model described here may be considered more clinically relevant.  
5.2 Experimental Design  
An initial series of transplantation experiments was performed to determine a suitable 
dose of PTL006, i.e. one that would enable anticoagulation but avoid system 
anticoagulation and potential bleeding during transplant surgery. Syngeneic 
transplantation was carried out between DA donors and recipients, using a perfusion 
volume of 5ml and concentration of PTL006 at 5 or 1 μM. Allogeneic transplant 
experiments were then performed between DA donors and naïve (i.e. non-sensitised) 
Lewis recipients using the same dosing regimen. During the transplant surgery, any 
bleeding at the site of the anastomosis after release of the microvascular clips was 
scored. Controls included DA kidneys treated with vehicle Soltran solution alone. 
Subsequent transplant experiments between DA donors and hyperimmune Lewis 
recipients used a perfusion volume of 5ml to deliver the PTL006 intra-renally at 
concentrations of 5, 1, 0.1 or 0.01 μM. The same controls and intra-graft delivery 
perfusion protocol were used (as described in Chapter 3). A smaller set of experiments 
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involved transplantation of DA kidneys treated with 2 μM PTL006 (concentration based 
on in vitro data, Melchionna T, unpublished data) into the sensitised Lewis recipients.  
To establish the distribution of retained anticoagulant in the donor kidney, DA kidneys 
were perfused with FAM-labelled PTL006 and transplanted into syngeneic recipients. 
The grafts were removed at 0.5 (n=1) and 24 (n=1) hours post-transplantation and 
frozen kidney sections were prepared and examined by fluorescence microscopy. Tissue 
from kidneys perfused with Soltran solution alone and harvested at the same time points 
served as negative controls (n=1 per time point).   
For the transplants involving hyperimmune recipients, two treatment groups were 
studied. The first group involved PTL006 given alone (to the donor kidney); the second 
group involved a combination of PTL006 and APT070 given to the donor organ. The 
purpose was to look for any additive effects of coagulation and complement inhibition 
on graft survival. As before, graft survival, renal function (BUN) and graft morphology 














5.3 In vivo Dose-finding study of Coagulation Inhibitor PTL006 
PTL006 is the first of a series of novel cytotopic anticoagulants which vary in the nature 
of their membrane-interactive tail. This derivative contains polyethylene glycol (PEG) 
and it has been shown to be a powerful anticoagulant in vitro (Melchionna T et al., 
unpublished data). My transplant experiments describe the first in vivo use of PTL006, 
and are listed in tables 5.1 and 5.2 below. 
For the first set of experiments, syngeneic DA donor organs were treated with Soltran 
containing PTL006 using an intrarenal infusion rate of 1ml/min over 5 minutes. The aim 
was to exclude any toxicity to the graft and any tendency to bleed induced in the 
recipient by PTL006.  These recipients recovered quickly and survived in good health 
for the entire length of the experiment due to the functioning graft (which was life-
supporting as bilateral nephrectomy was performed the day of the transplantation). The 
doses used in these initial experiments were 5 ml at 5 μM (n=2) and 1 μM (n=2) (based 
on in vitro results, Melchionna T, unpublished data). Recipient rats showed no sign of 
distress and were killed at day 10 post transplantation (Table 5.1).  However, post 
operative bleeding (heavy but manageable) was noted at the site of the anastomosis in 
recipients of PTL006-treated grafts. In these animals, bleeding was prolonged and 
required repetitive application of pressure and continuous swabbing with surgicel.   This 
was in contrast to recipients of Soltran-treated control isografts (n=2), where no 
bleeding was observed. In the second group of transplants, where naive Lewis recipients 
were transplanted with DA allograft treated with the same doses of PTL006, prolonged 
bleeding was also noted. This occurred for both the 5 μM and 1 μM PTL006 treatment 
groups. Again, no bleeding was observed for the Soltran-treated donor kidneys (Table 
5.1). 
Apart from the local bleeding, all recipients of PTL006-treated kidneys recovered well, 
with no apparent compromise of survival in syngeneic transplants, or in allogeneic 
transplants in the non sensitised group of recipients. In the latter group, the graft 
survival data correspond to the figures for control allogeneic DA to naïve Lewis kidney 
transplants described in Chapter 3 (MST 5 days). A summary of all the transplants 








+ + heavy but manageable, + normal bleeding,   
Table 5.1: Summary of syngeneic and allogeneic kidney transplants performed between 
DA donors and DA or naïve Lewis recipients. Grafts perfused with PTL006 (1 μM or 5 
μM in 5ml).  Bleeding scores at the anastomosis site are shown. Bleeding did not affect 
graft survival.  
As described previously, PTL006 caused abnormally heavy bleeding upon release of the 
microsurgical clips, however it was successfully controlled.  
The next set of experiments explored the effect of PTL006 in presensitised Lewis 
recipients of DA donor kidneys using the same treatment protocol as above. This used 
the same dose of PTL006 as in the previous experiments, with naïve recipients. In this 
case, where sensitised recipients were used, severe and uncontrolled bleeding occurred 
at the site of the anastomosis and all efforts to rescue the grafts failed, resulting in all 
grafts becoming ischaemic. Disparity of vessel sizes was thought to be pivotal to this 
problem and unavoidable for a number of reasons.  
Experiments were carried out to find the minimum dose for efficacy in sensitised 
recipients. These revealed that PTL006 at 5 (n=1), 1 (n=2) and 0.1 (n=2) μM also 
resulted in severe bleeding. However further dose reduction of PTL006 to 0.01 μM 
(n=3) avoided this problem, so that the rats survived the transplant procedure at this 
dose of treatment. Although no extension of graft survival occurred in the sensitised rats 
(MST 2 days post-transplantation) compared to treatment with Soltran (MST 2 days), 
this experiment confirmed that the bleeding tendency in PTL006-treated kidneys was 
dose-related. In order to deal with the possibility that not all of the infused material was 
bound to the donor kidney endothelium, a change in the perfusion protocol was 
employed. Two extra steps were added: at the end of the 5 minute intrarenal perfusion 









end at d102SOLTRAN DADA
end at d1021 DADA
end at d1025DADA
DONOR RECIPIENT DOSE (μM) n SURVIVAL
DA Lewis 5 2 d7
DA Lewis 1 2 d7
DA Lewis SOLTRAN 2 d5
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time of 10 minutes was introduced to allow the reagent to bind to the endothelium and a 
second flush of the donor organ was introduced with 5 ml of Soltran solution (at 1 
min/ml rate for 5 minutes) to remove any unbound material. In this modified perfusion 
protocol, the optimal concentration of PTL006 was 2 μM (a compromise between the 5 
and 1 μM doses). For the first time in the pre-sensitised recipient, treatment of the donor 
organ with a single cytotopic reagent prolonged the graft survival from MST day 2 to 
day 5 in (n=2). The treatment protocol for future experiments in sensitised recipients 
was based on these conditions. A summary of the transplants performed for this set of 
experiments in hyperimmune recipients is shown in table 5.2.  
 
+ + + severe bleeding, + normal bleeding  
Table 5.2: Summary of kidney transplants performed between DA donors and pre-
sensitised Lewis recipients. Perfusion of the donor organ with PTL006 at 5, 1 and 0.1 
μM resulted in severe bleeding and the recipients did not survive. At 0.01 μM of 
PTL006 the bleeding was normal, but the anticoagulant failed to extend survival. In the 
bottom-row (highlighted), two changes were made: the infusion dose of PTL006 was 2 
μM; and a dwell-time of 10 minutes was introduced before flushing out the kidney with 
Soltran. This eliminated the bleeding tendency and enabled a higher dose of 







5.4 Tissue Distribution of PTL006 in the Kidney Transplant  
The tissue distribution of the anticoagulant was determined by perfusion of DA kidneys 
with 2μM PTL006 directly labeled with FAM (PTL006-FAM), a FITC-like 
fluorochrome. PTL006 becomes inactive (that is, the therapeutic functional activity is 
lost when labelled with FAM but the tail binding is retained), therefore, this reagent was 
used for purely distribution purposes.  PTL006-FAM-treated kidneys were transplanted 
into syngeneic recipients and Soltran-treated kidneys were used as controls.  Following 
the modified perfusion protocol incorporating the extra dwell-time and flush, kidneys 
were transplanted and then removed at 0.5 (n=1) and 24 (n=1) hours post-
transplantation. The kidneys were snap frozen for storage in liquid nitrogen and tissue 
sections later analysed by fluorescence microscope. As shown in figure 5.1 PTL006-
FAM was clearly retained on the glomerular capillary wall at 0.5 hours post 
transplantation. At 24 hours post transplantation, fluorochrome-labelled anticoagulant 
was strongly detected on both distal and proximal tubular epithelium, but no longer on 
the glomerular capillary tuft. Control Soltran-treated kidneys removed at both time 















Figure 5.1: Immunofluorescent detection of PTL006-FAM in DA donor graft removed 
from syngeneic recipients. A:  PTL006-FAM observed in the glomeruli at 0.5 hours 
post-transplantation. B: No detection in DA donor Soltran-treated graft at 0.5 hours 
post-transplantation.  C: Strong PTL006-FAM deposition on distal and proximal tubules 
at 24 hours post-transplantation. D:  No detection in DA donor graft treated with Soltran 
perfusion solution at 24 hours post-transplantation. Representative images were taken at 






5.5 Graft Survival in Pre-sensitised Lewis Recipients of PTL006-treated DA donor 
Kidneys  
Employing the modified perfusion protocol, DA donor kidneys were treated with 
PTL006 or control Soltran solution alone before transplantation into presensitised Lewis 
recipients. Following transplantation, the effect of the coagulation inhibitor on graft 
survival was observed. The results showed that DA donor kidneys pre-treated with 2 
μM PTL006 had significant prolongation of survival in the hyperimmune Lewis 
recipient (MST 4.6 days), compared to Soltran perfused kidneys (MST 1.8 days) 
(Figure 5.2).   
In the PTL006-treated group (n=8) there was 100% graft survival at 24 hours post 
transplantation compared to the Soltran-treated group in which 16.6% of grafts had 
failed (1 of 6). The remaining grafts of the control group (83.3%) had failed by 48 hours 
post transplantation (5 of 6). In contrast, only 12.5% of PTL006-treated grafts had failed 
by 48 hours post transplantation (1 of 8), the average MST for survival of pre-sensitised 
recipients in this hyperimmune model. 50% of animals that received PTL006-treated 
kidneys (4 of 8), had prolonged graft survival to day 5 post transplantation. The survival 
of the remaining 3 animals was extended to day 3, day 4 and day 6 (1 of 8 at each time 
point) (Figure 5.2). Graft loss was defined as high serum BUN, death of the recipient, or 
when the animal had to be killed due to obvious distress, which ever came earliest. 
Thus, a consistent increase in graft survival corresponded to the application of PTL006, 
(2 μM in 5 ml) to donor kidney despite the presence of high titre antidonor antibodies, 
which in the control group led to predictably aggressive graft loss. Given the severity of 
the unprotected injury, survival-increase by several days was a significant feat, as was 
the ability to perform transplant surgery with no bleeding complications. 
 































Figure 5.2: Graft survival curve following transplantation of DA kidneys treated with 
PTL006 or Soltran alone into pre-sensitised Lewis recipients. PTL006 treatment of 
donor organs (5 ml at 2 μM) transplanted into pre-sensitised rats (n=8) achieved 










5.6 Renal Function in Pre-sensitised Lewis Recipients of PTL006-treated Kidneys 
from DA donors 
The renal function of graft recipients in the experiment described in section 5.5 was 
monitored daily until graft failure occurred. The BUN levels for sensitised recipients 
that received DA kidney pre-treated with 5 ml of 2 μM of PTL006 were lower and 
increased more gradually compared to that of recipients of Soltran-treated transplants 
(Figure 5.3A). Given the severity of the vascular injury by 24 hours post-transplantation 
in the untreated HAR model, it is remarkable that the renal function of the PTL006-
treated group was almost in the normal range (BUN<10mmol/L) at this time-point, 
whereas the BUN in the Soltran-treated group was significantly impaired with BUN 
approximately 30 mmol/L (Figure 5.3B).  
So, while treatment with the complement regulator APT070 had provided little or no 
benefit (Chapter 4), the anti-thrombin protocol developed for PTL006 appeared 
promising, since a safe dose of PTL006 (2 μM) prevented sudden loss of graft function 























































Figure 5.3: Renal function (BUN) post-transplantation following treatment of the donor 
organ with PTL006 (5 ml at 2 μM) or Soltran control. A: PTL006 treatment of DA 
donor organ slowed the decline of renal function in hyperimmune Lewis recipients. In 
contrast, there was immediate dysfunction in recipients of Soltran-treated grafts. B: 
BUN at 24 hours post-transplantation (p=0.0426) showing good immediate preservation 




5.7 Graft Pathology in Pre-sensitised Lewis Recipients of PTL006-treated Kidneys 
from DA donors 
As mentioned, MST for PTL006-treated grafts transplanted into hyperimmune 
recipients was 4.6 days post-transplantation, compared to 2 days for controls. 
Histological examination of protected grafts was carried out at day 5 (n=4) and 
compared to those of Soltran-treated grafts (n=5) rejected at day 2 post-transplantation 
(MST was 1.8 days post-transplantation).  
Histology of the treated kidneys showed signs of antibody-mediated rejection, namely 
extensive fibrinoid necrosis and glomerular thrombosis with the presence of 
inflammatory cells on the peritubular capillaries. In addition, there was evidence of cell-
mediated rejection, i.e. diffuse lymphocytic infiltrate with invasion of the renal tubular 
epithelium and the glomerular and arterial endothelium (Figure 5.4). In contrast, the 
Soltran-treated kidneys (at day 2 post-transplantation) revealed only antibody-mediated 
rejection and absence of infiltrating T-cells (Figure 5.5).  
This assessment of graft morphology (at these 2 different time points) revealed that a 
single intrarenal dose of PTL006 was able to slow the rejection process from an 
aggressive, instant antibody-mediated rejection and convert it into a less vigorous acute 
antibody and cellular rejection. This could have important clinical implications as the 
latter may be more treatable or preventable with the addition of conventional 


























Figure 5.4: Histology of donor kidneys treated with PTL006. A: Representative tissue 
from a DA kidney allograft treated with PTL006 (n=4), taken from a pre-sensitised 
Lewis recipient at day 5 post-transplantation showing widespread lymphocytic tubulitis 
(H&E; x100).  B: Tubulitis and glomerulitis (H&E; x200). C: Thrombosed glomerulus 
and surrounding tubules with characteristic lymphocytic infiltration (MSB; x400). D: 
Fibrinoid necrosis (MSB; x200). E: Fibrin deposition in a glomerulus (MSB; x400). F: 










Figure 5.5: Control donor kidneys treated with Soltran alone. A: Histology of 
representative DA kidney allograft treated with Soltran (n=5) and removed from a pre-
sensitised Lewis recipient at day 2 post-transplantation showing extensive 
thromboangiopathy (arrows), neutrophilic and monocytic infiltration on the PTC and 
general infarction (MSB; x100). B: Thrombotic glomeruli (arrow) and surrounding 












5.8 Results of Combined PTL006/APT070 Treatment of donor Kidney in 
Sensitised Recipients 
After investigating the effects of the coagulation inhibitor PTL006 alone, an additional 
set of transplants was carried out. In this group, hyperimmune Lewis rats received DA 
kidneys that had been treated simultaneously with a mixture of PTL006 and APT070, to 
investigate potential synergy of coagulation and complement blockade on graft survival. 
DA donor kidneys pre-treated with 2 μM of PTL006 and 80 μg/ml of APT070 resulted 
in a significant prolongation of survival of the hyperimmune Lewis recipients (MST 
5.5), compared to the recipients that received Soltran perfused kidneys (MST 1.8 days).    
In the PTL006/APT070-treated group (n=8) no graft loss occurred within 48 hours of 
transplantation, whereas in the Soltran-treated group 100% of the kidneys were rejected 
by 48 hours post-transplantation. The remaining animals of the control-treated group 
(83.3%) had to be culled at 48 hours post transplantation (5 of 6) with no survival 
beyond this time point. In contrast, 25% of the PTL006/APT070-treated group had a 
prolonged graft survival to day 4 post-transplantation (2 of 8) and the remaining grafts 
were lost by day 7 (Figure 5.6).  
Thus, simultaneous inhibition of coagulation and complement following a single 
treatment of membrane-localizing inhibitors, PTL006 (5 ml of 2 μM) and APT070 (80 
μg/ml) achieved significant prolongation of survival compared to control treatment of 



































Figure 5.6: Graft survival curve following transplantation of DA kidneys treated with 
PTL006/APT070 into pre-sensitised Lewis recipients. The combined treatment of donor 
organs with 5 ml of 2 μM PTL006 and 80 μg/ml APT070 (n=8) achieved significant 









5.9 Renal Function in Pre-sensitised Lewis Recipients of DA Kidneys treated with 
a combination of PTL006 and APT070 
The BUN levels for the experimental groups described in section 5.8 were found to 
correspond with the graft survival data. The BUN levels showed a more gradual renal 
decline (BUN increase) over time, compared to recipients with Soltran-treated donor 
organs (Figure 5.7 A). There seemed to be a clear (but not significant) difference in the 
level of protection provided by the combination therapy at 24 hours post transplantation. 
BUN in the control group was approximately 30 mmol/L whereas in the 
PTL006/APT070-treated group, the mean BUN was approximately 15mmol/L (Figure 
5.7 B).  
These data indicate that pre-treatment with PTL006 and APT070 protected the donor 
organ against instant loss of renal function after transplantation into a hyperimmune 
recipient. This was apparent at 24 hours post-transplantation after the onset of HAR. It 
is not yet clear if this combination is more effective than PTL006 alone, since no direct 























































Figure 5.7: Renal function with combined PTL006/APT070 intervention. A: 
Combination treatment of the DA donor organ with 5 ml of 2 μM of PTL006 and 80 
μg/ml of APT070, improved initial renal function of the kidneys in transplanted 
hyperimmune Lewis recipients with a relatively gradual impairment observed over     
time. This was in contrast to the immediate dysfunction of the kidneys in the Soltran-
treated group. B: A difference in BUN between the PTL006/APT070-treated group and 
Soltran group at 24 hours post transplantation was observed but it was not significant 
(p=0.0593). Data shown was generated simultaneously to that shown in Figure 5.3. The 
same control group is shown in each graph for comparison.  
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5.10 Graft Pathology of PTL006/APT070-treated donor organs transplanted into 
Pre-sensitised Lewis Recipients  
An MST of 5.5 days was achieved in donor organs pre-treated with a combination of 
PTL006 and APT070, following transplantation into sensitised Lewis rats. This was in 
contrast to MST 2 days for Soltran-treated controls. Histological data was obtained for 
kidneys rejected from three animals at day 5 post-transplantation and from three animals 
at day 7 post-transplantation.  
Essentially, the changes produced by the treatment combination were similar to those 
described with PTL006 treatment alone, earlier in this chapter. Kidneys assessed at day 
5 and day 7 post-transplantation showed signs of humoral as well as cellular rejection 
(Figure 5.8). This mixed pattern of rejection involved significant lymphocytic 
infiltration and invasion of the basement membranes of the renal tubules, causing tissue 
disruption. In parallel there was ongoing acute AMR with monocytes in the glomerular 
and peritubular capillaries. Fibrinoid necrosis was present in all grafts.  This is in 
contrast to the Soltran-treated kidneys, which at day 2 post-transplantation exhibited 
features of pure AMR, with a clear absence of lymphocytes (Figure 5.5).  
Thus, combined intrarenal delivery of PTL006 and APT070, morphologically, was able 
to modify the rejection pattern from an early aggressive, primarily vascular type of 
rejection, and convert it into to a predominant pattern of cellular rejection alongside 
milder vascular changes, which may have important implications for therapy.     












Figure 5.8: Histology of DA donor kidneys treated with PTL006 and APT070 following 
transplantation into pre-sensitised Lewis rats. A-D: Representative findings from 
allografts rejected at day 5 post-transplantation (n=3). A: Area of extensive lymphocytic 
tubular infiltration and peritubular capillaritis (H&E; x100). B: Fibrinoid necrosis 
(H&E; x400). Inset shows glomerulitis and tubulitis (H&E; x400). C: Lymphocytes 
entering the tubular basement membranes (H&E; x400). D: Arterial fibrinoid necrosis 
(MSB; x200). E and F: Representative findings from treated kidney allografts rejected 
at day 7 post-transplantation (n=3). E: Fibrinoid necrosis (MSB; x400). F: Lymphocytic 
infiltration (PAS; x100).   
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5.11 Discussion   
The main objective of the experiments described in this chapter was to characterize in 
vivo the novel cytotopic coagulation inhibitor PTL006. More specifically, it aimed to 
determine a safe working concentration for intrarenal delivery, confirm binding of 
PTL006 within the kidney and determine its distribution. A final aim, once defining the 
desired characteristics, was to test this thrombin inhibitor in the model of HAR.  
The dose-ranging study was performed using a series of syngeneic and allogeneic 
transplants between DA donors and DA or naïve Lewis recipients. The syngeneic 
transplants, in which the DA kidney was perfused with varying concentrations of 
PTL006, showed that PTL006 was not directly pathogenic to the kidneys and graft 
survival was unimpaired, compared to recipients of Soltran-treated control grafts. Two 
different concentrations of the inhibitor were tested: 5 ml per kidney of 5 and 1 μM (for 
both the syngeneic and allogeneic transplants).  
An important observation during the transplant surgery in this group was heavy 
bleeding at the site of the anastomosis, related to the use of PTL006. This was not noted 
in recipients of Soltran-treated kidneys. The bleeding was unexpected as the unique 
aspect of this therapy is that the modified inhibitor has a novel synthetic tail which 
tethers the therapeutic agent (here an anti-thrombin) to the phospholipid bilayer of cell 
membrane. This cytotopic delivery should minimize any systemic effects of 
administering the inhibitor that could harm the recipient, in this case prolonged 
bleeding. However, it appeared that some of the reagent was unbound to the donor 
organ and upon blood reperfusion entered the circulation. Thus heavy bleeding occurred 
when the renal artery (not the vein) was anastomosed to the recipient circulation. 
Bleeding was also occurring at the ureteric anastomosis. Nonetheless, in these 
syngeneic and allogeneic transplants involving recipients, the heavy bleeding related to 
PTL006 was manageable and successful transplantation was achieved. Bleeding was 
controlled by prolonged and repetitive application of pressure and continuous swabbing 
with surgicel. When transplantation was performed in hyperimmune recipients, the 
same dose of PTL006 administered to the donor kidney was associated with 
uncontrollable bleeding at the arterial anastomosis, causing the death of the animal 
(under anaesthesia) or total ischaemia of the donor organ. This problem was 
exacerbated by an inherent difference in size of the two rat strains, Lewis rats being 
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significantly larger than age-matched DA rats. This resulted in controllable bleeding in 
unsensitised recipients. The vessel size disparity is exaggerated after the two month 
period required for Lewis sensitisation. In many cases, the renal artery of the sensitised 
Lewis rat was twice the diameter of the donor DA renal artery. Perfusion of the kidneys 
with lower doses of PTL006 (5 ml at 0.01 μM) reduced the bleeding, but efficacy was 
lost.  
Further modification of the PTL006 infusion protocol by introducing two additional 
steps proved helpful. Rather than being immediately transplanted into the pre-sensitised 
recipient, the PTL006-treated kidney was allowed to rest on ice and kept moist with 
cold saline for a period of ten minutes. Following this, an additional perfusion (wash 
through) with 5 ml of Soltran (over 5 minutes) was performed to remove any unbound 
material. The dose of PTL006 used for these transplants was 5 ml at 2 μM per kidney. 
The modifications of the protocol resulted in a clear prolongation of the survival of the 
treated grafts (in hyperimmune recipients) to MST day 5 post-transplantation.   
Binding of PTL006 in perfused DA kidneys transplanted into syngeneic recipients was 
confirmed using the fluorescent conjugate PTL006-FAM, which enabled direct 
visualization using a fluorescence microscope. Each kidney was perfused with 5 ml 
PTL006-FAM at 2 μM, and strong staining was detected on the glomerular capillary 
surface at 0.5 hours post-transplantation. Although the image was bright, it would have 
been possible to increases the sensitivity by using an antibody against the hirulog 
peptide (HLL) component of PTL006. This additional layer could have potentially made 
the signal stronger and possibly revealed staining in less obvious areas of the kidney 
such as the peritubular capillaries.  
Having generated preliminary data using PTL006 at a dose of 5 ml at 2 μM per kidney, 
showing an effect on transplant survival in the primed Lewis rats, a further experiment 
with a larger number of transplants under identical conditions was carried out for the 
purpose of statistical analysis. The data generated showed that a single anticoagulant 
treatment of the graft led to prolonged graft survival (MST 4.6 days, n=8) in 
comparison to Soltran-treated grafts (MST 1.8 days, n=6). The pathological mode of 
rejection after PTL006 treatment of the organ appeared to switch from a pure, 
aggressive form of AMR (at 2 days post-transplantation) to a mixed picture with 
features of cell mediated rejection as well as AMR (at 5 days post-transplantation). 
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These features included lymphocytic infiltration of the renal tubules and arteries 
indicative of cell mediated rejection, and thrombotic microangiopathy consistent with 
AMR. As expected, Soltran-perfused kidneys rejected at day 2 post-transplantation 
exhibited marked histological features AMR with extensive thrombosis and overall 
infarction.    
The mechanism by which PTL006 delayed and reduced the vascular component of 
injury can be related to the inhibition of thrombin by the active component (hirulog). 
Thrombin is a multifunctional serine protease that plays a pivotal role in coagulation. It 
recruits platelets and converts soluble circulating fibrinogen into fibrin monomers, 
which polymerize to form an insoluble blood clot. Thrombin is short lived in the 
circulation; however under pathogenic conditions accumulation of coagulation factors 
with extravascular Tissue Factor initiates the enzymatic process of coagulation. As a 
result, thrombin acts near the disrupted site at which it is produced (Esmon CT et al., 
1999 310). In this model, thrombin is generated when alloantibody is deposited onto the 
transplanted endothelium. Upon treatment of the graft with PTL006, the procoagulant 
effects mediated by thrombin are likely to have been inhibited by reducing formation of 
a platelet plug and fibrin clot. Since PTL006 was shown to be retained by the small 
vessels of the graft at 0.5 hours post-reperfusion, its therapeutic effects will have been 
active during the window in which HAR occurs. In addition, since thrombin has the 
ability to amplify its own activity, the use of PTL006 could prevent feedback activation 
of coagulation, which is likely to have contributed to the severity of vascular injury seen 
in the untreated model. 
The therapeutic effects of PTL006 on graft survival and minimizing injury could also 
have been due to inhibition of the pro-inflammatory properties of thrombin. A study 
reported by Chen D et al. sheds some light on this. In a xenotransplantation setting, 
mice hearts were transplanted into rats that had been treated with ANCROD, thus 
depleting fibrinogen. However, fibrinogen-depletion had no effect on the prolongation 
of survival or influx of inflammatory cells (predominantly macrophages and NK cells). 
In the same study, parallel experiments were carried out involving transplantation of 
hearts from transgenic mice expressing endothelial tethered anti-coagulant hirudin 
protein, into rat recipients. The results showing prolonged graft survival and marked 
reduction of inflammatory cells and expression of MCP-1 highlighted the anti- 
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inflammatory properties of thrombin blockade, as opposed to the impact of fibrinogen 
depletion  (Chen D et al., 2008 311). In a similar manner, the effects of PTL006 on the 
survival of the treated kidneys in primed Lewis rats may also have been due to targeting 
the proinflammatory properties of thrombin.  
Thrombin signalling is mediated by a small family of G-proteins coupled to protease 
activated receptors (PARs) (Coughlin SR, 2000 129) and thrombin-mediated PAR 
receptors are expressed on the endothelium which, upon ligation, promote the release of 
chemokines (such as MCP-1). Indeed, thrombin, acting through PAR receptors, can 
have a variety of effects on endothelial cells, all contributing to cell injury. Thrombin 
causes the release of vWf from the endothelium which stimulates other 
proinflammatory responses, such as exocytosis of P-selectin (Lowenstein CJ et al., 2005 
100). P-selectin is extremely important because it can mediate platelet aggregation and 
leukocyte adhesion (Yamakuchi M et al., 2007 307). In an in vivo model of cardiac 
allotransplantation, blocking P-selectin expression reduced monocyte recruitment 
mediated by the ligation of MHC Class I antibody to the endothelium (Valenzuela NM 
et al., 2013 312).  
Thrombin is one of the most potent activators of platelets. Through interactions with the 
glycoprotein GP (Ib-V-IX) complex and vWf, the initial capture of platelets by the 
endothelium takes place. However, for sustained platelet activation, this process must be 
reinforced by locally generated thrombin. Inhibiting thrombin with PTL006 could 
potentially lead to platelet impairment. Platelets are pivotal to the rejection of 
vascularized organs (Kirk AD et al., 2009 104). Under the influence of potent agonists, 
especially thrombin, platelets release microparticles (MP) containing P-selectin 
contributing further to the inflammatory responses. Platelets not only express P-selectin 
but also CD40L (CD154) which further enhances their interaction with leukocytes. Thus 
treating DA kidneys with the coagulation inhibitor PTL006 prior to transplantation into 
pre-sensitised Lewis recipients, could have had a significant anti-platelet effect, 
dampening local inflammation that contributed to HAR in my model. 
In AMR, it is known that complement activation is identified through C4d positive 
staining on the PTC. Complement inhibition alone did not have an effect on retarding 
the process of rejection. Complement may be activated in this model by the classical 
pathway, but in addition proteases of the coagulation cascade, especially thrombin, are 
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known to cleave pivotal complement components (e.g. C3 to C3a and C3b, or C5 to 
C5a and C5b) therefore amplifying complement activation (Markiewski MM et al., 
2007 186). If, in vivo, thrombin can act as a convertase generating biologically active 
anaphylatoxins by direct cleavage of C3, C4 and C5, it will bypass standard 
complement inhibition at the convertase level. This would explain a lack of effect by 
complement inhibitor APT070 (Mirococept). As a result, inhibiting thrombin could 
potentially affect both complement-independent and complement-dependent 
mechanisms involved in HAR. Consequently, an extra group of DA transplants were 
prepared, in which the donor organ was treated with a combination of APT070 and 
PTL006 by intrarenal perfusion before transplantation into primed Lewis recipients. A 
non-significant additive effect was noted compared to the PTL006 alone treatment 
group, although according to the data generated previously, survival could only be 
attributed to the anticoagulant (PTL006) action. Finally, histological analysis of the 
kidneys treated with the combination therapy gave a very similar picture to that of 
PTL006-treated kidneys. A mixed immune response with elements of both cellular and 
humoral arms of rejection was observed. Indeed, the extent of cellular infiltration of the 
tubules and interstitium suggested that the T cell response against the donor organ made 
a significant contribution to the cause of graft rejection, whereas the untreated grafts 
were rejected though a humoral, antibody-mediated process.  
The PTL006 cytotopic therapy introduced in this study does not directly target 
antibodies, nor does it have a known effect on lymphocytes, which in this model, start 
making an appearance at day 3 post-transplantation (data not shown). For this reason, 
the next chapter will focus on targeting the cellular responses (using standard 
immunosuppression) in animals that receive PTL004 (Thrombalexin)-treated kidneys. 
As noted elsewhere, PTL004 is the result of further development (as will be discussed 
later) of PTL006 with a number of potential advantages (including ease of synthesis).    






Chapter 6 - Therapeutic Intervention using a novel Inhibitor of Coagulation 
PTL004 (Thrombalexin) in a Rat Model of HAR  
 
6.1 Introduction  
A newly developed anti-coagulant reagent called PTL004 (Thrombalexin) was 
produced using the same peptide sequence (hirulog-like peptide, HLL) as PTL006, but 
with a different membrane-inserting tail. As was mentioned in chapter 5, PTL006 has a 
polyethylene glycol (PEG) tail, which facilitates binding and insertion to the 
phospholipid bilayer and also increases agent solubility. In contrast, in PTL004, the 
HLL peptide is linked by a disulphide bond to a double myristoyl (bis) tail. The bis-
myristoyl tail is likely to be better retained at the site of attachment than its counterpart 
(with a single myristoyl). Finally, PTL004 is quite a small molecule (4.6 kDa) – about 
the same size as insulin (5.8 kDa). 
Following the same rationale, that by treating DA kidneys with this cytotopic reagent 
before transplanting into hyperimmune Lewis recipients, the immune insult to the 
endothelium mediated by thrombin’s pro-coagulant and pro-inflammatory properties 
could be reduced, the effects of PTL004 were tested in this HAR rat model. Use of this 
potentially more efficient anti-thrombin reagent may further prolong graft survival. In 
addition, studies were extended to also target lymphocyte-mediated rejection, which in 
this highly sensitised model is observed from day 3 post-transplantation (data not 
shown). Specifically, the effects of standard immunosuppression (the calcineurin 
inhibitor Cyclosporine A or the mTOR inhibitor Rapamycin) with PTL004, were 
investigated.   
 
6.2 Experimental Design 
PTL004 was used in the pre-sensitised model of allotransplantation between DA donors 
and Lewis recipients. The experiments included DA kidneys perfused intrarenally with 
2 μM PTL004 in 5 ml of, Soltran, before being transplanted into pre-sensitised Lewis 
recipients. The modified perfusion protocol was used for the intragraft delivery, which 
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included a 10-minute dwell-time and a final flush of the kidney to avoid excess bleeding 
at the site of arterial anastomosis. A control group was perfused with Soltran solution 
alone. Soluble anticoagulant (untailed HLL) was not used as a control to avoid the risk 
of systemic anticoagulation in the recipients. An additional group received 5 ml of 2 μM 
PTL004 and T-cell immunosuppression by Cyclosporine A (CsA). Administration of 
CsA to the recipient commenced 2 days prior to renal transplantation at a dose of 
10mg/kg/day given intraperitoneally and continued daily until rejection of the 
transplant, as defined in Chapter 2. A control group of pre-sensitised Lewis rats 
received the CsA but kidneys were perfused with Soltran alone (no PTL004).  
Alternatively, Rapamycin was also used as the T-cell immunosuppressive reagent in a 
second set of experiments. Presensitised Lewis rats received PTL004-treated DA 
kidneys with simultaneous intraperitoneal administration of Rapamycin at a dose of 
1.5mg/kg/day, on the day of transplantation. Rapamycin therapy continued daily, until 
the end of the experiment. A control group comprised of pre-sensitised Lewis rats that 
received Rapamycin and Soltran-treated kidneys. Following transplantation, survival of 
the transplant was monitored as before, including renal function measured by daily 
serum analysis of blood urea nitrogen (BUN). Graft pathology was also assessed in the 
experimental groups described.  
Finally, for mechanistic evaluation, a third group of DA kidneys were perfused with 
PTL004 and transplanted into hyperimmune Lewis recipients, and in this case the 
recipients were then sacrificed at 24 (n=2) and 48 hours (n=2) post-transplantation so 
that the transplant organ could be stained for MAC (C5b-9) before the organ had ben 
rejected. In this experiment, the aim was to determine whether inhibition of coagulation 








6.3 Graft Survival in Pre-sensitised Lewis Recipients of PTL004-treated Kidneys 
from DA donors 
DA donor kidneys pre-treated with 5 ml of 2 μM PTL004 had a significant prolongation 
of survival in hyperimmune Lewis recipients (MST 5.1 days), compared to the 
recipients that received Soltran-perfused kidneys (MST 1.5 days).   
The PTL004-treated group (n=6) exhibited 100% graft survival at 24 hours post 
transplantation, as opposed to 50% for the Soltran-treated group (2 of 4). The remaining 
donor organs of the control-treated group survived to 48 hours post transplantation (2 of 
4). In contrast, of the animals that received PTL004-treated kidneys (3 of 6), 50% had 
extended graft survival to day 5 post transplantation. The survival of the remaining 
animals was equally distributed (1 of 6) between days 3, 6 and 7 (16.6% each) (Figure 
6.1).  
PTL004, in a perfusion-concentration of 2 μM, was therefore effective in prolonging 
graft survival in hyperimmune recipients. By comparison with earlier results for 
PTL006 (Chapter 5), there was no clear difference in graft survival. This indicated that 
regardless of the tail possessed by the anticoagulants (PEGylated in PTL006 and bis-






























Figure 6.1: Graft survival following transplantation of DA kidneys treated with PTL004 
into pre-sensitised Lewis recipients. PTL004 treatment of donor organs at a dose of 5 ml 
at 2 μM (n=6) achieved significant prolongation of survival compared to Soltran-treated 











6.4 Renal Function in Pre-sensitised Lewis Recipients of PTL004-treated Kidneys  
Renal function in the Lewis recipients was monitored daily post transplantation until 
graft loss. BUN measurement showed the decline in renal function after transplantation 
was delayed, relative to the decline in recipients of Soltran-treated control transplants 
(Figure 6.2 A). Significant protection by PTL004 therapy was evident at 24 hours post 
transplantation. The average BUN value in the Soltran-treated group was >35 mmol/L 
whereas the BUN for kidneys that received PTL004 was normal, i.e. <10mmol/L at this 
time (Figure 6.2 B).  
Kidney protection with 5 ml of 2 μM PTL004 was therefore effective at postponing the 


































































Figure 6.2: Renal function after PTL004 intervention. A: PTL004 treatment of DA 
donor organs, at a dose of 5 ml at 2 μM, prevented immediate deterioration of renal 
function following transplantation into hyperimmune Lewis recipients. Control 
treatment with Soltran was ineffective. B: There was significant improvement of BUN 
(lower normal levels) at 24 hours post transplantation (p=0.0190) for the PTL004-
treated group.   
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6.5 Histology of PTL004-treated DA donor Kidneys rejected by Pre-sensitised 
Lewis Recipients  
Since the MST for PTL004-treated grafts was 5.1 days and for control grafts was 1.5 
days, histology of rejected PTL004-treated grafts was possible at day 5 (n=3) and on 
day 2 post-transplantation for the control group (n=2).  
Results for the PTL004-treated group showed evidence of both cell-mediated rejection 
(lymphocytes in the tubules and glomeruli) and antibody-mediated rejection 
(inflammatory cells in the PTC and fibrin in the microvasculature) at day 5 post-
transplantation (Figure 6.3). However, the overall impression was that there was less 
thrombosis although a quantitative study was not carried out.  In contrast the Soltran-
treated kidneys at day 2 post-transplantation showed only antibody-mediated rejection, 
no lymphocytic infiltrates (Figure 6.4).  
This assessment of graft morphology revealed that a single intrarenal delivery of 
PTL004 was able to slow the rejection process from an aggressive, accelerated 
antibody-mediated rejection to a less vigorous acute antibody and cellular rejection. 














   
Figure 6.3: DA donor kidneys treated with PTL004 and rejected by pre-sensitised Lewis 
recipients on day 5 post-transplantation (n=3). A: Typical section showing signs of 
lymphocyte-mediated rejection in the form of tubulitis (PAS; x200) and glomerulitis 
(inset) (PAS; x400). B: Extensive peritubular capillaritis with presence of monocytes in 
the PTC (PAS; x400). C: Small vessel fibrinoid necrosis (MSB; x400). D: Glomerular 









Figure 6.4: DA donor kidneys treated with Soltran and rejected by pre-sensitised Lewis 
recipients at day 2 post-transplantation (n=2). A: Representative allograft showing 
features of HAR with infarcted area of tubules, thrombosed glomerulus and arteriole 
(MSB; x200). B: Extensive fibrinoid necrosis on arterial wall, neutrophilic and 












6.6 Impact of CsA or Rapamycin on survival of PTL004-treated Grafts in 
Hyperimmune Recipients  
In section 6.3 it was shown that most PT004-treated grafts were rejected by 
hyperimmune rats between days 5-7 post transplantation, coinciding with a dense 
lymphocytic infiltrate. My hypothesis for the next set of experiments was that control of 
T cell mediated rejection using conventional T cell suppressive agents would extend the 
graft survival beyond that enabled by PTL004 graft treatment alone. Cyclosporine A 
(CsA) was initially used, as this calcineurin inhibitor has an established record of 
suppressing T cell mediated rejection, in the clinic and in experimental animals.  
CsA treatment of pre-sensitised Lewis recipients commenced 2 days before 
transplantation, using a dose of 10mg/kg/day intraperitoneally. The treated 
hyperimmune rats then received a DA kidney pre-treated with 5 ml of 2 μM PTL004 in 
Soltran (n=8). Daily CsA treatment continued until graft loss.  Graft loss in animals that 
received this combination therapy was unexpectedly biphasic. 50% of the animals (n=4) 
rejected the kidneys in an accelerated fashion whereas 50% had prolonged survival in 
comparison to CsA treatment alone, i.e. the kidney was perfused only with Sotran (n=6) 
(Figure 6.5). In detail, 37.5% of recipients that received both CsA and PTL004, lost 
their graft at 24 hours post-transplantation (3 of 8) and one (12.5%) had graft loss by 48 
hours post-transplantation (1 of 8). In contrast, the remaining 4 animals of the 
PTL004/CsA group had substantially extended survival. 12.5% of the animals survived 
to day 7 post-transplantation (1 of 8) whereas 25% survived to day 8 post-
transplantation (2 of 8). Remarkably for this model, 12.5% (1 of 8) survived to day 10 
post-transplantation. Overall, the MST of the PTL004/CsA group was 4.8 days post 
transplantation and did not result in significant prolongation of graft survival compared 
to the control group. Animals that received CsA treatment and Soltran-perfused kidneys 
rejected their grafts in an accelerated manner, as expected. This meant 66.7% of the 
grafts had failed at 24 hours post-transplantation (4 of 6) and the remaining 33.3% 
grafts had failed at 48 hours post-transplantation (2 of 4), with an MST of 1.3 days post-
transplantation. Thus, CsA in the stated dose had no overall benefit in this pre-sensitised 
model. However, this calculation of the mean survival time may be misleading, since 
the graft loss in the combined treatment group was biphasic, suggesting that in half of 
the group that benefit of PLT004 was actually lost. 
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Figure 6.5: Graft survival curve for PTL004-treated DA donor organs transplanted into 
pre-sensitised CsA-treated Lewis recipients. The combination of PTL004 (5 ml of 2 
μM) treatment of donor organ and CsA (10mg/kg/day) treatment of the recipient (n=8) 
failed to significantly prolong graft survival compared to treatment with CsA alone, i.e. 
where the donor organ was Soltran-treated (n=6) (p=0.0633).  
 
Paradoxically, one of the major limitations of CsA in clinical and experimental use is 
nephrotoxicity. It can cause acute necrosis of the renal tubule and less commonly can 
mediate acute endothelial injury of the donor vasculature (Davies DR, 2000 313), 
Malyszko J et al., 1996 314).  Although the dose of CsA used in my experiments was 
based on successful use in rat kidney transplant models (Chen D et al., 2008 311), it is 
possible that endothelium could have been sensitised by CsA to antibody mediated 
rejection and hence offset the beneficial effect of PTL004 identified in the absence of 
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CsA. Nonetheless, the inconsistent results and overall failure of CsA to extend graft 
survival prompted a change of immunosuppression to Rapamycin.  
In the following exploratory experiment rapamycin was administered intraperitoneally 
at a dose of 1.5mg/kg/day to the pre-sensitised Lewis recipients on the day of 
transplantation. The DA donor kidney was perfused with 5 ml of 2 μM PTL004 before 
implantation.  Rapamycin treatment continued daily until graft failure.  
With this combined treatment of PTL004 and Rapamycin (n=6), graft survival was 
significantly prolonged compared to Rapamycin alone in recipients of a Soltran-treated 
kidney (Figure 6.6). Namely, in the combined treatment group, graft failure was equally 
distributed (16.7%) between days 1, 4, 5 and 9 (1 of 6 at each time point) whereas 
33.3% of animals had extended graft survival to day 8 post-transplantation (2 of 6). 
MST was 5.8 days post-transplantation compared to the group that received Rapamycin 
and Soltran-perfused kidneys (n=4) with an MST of 1.5 days post-transplantation 
(Figure 6.6). In this group, 50% survived 24 hours (2 of 4) and 50% to 48 hours post-
transplantation (2 of 4).   
In conclusion, the combination of Rapamycin treatment of the recipient and PTL004 
treatment of the donor kidney was associated with enhanced graft survival compared 
with Rapamycin treatment alone. The MST achieved with this combination was 
amongst the best out of the other treatment protocols (Figure 6.1) and the results with 
Rapamycin were more consistent than with CsA in this combined treatment model (Fig 
6.5).  The next step would have been to optimize the combined treatment protocol (of 
Rapamycin/PTL004) by direct comparison with PTL004 alone and also by escalating 
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Figure 6.6: Graft survival following transplantation of DA kidneys treated with PTL004 
into pre-sensitised Lewis recipients receiving Rapamycin. The combination of PTL004 
(5 ml of 2 μM) treatment of donor organs and Rapamycin (1.5mg/kg/day) treatment of 
the recipients (n=6) achieved significant prolongation of graft survival (p=0.0188) 











6.7 Renal Function in Pre-sensitised Lewis Recipients treated with CsA or 
Rapamycin and transplanted with PTL004-treated DA Donor Kidneys  
In both combination groups, PTL004/CsA and PTL004/Rapamycin, renal function in 
the Lewis recipients was monitored by BUN measurement on each day after 
transplantation until the time of transplant failure. The treatment protocols for CsA, 
Rapamycin and PTL004 are described in Section 6.2. 
For the CsA group, BUN levels are shown in figure 6.7. BUN measurements identified 
two divergent sub-groups in the combined PTL004/CsA: those with rapid onset graft 
failure and those with delayed graft failure (Figure 6.7 A). Taking the group as a whole, 
however, at 24 hours post-transplantation BUN levels were significantly lower in the 
PTL004/CsA group compared to the CsA/Soltran treatment group (Figure 6.7 B).  
For the Rapamycin group, BUN levels appear in figure 6.8. Combined treatment with 
PTL004/Rapamycin was associated with delayed onset and a slower progression of 
renal transplant failure compared to Rapamycin/Soltran treatment group (Figure 6.8 A). 
Significant protection against graft failure was afforded by PTL004/Rapamycin therapy 
at 24 hours post-transplantation in comparison to the Rapamycin-treated group 
receiving Soltran-perfused kidneys (Figure 6.8 B).  
Consistent with the findings on graft survival, these functional measurements showed 
no overall benefit of CsA treatment in the recipient added to treatment of the donor 
organ with PTL004, when compared with PTL004 alone, although there was a transient 
benefit at 24 hours post-transplantation. In contrast, substitution of CsA with 
Rapamycin caused a more gradual onset of renal impairment compared to the 
Soltran/Rapamycin group; nonetheless, functional deterioration was observed in all 























Figure 6.7: Renal allograft function with PTL004/CsA intervention. A: PTL004/CsA 
treatment led to improved renal function in 50% of the transplanted hyperimmune 
Lewis recipients compared with the Soltran/CsA-treated group. B: BUN measurement 
at 24 hours post-transplantation  showed better renal function  in the PTL004/CsA 
group compared to Soltran/CsA controls (p=0.02).  
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Figure 6.8: Renal allograft function with PTL004/Rapamycin intervention. A: 
PTL004/Rapamycin treatment improved renal function compared with the 
Soltran/Rapamycin-treated group. B: There was marked protection against transplant 
failure at 24 hours post-transplantation (p=0.0381) in the PTL004/Rapamycin treatment 
group compared with Soltran/Rapamycin controls.   
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6.8 Histology of PTL004-protected grafts transplanted into Hyperimmune 
Recipients treated with CsA or Rapamycin 
In the CsA study, pathology was assessed in the graft tissue from animals that had 
received 5 ml of 2 μM-PTL004-perfused kidneys and daily intraperitoneal injections of 
CsA at 10mg/kg/day.  
In the sub-group of 4 transplants with rapid rejection (50% of the whole group treated 
with CsA/PTL004), histological examination showed evidence of extreme infarction 
and vacuolated renal tubules, a phenotype often associated with CsA-induced 
nephrotoxicity. Vacuolation of renal tubules was extensive. In addition, the presence of 
haemorrhage and thrombosis in association with neutrophils in PTC was indicative of 
antibody-mediated rejection (Figure 6.9). Toxicity mediated by CsA administration 
could explain why transplant survival in this sub-group was poor.  
In the CsA/PTL004 subgroup with prolonged graft survival (n=4), the renal transplant 
tissue was substantially better preserved, even though the features of CsA-toxicity were 
present. In these recipients, areas of renal vacuolation were widely distributed in the 
tissue. There were also some signs of AMR such as glomerulitis and peritubular 
capillaritis. There was a clear absence of lymphocytes, even from the late graft losses, 
indicating that CsA treatment had been effective in suppressing T cell-mediated 
rejection (Figure 6.10).  
CsA alone in the absence of cytotopic therapy (with PTL004) offered no protection 
against HAR, as portrayed in the histology results (for rejected grafts, by day 2). These 
showed severe infarction and also showed widespread tubule vacuolation and 
calcification, which is typical for CsA toxicity (Figure 6.11).  
These data indicate that acute CsA-induced toxicity was a prominent feature in the 
whole group of transplants at the time of rejection, even those rejected within the first 2 
days of transplantation.  CsA could possibly have played a role in the abnormal results 
generated in the group that received combined treatment of PTL004 and CsA indicating 
that for this model CsA might not have been a suitable choice as a T-cell 






Figure 6.9: An example of donor kidneys treated with PTL004 and grafted into pre-
sensitised recipients treated with CsA, rejected in an accelerated manner (n=4). A: 
Histology of a representative DA kidney rejected at day 1 post-transplantation despite 
treatment with PTL004/CsA and showing marked vacuolation of tubules, a possible 
indication of CsA toxicity (MSB; x400). B: Extensive infarction and thrombosis (MSB; 
x200). C: Graft rejected at day 2 post-transplantation with tubules showing infarction 








Figure 6.10: Examples of donor kidney treated with PTL004 and grafted into pre-
sensitised recipients treated with CsA, with prolongation of survival (n=4). A: 
Representative DA allografts rejected at day 8 post-transplantation showing vacuolation 
of tubules, a possible sign of CsA toxicity (MSB; x200). B: Renal tubule vacuolation 
(PAS; x200). C: Vacuolation (MSB; x400). D: Glomerular fibrin thrombi (MSB; x400). 




















Figure 6.11 Soltran-perfused donor kidney transplants rejected by recipients treated 
with CsA (n=6). A: Histology of representative DA kidney allografts taken from a pre-
sensitised Lewis recipient treated with Soltran/CsA at day 1 post-transplantation 
showing extreme infarction (PAS; x100). B: Renal tubule vacuolation (PAS; x400). C: 









Due to possible harmful effects caused by CsA, the immunosuppressive regimen was 
changed to the mTOR inhibitor Rapamycin. The treatment regimens that included 
Rapamycin are described in Section 6.2. As described in Sections 6.6 and 6.7, 
Rapamycin, when given in combination with PTL004-treated kidney prolonged graft 
survival to give MST 5.8 days, compared to 1.5 days when Rapamycin was given to 
recipients of a Soltran-treated kidney.   
For the combined Rapamycin/PTL004 treatment group, histological analysis is shown 
in figure 6.12.  Here, representative micrographs are shown from animals that rejected 
their graft at day 5 (n=1), day 8 (n=2) and day 9 (n=1). Surprisingly, histological 
analysis for all time points revealed presence of extensive lymphocytic infiltration 
despite treatment with Rapamycin. Furthermore, all animals developed fibrinoid 
necrosis revealing the presence of ongoing AMR.  
In contrast, for the Rapamycin-only treatment group (where the donor kidney was 
perfused with Soltran alone), rejected kidneys only showed features of HAR with 
thrombosis and necrosis (Figure 6.13)  
In conclusion, treatment with the immunosuppressant Rapamycin did not lead to 
obvious cell toxicity visible by microscopy. Disappointingly, however, Rapamycin did 
not prevent lymphocytic infiltration of the graft. Rapamycin, therefore, may not 
effectively eliminate cellular immune responses in the dosing regimen and model used. 
It is not clear if there is any distinct advantage of adding Rapamycin over PTL004 
alone, in terms of histological damage, since no direct comparison between 














Figure 6.12: Sections from DA donor kidney allograft rejected by pre-sensitised 
recipients despite treatment with PTL004/Rapamycin. A: Allograft rejected at day 9 
post-transplantation showing extensive lymphocytic infiltration, (PAS; x200). The inset 
shows arteritis (PAS; x400). B: Vessel wall from the same graft showing fibrinoid 
necrosis (MSB; x400). C: Allograft rejected at day 8 post-transplantation showing 
cellular rejection (PAS; x200). The inset shows arteritis (PAS; x400). D: Fibrin thrombi 
on the vessel wall of the same graft (MSB; x400). E: Allograft rejected at day 5 post-
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transplantation showing widespread lymphocytic infiltration of the graft (PAS; x200). 































Figure 6.13: Sections of Soltran-perfused kidneys from recipients that received 
Rapamycin (n=4). A: Representative section of DA kidney allograft rejected at day 1 
post-transplantation by a pre-sensitised Lewis recipient after Soltran/Rapamycin therapy 
showing widespread infarction, TMA and haemorrhage (MSB; x100). B: Extensive 













6.9 Detection of Membrane Attack Complex (C5b-9) in rejected PTL004-treated 
Kidneys 
Given the two-way interaction between complement and coagulation activation 
(reviewed in Chapter 1), my expectation was that anti-thrombin treatment, e.g. with 
PTL004, would inhibit complement activation (at the level of C3 or C5).  To address the 
possible mechanisms by which PTL004 extended the graft survival, graft tissue was 
stained for the terminal complement activation product MAC (C5b-9). This would 
provide evidence of whether PTL004-mediated thrombin inhibition had an effect on 
complement activation, either by a direct action on the complement system or through 
preventing tissue damage mediated by the coagulation cascade. In this set of 
experiments, hyperimmune Lewis recipients were transplanted with Soltran-treated 
kidneys (n=2) or PTL004 pre-treated kidneys (n=2). In both cases the transplants were 
removed on day 1 or day 2 post-transplantation to enable direct comparison at the same 
time-points. Immunofluorescent staining of snap frozen tissue showed C5b-9 deposition 
in both groups and quantification was attempted, since it was clearly different. 
However, extreme infarction of the control tissue meant there were insufficient viable 
areas for comparison with the PTL004-treated tissue. Nonetheless, these experiments 
showed a striking contrast between the level of infarction in the Soltran-treated group 
and the level of protection in the PTL004-treated grafts. Although C5b-9 deposition was 
present in the treated group, it was focal rather than diffuse supporting a beneficial 
effect of PTL004 in the acute phase of accelerated rejection (Figure 6.14). The same 
pattern was found upon analysis of control and PTL004-treated tissue at 48 hours post-
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Figure 6.14: Donor kidneys were treated with 5 ml of 2μM PTL004 or Soltran alone and harvested at 24 hours post-transplantation. Kidneys 
were stained by immunofluorescence for C5b-9. A: Soltran-perfused allograft showing infracted tissue (x100). B: Infarction (x200), inset 
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showing linear deposition of C5b-9 on tubules in few viable areas (x400). C: PTL004-treated graft showing well preserved tissue and some 















Figure 6.15: Donor kidneys treated with 5 ml of 2μM PTL004 or Soltran alone and removed from the pre-sensitised recipient at 48 hours post-
transplantation. A: C5b-9 immunofluorescent staining of a Soltran-perfused allograft undergoing HAR showing severe infarction (x100). B: The 
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same kidney with infarction and some positive tubular staining for C5b-9 (x400). C: C5b-9 staining of a PTL004-perfused DA allograft 
undergoing AMR in a pre-sensitised Lewis recipient showing well preserved tissue and some positive C5b-9 staining (x100). D: Viable area of 
the same kidney with slight C5b-9 positive staining (x200). E: Intense staining of C5b-9 without necrosis (x200). F: High power of tubules 










6.10 Discussion  
Following the encouraging results with PTL006 described in Chapter 5, the aim of the 
experiments described in the present chapter was to test the ability of a second thrombin 
inhibitor, PTL004, in reducing HAR in a rat allograft model. A second aim was to try a 
combination treatment comprising the thrombin inhibitor (targeting AMR) and standard 
immunosuppression (targeting cell-mediated rejection). 
PTL004 and PTL006 are both thrombin inhibitors, but PTL004 has a novel membrane-
inserting tail that is different to PTL006 (pegylated tail). The PTL004 has a double (bis) 
myristoyl group that creates the possibility of a more potent tail than that incorporated 
in PTL006 in terms of binding strength to the cell phospholipid bilayer membrane. 
Synthetic considerations  and the observation that PTL006 was found to transfer 
(“painted”) from loaded to unloaded cells more rapidly than PTL004 (Melchionna T, 
unpublished) led me to use PTL004 for further investigations. 
Despite speculation that the bis-myristoyl tail of PTL004 may have a greater binding 
affinity than its predecessor molecule (PTL006), results generated using PTL004 were 
very similar to the ones produced using PTL006 in the previous chapter. One limitation 
to this observation is that PTL004 and PTL006 were never directly compared in a single 
experiment, and therefore exact conditions (including antibody status) may have 
differed. However, in broad terms the MST with both cytotopic antithrombins were 
similar. Intragraft perfusion of DA kidneys with PTL004 at 2 μM and transplantation 
into pre-sensitised Lewis recipients, significantly prolonged the graft survival (MST 5.1 
days) compared with recipients of control Soltran perfused kidneys (MST 1.5 days). 
These results indicated that there is minimal influence of the tail on function of the 
inhibitor. Both tails mediate binding to the cell membrane. The level of protection of the 
renal vasculature from aggressive pro-inflammatory and pro-coagulant thrombin effects 
was no different, whether the hirulog peptide was attached to a pegylated or bis-
myristoylated tail. Similarly to PTL006, the mechanisms by which PTL004 prolonged 
survival and protected from immediate renal dysfunction may be predicted to involve 
targeting of both complement-dependent and independent mechanisms (as discussed in 
detail in results chapter 5). In conclusion, PTL004 appeared to change the mode of 
rejection from hyperacute to acute, and histological analyses of graft tissue generated 
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after treatment with the thrombin inhibitor showed the consequences of mixed antibody 
and cellular immune responses. 
An important aspect of this research was to investigate the suitability of these cytotopic 
agents (and their therapeutic protocol) for translation to the transplant clinic. For this 
reason, studies were extended to include standard immunosuppressive drugs to 
determine if the cell-mediated arm of rejection can be overcome by using combination 
therapy. This could maximise the chance of attaining graft acceptance against the most 
severe of immune barriers. Consequently, the sensitised recipients of PTL004-treated 
DA kidneys were treated with CsA before and after transplantation.   
CsA failed to improve graft survival, despite the observation that in 50% of cases the 
cellular infiltration was abated by inclusion of CsA in the treatment protocol. The 
absence of improved outcome could have been due to the observed presence of tubular 
vacuolation and calcification which was unique to the CsA group, suggesting CsA 
toxicity. The combination of CsA toxicity with AMR could have aggravated tissue 
damage thereby negating any protective effect of PTL004. Why some recipients with 
signs of tubular injury succumbed immediately following transplantation while others 
survived longer is not clear but it could be due to variation in CsA pharmacodynamics 
and sensitivity in individual animals of the same species. Finally, it is possible that 
without the toxic effects, the longer surviving grafts of CsA-treated group could have 
had even more prolonged graft survival.  
It is quite possible that the dose used in this model (10mg/kg/day), was causing severe 
nephrotoxicity, a feature that often has been associated with CsA during its use in acute 
experimental models of nephrotoxicity in the rat (Andoh TF et al., 1996 315). 
Moreover, the use of CsA has been associated with renal vascular thrombosis (Remuzzi 
G et al., 1989 316) and this may explain why in about half the animals the beneficial 
effect of PTL004 was no longer found. Indeed, recent research showed that CsA 
enhances the procoagulant properties of platelets by interaction with the platelet cell 
membrane (Tomasiak M et al., 2007 317). Spontaneous activation of platelets may 
result in enhanced thrombin generation, which ultimately causes expression of 
fibrinogen receptors (Fishman SJ et al., 1991 318). In other words, the susceptibility to 
graft thrombosis induced by antidonor antibody in this model could have been increased 
by CsA, obscuring the anticoagulant properties of PTL004 in a high proportion of 
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animals. Rapamycin inhibits the mammalian target of rapamycin (mTOR Complex 1) 
and therefore prevents proliferation and survival of lymphocytes (Ballou LM et al., 
2008 319).  
The results with Rapamycin were more consistent than those with CsA. More 
specifically, 5 out of 6 had prolonged graft survival, however no graft survived beyond 
10 days in either treatment group. A potential benefit of CsA treatment was that it 
appeared to prevent lymphocytic infiltration of the graph  but these effects were limited 
by tubular toxicity and possibly arterial thrombosis, although tubular toxicity and 
possibly arterial thrombosis were observed. In contrast, recipients treated with 
Rapamycin showed no signs of toxicity but grafts had a substantial lymphocytic 
infiltration. Further adjustments in the dose of immunosuppressive agent -a decrease in 
the case of CsA and an increase for Rapamycin- could be productive in future 
experiments. This was not possible during the research described here due to limitations 
of time. Dose adjustment might be useful in the context of clinical translation, as it has 
been beneficial in man to prevent acute cell-mediated rejection.  
Finally an experiment was carried out to find out if at least some of the therapeutic 
effects of PTL004 could have been due to an effect on complement activation, as well 
as on the coagulation cascade. Since thrombin is reported to directly cleave C5, I 
examined the formation of C5b-9 in transplanted kidneys that had been pre-treated with 
the anti-thrombin PTL004.  The treated tissue was compared to that from Soltran-
perfused kidneys. Residual staining was visualized as clear linear deposits on the 
tubular basement membranes, but the reduction seen compared with the Soltran-alone 
control group was not quantifiable in due to extensive tissue infarction in the control 
group. Nonetheless, this experiment was important since it showed that despite C5b-9 
deposition in the PTL004-treated tissue, many areas were well preserved at 24 and 48 
hours post transplantation. This was in contrast to the severely necrotic control tissue.  
Finally, these data support our hypothesis, that PTL004-mediated protection was taking 






Chapter 7   
 
7.1 Conclusions 
Transplants are powerful stimulants of alloantibody generation which are pivotal to 
graft rejection and loss. The risk for immediate transplant loss is highest in patients with 
preformed antibody (specific for ABO and/or HLA) against their donors. Nowadays, 
crossmatching techniques are used prior to transplantation to detect cross reactivity and 
avoid devastating HAR, however, memory generated due to pre-exposure still poses a 
barrier to successful long term transplantation.  
The initial aim of the research presented in this thesis was to establish a rat transplant 
model in which a vascularized allogeneic kidney rejected in an aggressive and 
accelerated manner, resembling HAR in the clinic. Using a stringent rat strain 
combination, DA (RT1
a
) to Lewis (RT1
i
) with multiple donor skin transplant pre-
sensitisation prior to kidney transplantation, a model akin to HAR was established. 
Using the universal criteria for the diagnosis of AMR, it was confirmed that the Lewis 
recipients had developed high titres of anti-DA specific alloantibody in their serum prior 
to kidney transplantation from the same donor strain. Aggressive humoral immune 
responses associated with high serum titres of alloantibody resulted in endothelial 
activation and subsequent initiation of the complement and coagulation cascades.  
Using histological and immunopathological assessments, it was confirmed that 
coagulation- and complement- mediated injury was present in the graft removed from 
the pre-sensitised Lewis recipients. Acute tissue injury was evident, with extensive 
neutrophilic influx in the PTC and widespread necrosis. Most importantly, acute 
thrombotic microangiopathy (TMA) was seen in the presence of haemorrhage and 
fibrinoid necrosis. In addition, evidence for the involvement of complement in 
mediating tissue injury was revealed through C4d positive stained tissue in the rejected 
kidneys of pre-sensitised Lewis recipients.  
Having established a model of HAR of renal allotransplants, an attempt was made at 
therapeutic intervention targeting one of the major rejection mechanisms involved in 
HAR, the complement cascade.  
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To target complement and the damaging effects of its split products, a well-
characterized complement inhibitor, APT070 (Mirococept), was employed. APT070, a 
derivative of human soluble complement receptor 1 (CR1; CD35) derived from N-
terminal 3 short consensus repeats and attached to a membrane inserting tail which 
allows it to efficiently bind to cells. This complement inhibitor retains the complement 
control mechanisms of CR1 (i.e decay acceleration and factor I cofactor activity). It has 
been successfully used in a variety of experimental models and humans (phase 1 trials 
for evaluation of safety, tolerability, pharmacokinetics and pharmacodynamiscs in 43 
subjects in total) (study report ME0579, KCL, unpublished). Prior to proceeding to 
therapeutic intervention in vivo, in my model, experiments confirmed the capacity of 
APT070 to inhibit complement in vitro. Its ability to bind cells and its distribution in 
vivo after intrarenal delivery was also confirmed. 
An important novel aspect of this model is that therapeutic intervention is administered 
directly to the kidney via the aorta and the renal artery thereby minimizing effects on 
systemic complement activity (Patel H et al., 2006 291). APT070 in Soltran was 
perfused intrarenally into DA donor kidneys which were then transplanted into 
hyperimmune Lewis recipients. The soluble non-tailed CR1 construct (APT154) was 
used as a control. APT070 was tested at two different doses (5 ml at 40 and 80 μg/ml) 
however, neither of the doses used, had any effect on recipient survival. The recipients 
of either APT070 or APT154 rejected their grafts by 48 hours post-transplantation 
(similar to that of recipients of Soltran-perfused control kidneys in chapter 3). A 
moderate improvement in renal function (BUN) and marginally better preserved graft 
tissue seen by histological examination was observed in the group that received kidneys 
treated with 80 μg/ml APT070. Nonetheless, the perfusion of DA kidneys with the 
APT070 complement inhibitor prior to transplantation into sensitised recipients did not 
extend graft survival.  
HAR is the result of a well-orchestrated and complex immune response in which many 
mediators promote a local inflammatory environment thus promoting tissue injury. 
Having examined the possibility of targeting complement activation to improve graft 
outcome, targeting complement-independent mechanisms was then investigated.    
In this model, the transplantation of DA kidneys into highly sensitised Lewis recipients 
resulted in graft histology showing extensive thrombosis. Thus, novel therapeutics 
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targeting thrombin (the central enzyme of the coagulation cascade) and their effect on 
graft outcome was investigated. In addition to targeting coagulation the inflammatory 
responses mediated by PAR receptors on a variety of cells could also be inhibited by an 
anti-thrombin strategy. The therapeutic reagent PTL006 was initially used. It was 
constructed following the same principle as APT070, that is, to be delivered directly in 
the target cell membrane.  
The PTL006 thrombin inhibitor comprises the anti-coagulant hirulog-like peptide 
derived from the medicinal leech Hirudo medicinalis, coupled to a polyethelene glycol 
(PEG) tail. A major problem became evident during these studies, that is, excessive 
bleeding was occurring at the site of the arterial anastomosis (a condition which was 
amplified by the natural differences in size of the vessels between the donor and 
recipients rat strains). As a result, the intragraft perfusion protocol was modified to 
include two steps: 1) a ten-minute dwell-time following graft perfusion to allow longer 
for the reagent to bind cells followed by 2) an additional perfusion with 5 ml of Soltran 
solution to wash out any excess unbound material. These steps effectively eliminated 
uncontrolled bleeding during the transplantation procedure and enabled PTL006 (5 ml 
at 2 μM) to be perfused into the DA kidneys prior to successful transplantation into 
Lewis recipients. The anti-coagulant used under these conditions was able to 
significantly prolong graft survival (MST 4.6 days post-transplantation) in comparison 
to the Soltran-treated kidneys (MST 1.8 days post-transplantation). This was a pivotal 
finding since it changed the mode of rejection from rapid and extremely aggressive 
rejection to a slower acute response which might be more susceptible to therapeutic 
control. Progressive deterioration of renal function (BUN) occurred in the presence of 
both humoral and cellular rejection based on histological examination at the later time 
points of survival.  
Hence, in this severe rejection model where the inhibition of complement activation had 
limited effects, blocking the coagulation cascade revealed that a degree of control was 
possible. A potential for therapeutic intervention therefore exists. Indeed, the inhibition 
of thrombin has a variety of effects, inhibiting both procoagulant and proinflammatory 
effects of alloantibody resulting in the protection of the graft. The therapeutic potential 
of combined treatment of DA kidneys perfused with PTL006/APT070 was explored. No 
significant additive effect was observed (MST 5.5 days post-transplantation) compared 
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to the anti-coagulant PTL006 alone, indicating once again the importance of the 
complement-independent alloantibody mechanism on the endothelium. These data 
question the role of complement activation in this model of HAR: complement 
activation might happen as result of it, but not cause it.  
The successful extension of graft survival with PTL006 therapy required further 
investigation, with the aim to increase the life of the therapeutic on the vascular surface, 
which was suggested by immune staining to be less than 24 hours. For this, the 
thrombin inhibitor was changed to PTL004 (Thrombalexin).  PTL006 has a PEGylated 
tail. As noted in Chapter 6, cell-bound PTL006 has the property of transferring rapidly 
to cells not bearing the agent whereas PTL004 appeared to be more stably bound 
(Melchionna T, unpublished data). PTL004 comprises the HLL peptide attached to a 
bis-myristoyl tail (an extra myristoyl group compared to APT070) thus potentially 
increasing its binding affinity to the phospholipid bilayer. DA kidneys perfused with 5 
ml of 2 μM PTL004 were transplanted into hyperimmune Lewis recipients and similar 
survival was achieved compared to PTL006 (MST 5.1 days post-transplantation). These 
findings indicated that irrespective of the tail attached to the anti-thrombin HLL, this 
was the maximum survival which could be achieved in this model using a single 
intrarenal dose of the coagulation inhibitor.  
The addition of a standard immunosuppressant was investigated to try and prevent the 
cell mediated component of rejection and further extend graft survival in this model, 
where rapid antibody-mediated responses have been dampened, at least during the acute 
phase of 24 hours post-transplantation. CsA with PTL004 was initially used, however 
tissue harvested from these recipients showed signs of nephrotoxicity, although for 
some of the animals prolongation of survival compared to recipients of CsA alone was 
achieved. As an alternative, Rapamycin was used in combination with PTL004-treated 
kidneys. Despite longer graft acceptance with this combination (MST 5.8 days post-
transplantation) compared to the Rapamycin alone group (MST 1.5 days post-
transplantation), tissue from the PTL004/Rapamycin group, was characterized by 
lymphocytic infiltration. This was an indication that the administration of Rapamycin in 
this model had not been completely effective in preventing lymphocyte migration into 
the grafts.  
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In summary, this thesis describes a novel therapeutic approach whereby coating the 
donor kidney with a membrane-adherent anti-thrombin reagent can slow the pace of 
rejection, which may then become more susceptible to control. In addition, it reveals 
that transplant surgery is feasible by reducing susceptibility for coagulation of the donor 
endothelium without inducing the risk of a major coagulation defect in the recipient. 
Efforts were made to measure systemic coagulation using a standard method and 
coagulometer (MC4 Plus Coagulometer, MERLIN medical, distributed by HART, UK). 
However data obtained were inconsistent and non reproducible. Alternative methods to 
detect the presence of the anticoagulant in the circulations are currently being 
developed. In a markedly pro-thrombotic environment, graft thrombosis/inflammation is 
significantly reduced probably for the duration of the cell surface activity of the tailed 
anticoagulant. The objective of this therapeutic strategy was to investigate the potential 
of localised therapy to prevent the deleterious effects of the alloresponse in pre-
sensitised renal transplant recipients, without increasing the risk of systemic side 
effects. This study provided proof of concept for that strategy using a coagulation 














7.2 Future Work  
The work described in this thesis could be expanded in a variety of ways. Restrictions in 
time and difficulties in obtaining DA rats (due to breeding problems of the supplier) 
prevented some important experiments being carried out that could be addressed in the 
future.  
The hyperimmune model described undeniably results in HAR. This provides a 
stringent test of the full potential of the therapeutic reagents as it is very severe 
transplant setting. Through crossmatching techniques between donors and recipients, 
HAR is not a phenomenon that often occurs in the clinic, therefore a less severe model 
of acute AMR may have been more appropriate in reflecting the situation of patients 
undergoing humoral rejection. However, the stringent model used was the ultimate test 
of efficacy. Nonetheless, this study is still highly relevant in view of the large number of 
pre-sensitised patients who would benefit from additional graft protection and who 
might otherwise be non-transplantable. 
Attempts to target cellular rejection in this model were not effective using CsA or 
Rapamycin. This should be investigated further using a range of doses appropriate for 
each immunosuppressive reagent while treating the donor kidney cytotopically.  
Finally, further investigations are required to dissect the mechanisms by which the anti-
coagulants PTL006 and PTL004 protect the graft and change the type of rejection 
observed. For example, staining for expression of different endothelial proteins (such as 
vWf) in protected kidneys could give an explanation for this protective phenotype.    
Preliminary data in this thesis showed that protection with the anticoagulant reagent 
takes place with ongoing complement activation (C5b-9). Nonetheless, this in vivo 
study could be used to extend data generated by Krisinger MJ et al. where it was 
identified that thrombin, acting like a convertase, cleaves C5 at a different site to that 
cleaved by C5 convertase to generate novel C5 products. In vitro assays showed that 
MAC formed by thrombin cleavage of C5, possessed greater activity than MAC 
generated by the standard C5 convertase (Krisinger MJ et al., 2012 234). Utilizing this 
model, the first in vivo study to establish the differentiation between formulation and 
origin of these different MAC could be done (provided an antibody is available in 
recognising the specific epitope at which thrombin cleaves). This may explain a 
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mechanism behind the interaction between the complement and coagulation cascades, 
and the protection by our cytotopic anticoagulants.  
The work described here has formed the basis for a successful application to the 
Wellcome Trust for a Translation Award to advance Thrombalexin to first-in-man 
studies. The project has involved development chemistry to “fine-tune” the PTL004 
structure (for example, removing the disulphide bridge which is reducible with 
compounds such as glutathione which are present in perfusion solutions such as 
University of Wisconsin solution).  This project is well advanced and a selected 
compound is expected to be used in human studies within the next 18 months. 
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